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ABSTRACT 
 
Sexual dysfunction, body image distress and marital dissatisfaction in breast 
cancer patients of University Malaya Medical Centre (UMMC) 
 
Introduction:  Breast cancer is the commonest cancer amongst Malaysian women. 
Recent literature has shown that, the disease itself and adverse effects of the cancer 
treatment were associated with sexual dysfunction, body image distress and marital 
dissatisfaction. 
 
Aim:  The aim of the study is to determine the prevalence of sexual dysfunction in 
breast cancer patients who are in remission attending follow-up at the breast clinic in 
UMMC. 
 
Method:  This is a cross-sectional study conducted at the breast clinic in UMMC. The 
patients were given self-reported questionnaires, the Female Sexual Function Index 
(FSFI), Breast Impact of Treatment Scale (BITS), Golombok Rust Inventory of Marital 
State (GRIMS), Hospital Anxiety and Depression Scale (HADS) and Psychological 
General Well-Being Index (PGWBI). Socio-demographic, clinical, disease and marital 
data were obtained by interviewing the patients and also reviewing the medical notes. 
Ethical approval for the study was obtained from the Ethics Committee of UMMC. 
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Results:  A total of 100 breast cancer patients were recruited. The prevalence of sexual 
dysfunction as assessed by the Female Sexual Function Index (FSFI) with the cut-off 
score of ≤ 26.6 was 90.0%. By using the Breast Impact of Treatment Scale (BITS), the 
prevalence of body image distress was 42.9%. The prevalence of marital dissatisfaction 
determined by the Golombok Rust Inventory of Marital State (GRIMS) was 55.0%. The 
Hospital Anxiety and Depression Scale (HADS) was used to assess depression 
(prevalence of 9.0%) and anxiety (prevalence of 27.0%).  
Actual age of disease onset, total GRIMS score (marital dissatisfaction) and HADS-D 
sub-scale score (depression) were found to be independently associated with sexual 
dysfunction.  
 
Conclusion:  Breast cancer survivors experienced great level of sexual dysfunction, 
body image distress, marital dissatisfaction, depression and anxiety. These findings 
serve as an alarm for health care providers for early and routine assessment of these 
matters. A prompt referral to the mental health services may be required for further 
evaluation and appropriate treatment when indicated.  
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ABSTRAK 
 
Disfungsi seksual, tekanan berkaitan imej tubuh dan ketidakpuasan dalam  
perkahwinan di kalangan pesakit kanser payudara Pusat Perubatan Universiti 
Malaya (PPUM) 
 
Pengenalan:  Kanser payudara adalah merupakan kanser yang paling lazim dihidapi 
oleh wanita Malaysia. Kajian terkini telah mendapati bahawa kanser payudara sendiri 
dan kesan sampingan dari rawatan kanser mempunyai perkaitan dengan disfungsi 
seksual, tekanan berkaitan imej tubuh dan ketidakpuasan dalam perkahwinan. 
 
Objektif:  Objektif utama kajian ini dijalankan adalah untuk menentukan prevalens 
disfungsi seksual yang dialami oleh pesakit kanser payudara yang berada dalam remitan 
yang menghadiri rawatan susulan di klinik payudara di PPUM. 
 
Kaedah:  Ini adalah kajian keratan rentas yang dijalankan di klinik payudara di PPUM. 
Pesakit diberikan borang kajian soal selidik yang perlu dijawab sendiri,  yang terdiri 
dari borang “Female Sexual Function Index” (FSFI), “Breast Impact of Treatment 
Scale” (BITS), “Golombok Rust Inventory of Marital State” (GRIMS), “Hospital 
Anxiety and Depression Scale” (HADS) dan “Psychological General Well-being Index” 
(PGWBI). Data sosio-demografik, klinikal, penyakit dan perkahwinan diperolehi 
dengan menemubual pesakit dan juga menyemak nota perubatan pesakit. Kebenaran 
untuk menjalankan kajian ini telah diperolehi daripada Ahli Jawatankuasa Etika PPUM. 
 v 
 
Keputusan:  Seramai 100 orang subjek telah menyertai kajian ini. Prevalens disfungsi 
seksual diperolehi dengan menggunakan “Female Sexual Function Index” (FSFI) pada 
jumlah skor ≤ 26.6 adalah 90.0%. Prevalens tekanan berkaitan imej tubuh adalah 42.9% 
dengan menggunakan “Breast Impact of Treatment Scale” (BITS). “Golombok Rust 
Inventory of Marital State” (GRIMS) telah digunakan untuk memperolehi prevalens 
ketidakpuasan dalam perkahwinan, iaitu sebanyak 55.0%. Prevalens untuk kemurungan 
dan keresahan dengan menggunakan “Hospital Anxiety and Depression Scale” (HADS) 
adalah sebanyak 9.0% dan 27.0% masing-masing.  
Usia ketika permulaan kanser, jumlah skor bagi GRIMS (ketidakpuasan dalam 
perkahwinan) dan skor bagi skala HADS-D (kemurungan) menunjukkan perkaitan yang 
bebas dengan disfungsi seksual. 
 
Kesimpulan:  Subjek yang menghidapi kanser payudara yang menghadiri rawatan 
susulan di klinik payudara di PPUM mempunyai tahap disfungsi seksual, tekanan 
berkaitan imej tubuh, ketidakpuasan dalam perkahwinan, kemurungan dan keresahan 
yang tinggi. Keputusan yang diperolehi menunjukkan bahawa kakitangan perubatan 
harus peka dan berwaspada terhadap permasalahan ini. Penilaian awal dan berkala 
adalah perlu untuk pengesanan awal. Rujukan kepada pakar kesihatan mental haruslah 
dibuat pada kadar segera bagi tujuan penilaian lanjut dan seterusnya rawatan jika perlu.  
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CHAPTER ONE 
 
INTRODUCTION 
 
Breast cancer is the commonest cancer affecting women. Both women from 
developed and less developed countries are affected by it (WHO, 2014). It is the second 
most commonly diagnosed cancer worldwide, after lung cancer, with an estimate of 
1.38 million cases (10.9%) in 2008 based on the GLOBOCAN report. Although it ranks 
the fifth as cancer-related death in 2008, with 458,000 deaths (6.1%) recorded, breast 
cancer is still the commonest cause of cancer death in women globally (Ferlay et al, 
2010). Almost 50% of breast cancer cases and 58% of deaths were recorded in less 
developed countries, even though breast cancer is said to be a disease of the developed 
countries (GLOBOCAN, 2008). 
The lifetime risk for breast cancer is 1 in 20 women in Malaysia and breast 
cancer is the commonest malignancy in women (Lim and Halimah, 2003). Based on the 
National Cancer Registry 2007, breast cancer ranked number one among the top ten 
cancers in Malaysia. A total of 3292 cases were diagnosed in 2007, which was 18.1% of 
all cancer cases (National Cancer Registry, 2007). Commonly, women in Malaysia 
presented with bigger tumour size and at more advanced stages of the disease. These 
may be due to certain health beliefs, inaccurate information, and insufficient health care 
facilities that prohibited routine early detection and treatment of breast cancer (Yip and 
Omar, 2003). 
The diagnosis of breast cancer and its treatment modalities tremendously affect 
the patient’s life. Survivorship of the disease has improved over the years with greater 
use of screening mammography and advances in its treatment modalities (American 
Cancer Society, 2009; Bloom et al, 2004; Taylor et al, 2002; Qaseem et al, 2007). In the 
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United States alone, more than 2.9 million breast cancer survivors are recorded in the 
2012 (Siegel et al, 2012). Improvement in the survivorship of the disease has 
transformed breast cancer from a terminal illness to a disease with a chronic course 
(Sherman and Hossfeld, 1990).  Breast cancer does not only affect the patient 
physically, but it also has psychological and social impact (Bloom et al, 2004; Ganz et 
al, 2002). Its impact on quality of life is an increasing important area of study with the 
improvement of the survival rates (Taylor et al, 2002). Literature has reported a wide 
range of disturbances in the daily living secondary to the diagnosis of breast cancer 
(Rowland and Massie, 2009). Women with breast cancer may experience physical 
changes to their body as a result of cancer treatment. The disease may also lead to 
change in body image, self-esteem and psychological distress. Other psychosocial 
impacts of breast cancer are financial, relationship and work related issues. 
This disease threatens an organ that is closely related to attractiveness, 
femininity, sexuality, motherhood, and consequently with body and self- image, and 
self-esteem (Abdul Rahim, 2010). Cancer patients were found to have significant fears 
associated with the effects of surgery on the body and side effects due to chemotherapy 
(Farooqui et al, 2011). Common adverse effects of chemotherapy, radiation therapy, 
breast cancer surgery, and hormonal therapy are vaginal irritation and dryness, 
dyspareunia, decreased sexual desire, alopecia, nausea, vomiting, early onset  
menopause, and significant emotional disturbances (Bakewell and Volker, 2005). 
Cancer-related traumatic stress symptoms may be seen in 50% of breast cancer patients 
(Butler et al, 1999) and as high as 45% of early stage breast cancer patients suffer from 
anxiety or depression (Henson, 2002). 
Women with breast cancer were found to be more self-conscious (Walsh, 
Manuel and Avis, 2005), less attractive (Henson, 2002), and have poorer body images 
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compared to normal controls (Mock, 1993). Surgical treatment either modified radical 
mastectomy or segmental mastectomy are associated with some level of breast loss or 
breast change.  However, these options are less disfiguring compared to the previous 
Halstead radical mastectomy which involves the “amputation of the breast with a wide 
excision of the pectoral muscles and axillary lymph nodes” (Frierson, Thiel and 
Andersen, 2006). Altered body image is associated with breast cancer surgeries (Collins 
et al, 2011). Breast disfigurement and body image dissatisfaction can lead to 
psychological disturbances in women with breast cancer (Falk et al, 2010; Hemls et al, 
2008). 
Breast cancer treatments also have a substantial effect on sexual function, with 
as high as 50% to 76% of women with the disease experienced sexual difficulties after 
breast cancer treatment (Burbie and Polinsky, 1992; Goldfarb et al, 2009). Adverse 
effects of breast cancer treatments such as sex hormone deficiency (Buijs et al, 2008; 
Joly et al, 2000; Meyerowitz et al, 1999; Schover, 2008) or body image changes (Arora 
et al, 2001; Janz et al, 2005) may affect sexual functioning of women with breast 
cancer.  
The disease does not only affect the patient, but it also can be intensely 
distressing for the family (Ganz et al, 1998; Henson, 2002; Schover, 1991). Substantial 
amount of strains were experienced in relationships during breast cancer. A study 
conducted by Walsh and colleagues (2005) found that 25% of women suffering from 
breast cancer experienced difficulties in their relationship, 35% felt that their spouses 
were emotionally absent, and 12% reported separation. This study also found that the 
separations were mostly instigated by men who were not able to handle the issues 
pertaining to their wives’ or spouses’ cancer (Walsh, Manuel and Avis, 2005). 
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In this study, the breast cancer patients who are in clinical remission attending 
follow up at the breast clinic in University Malaya Medical Centre (UMMC) will be 
given a set of questionnaires after an informed and written consent was obtained. This 
study is to look at the interactions between, sexual dysfunction, body image distress, 
and marital dissatisfaction in breast cancer survivors who have been attending follow up 
at the breast clinic. These pertinent issues may be inter-related to each other which may 
affect the quality of life of breast cancer survivors.  Hence, the aim of this study is to 
look at sexual dysfunction and its association with body image distress, marital 
dissatisfaction and other confounding factors in breast cancer survivors (BCS). Sexual 
dysfunction and psychological aspects associated with it may persist even long after 
completion of breast cancer therapy and during clinical remission, thus play a vital part 
in the quality of life and survival of women with breast cancer. To date, there are no 
published data or studies regarding sexual dysfunction, body image distress, and marital 
dissatisfaction among BCS in Malaysia. 
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
2.1 EPIDEMIOLOGY OF BREAST CANCER 
 
Breast cancer is rapidly increasing globally. In 2002, there were 1.15 
million cases of breast cancer recorded in the world (Parkin et al, 2005).  In 
2008, there was an increase in the incidence of the disease detected to 1.38 
million and breast cancer is the second most common cancer type diagnosed in 
the world after lung cancer, which is 10.9% of all new cancer cases and 23% of 
all female cancers. It is the commonest cancer type in women both in the 
developed and less developed countries (WHO, 2014). There is geographical 
variation of the incidence rates around the world, with a higher incidence of 
greater than 80 per 100, 000 in more developed countries reported than in the 
developing countries. Less developed countries recorded lower incidence rate of 
less than 40 per 100, 000. Each region reported an estimate of 690, 000 new 
cases with the population ratio of 1:4 (GLOBOCAN, 2008). North America has 
the highest incidence rate of breast cancer with the age standardized rates of 99.4 
per 100, 000 population. The Eastern Europe, South America, Southern Africa, 
and Western Asia regions have moderate incidence rates and most African 
countries recorded the lowest incidence rates (Jemal et al, 2004). Breast cancer 
is associated with significant morbidity and mortality. Based on a report, 1 out 
of 8 women in the United States (US) are at risk to develop breast cancer 
throughout their lifetime (US Breast Cancer Statistics, 2013). According to the 
Breast Cancer Facts and Figures 2013-2014 by the American Cancer Society, an 
estimated of 232, 340 American women will be newly diagnosed with invasive 
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breast cancer in 2013. It was also estimated that there will be 39, 620 breast 
cancer deaths in US in the 2013, and breast cancer is the second cause of cancer-
related deaths in women, just behind lung cancer (American Cancer Society, 
2014). Globally, it ranked as the fifth killer from cancer overall with 458, 000 
deaths recorded in 2008. However, breast cancer is still the most common cause 
of death in women worldwide, with 189, 000 deaths in the developed regions 
and 269, 000 deaths in the less developed regions (GLOBOCAN, 2008). 
In Asia, the rates of breast cancer are lower compared to the Western 
countries. The incidence rates of breast cancer in the Asian region varied from 
15 to 50 per 100, 000 population based on a report by the International Agency 
for Research on Cancer in 2007 (Curado et al, 2007). The “more westernized” 
areas in Asia such as Singapore, Japan and Hong Kong recorded highest 
incidence rates whereas India, Korea and Thailand had the lowest rates in 2007 
(Curado, 2011). Despite the lower incidence rates, breast cancer is still the 
commonest cancer and cause of cancer-related deaths in Asian women (Curado, 
2011). 
In Malaysia, 3738 new cases of breast cancer were recorded in 2003 
based on the National Cancer Registry (NCR) with age standardized incidence 
rate (ASR) of 46.2 per 100, 000 women. An estimate of 1 in every 20 women in 
the country has risk of developing breast cancer throughout their lifetime. The 
ASR in the Chinese population is the highest, with 59.7 per 100, 000 population, 
and this is followed by the Indians and the Malays, with ASR of 55.8 per 100, 
000 population and 33.9 per 100, 000 population respectively. Approximately 1 
in 16 Chinese, 1 in 16 Indian and 1 in 28 Malay women has the risk of 
developing breast cancer throughout their lives (Lim and Halimah, 2003). 
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According to the National Cancer Registry, breast cancer is ranked number one 
among the top ten cancers in Malaysia in 2007 with the incidence of 3292 cases 
diagnosed (18.1% of all cancers). It accounted for 32.1% of all female cases 
diagnosed with cancer. It is the commonest cancer among Malaysian women, 
regardless of their ethnic origin and is also the most common cause of cancer-
related deaths among women in this country. The Chinese has the highest 
incidence rate with the age standardized incidence rate (ASR) of 38.1 per 100, 
000 population, and this is followed by the Indians with the ASR of 33.7 per 
100, 000 population. The lowest incidence of breast cancer is observed in the 
Malays with the ASR of 25.4 per 100, 000 population. The most susceptible age 
group for breast cancer among Malaysian women are seen in between 50 to 59 
years (National Cancer Registry, 2007). 
Based on an epidemiological study of breast cancer conducted in 
University Malaya Medical Centre (UMMC), the commonest age of 
presentation is between 40 to 49 years among women in the country. Women 
below the age of 50 years represented just over 50% of the cases, 16.8% below 
40 years and 2% below 30 years of age (Yip, Taib and Mohamed, 2006). From 
1993 to 2004, presentation at the early stages (Stages 1 and 2) of the disease was 
seen in about 60-70% of women and 30-40% presented with advanced stages 
(Stages 3 and 4) of breast cancer. Lump in the breast through breast self-
examination was the most common presenting complaint which is over 90% of 
the cases. The average tumour was 4.2cm. Malaysian women who were 
symptomatic waited for 3 months prior to seeking professional medical advice 
on the average. Malays were the highest presenting with advanced stage of the 
disease, with 40% reported to be in Stage 3 and 4 at the time of diagnosis. This 
was followed by the Indians, 20% and the Chinese, 15%. Malaysian women 
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presents at later stages of the disease compared to the Western countries, where 
more than 80% of women presented with early stage of breast cancer and 
smaller tumour size with the mean diameter of 2.0 cm resulting in poorer 
outcome (Yip, Taib and Mohamed, 2006). The latest data based on the NCR 
showed that 58% presented at Stage 1 and 2 of the disease and 42% presented at 
an advanced stage (Stages 3 and 4) in the year 2007 (National Cancer Registry, 
2007). Infiltrating ductal carcinoma is the commonest histological type of breast 
cancer seen in Malaysian women in both age groups of below and above 50 
years (Sheikh et al, 2012).   
 
2.2 SURVIVORSHIP OF BREAST CANCER 
 
Prevention, early detection and improvements in breast cancer treatments 
have led to positive changes with regards to the prognosis, outcome, and 
survivor of breast cancer patients. Breast cancer survivor was defined differently 
in the literatures. As an example, breast cancer survivor used to define only 
those patients who were in remission for at least 5 years after being diagnosed. 
The term has now evolved to be more comprehensive which include anyone 
who has been diagnosed with the illness until death which includes those who 
are asymptomatic or those living with recurrence of the illness (Ganz and Hahn, 
2008; Hewitt, Greenfield and Stovall, 2005; Pagani et al, 2010). In 2009, there 
were at least 2.4 million breast cancer survivors in the United States (Katz et al, 
2009). The number of survivors had increased to an estimate of 2.8 million in 
2013 based on the report produced by the American Cancer Society. The 10 
year-survival rate for breast cancer patients from a hospital based study 
conducted in Nottingham Hospital was reported to have improved from 55% to 
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77% recently (Blamet et al, 2007).  Globally it is reported that there are 4.4 
million breast cancer survivors living 5 years after the diagnosis of the illness 
(Epplein et al, 2011). The number of survivors is reported to be on the rise 
(Hickey et al, 2009). 
The survival of breast cancer patients depends on many factors. The 
essential prognostic factors determining the survival of patients with breast 
cancer are tumour stage at the point of diagnosis, tumour size, menstrual status 
and the histopathology of the cancer itself. The population structures which 
consist, the population age structure and ethnicity, socioeconomic background, 
the availability of an effective health care system and accessibility to high 
quality treatment are amongst other factors that could have influenced the 
survival of breast cancer patients (Hortobagyi et al, 2005; Tan et al, 2007). 
In a study conducted in University Malaya Medical Centre (UMMC), the 
overall 5 year survival rate was 59.1% among 413 patients diagnosed with breast 
cancer between 1993 to 1997 (Taib et  al, 2008). A retrospective cohort study 
conducted in Hospital Kuala Lumpur, Malaysia, indicated that the overall 
survival rate was the lowest in the Malay ethnic group with 39.7%, followed by 
the Indians and the Chinese, with survival rates of 47.2% and 48.2% 
respectively. Other factors that were accounted for poor survival identified in 
this study are larger tumour size, lymph node involvement, HER 2 and ERPR 
status, both breasts involvement and delayed presentation (Ibrahim et al, 2012). 
A study involving 166 breast cancer patients who were followed up for a period 
of 18 and 34 months in University Malaya Medical Centre (UMMC) found the 
mortality rate of 20.7% and recurrence rate of 10.3% (Yip and Looi, 1996). 
Based on a report produced by the International Cancer Screening Network, the 
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annual breast cancer mortality rate for Malaysia was 14.7 per 100, 000 
population in 2008. 
A more recent population-based retrospective cohort study conducted in 
Malaysia involving breast cancer patients who were diagnosed with the disease 
between the year 2000 to 2005, reported that the overall 5-year survival rate was 
49.4%. The median survival time for the 10, 230 breast cancer patients recruited 
into the study was 68.1 months. Indian women have the highest 5-year survival 
rate of 54.2%, and this is followed by Chinese women with the survival rate of 
49.1%. Malay women reported the lowest 5-year survival rate of 45.1% among 
the 3 main ethnics in Malaysia. The study also demonstrated that younger 
women aged less than 50 years have a significantly better survival compared to 
those aged above 50 years (Abdullah et al, 2013). 
Based on the National Cancer Institute’s Surveillance, Epidemiology, 
and End Results (SEER) database 2003-2009, 61% of patients were diagnosed 
with localized breast cancer, 32% with regional spread, 5% distant spread and 
2% unknown or unstaged breast cancer. The 5-year survival for localized breast 
cancer is 98.6%, and this is followed by regional spread and unstaged breast 
cancer, with 84.4% and 50.0% respectively. Distant spread has the lowest 5-year 
survival of 24.3% (Howlader, 2012). In another study conducted in Izmir, 
Turkey, out of 1786 patients with breast cancer recruited from 1995 to 2008, the 
average survival was 36.98 months with a maximum of 168 months. The overall 
survival rate for the first 5 years was 90%, and 77% after 14 years of diagnosis. 
Early-stage patients have a higher survival rate compared to the advance-stage 
patients. Stage I have been reported to have the highest 5-year survival rate of 
98%, and this are followed by Stage IIa with 93%. The lowest overall survival 
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rate was seen in Stage IIIb with 93%. The same observation was also made in 
the 14-year survival rate with 94% for Stage I, 84% for Stage IIa, 64% for Stage 
IIb, 74% for Stage IIIa, and 64% for Stage IIIb (Gokce, Karadogan and Akçay, 
2011). 
Local recurrence of breast cancer is defined as “a tumour that occurs in 
the original tumour bed (from residual cells) that has the same histopathologic 
features as the primary tumor” (Odle, 2011). The local recurrence rate for breast 
cancer is in between 1% to 2% per year (Usmani et al, 2010). Depending on 
cancer and treatment type, a woman with history of breast cancer has 7% to 30% 
risk of recurrence and a 45% to 90% risk of distant metastases (Pan et al, 2010). 
Despite the increase in the number of survivors, breast cancer is still the 
commonest cause of cancer death in women worldwide. An estimation of 
around 458, 500 female deaths in 2008 is related to breast cancer or nearly one 
in seven of all cancer deaths in women. Eastern Asia has the lowest female 
breast cancer mortality rates while Southern and Western Africa have the 
highest, with an around three-fold variation in the mortality rates between the 
regions of the world (Ferlay et al, 2008). 
 
 
 
 
 
 
 
 
 
 12 
 
2.3 SEXUALITY AND SEXUAL FUNCTION IN BREAST CANCER 
 
 Sexuality is an important aspect of life. It involves a complex interaction 
between the physical, psychological, interpersonal, and behavioural aspects of a 
person (National Cancer Institute, 2013). Sexuality is subjective and has a wide 
range of normality. The factors that have important roles in the determination of 
sexuality by individual patient and his/ her spouse are sex, age, personal 
attitudes, and religious, and cultural background (National Cancer Institute, 
2013). “Sexuality is a personal expression of one’s self and one’s relationship 
with others” (Pelusi, 2006). “Sexuality encompasses feelings about one’s own 
body, the need for touch, interest in sexual activities, communication of one’s 
needs to a partner, and the ability to engage in satisfying sexual activities” 
(Henson, 2002). Factors that are important in ensuring healthy sexuality are 
women’s perceptions, different gender roles and feelings of femininity 
(Wilmoth, 2001).  In contrast, sexual functioning involves desire, arousal, 
lubrication and orgasm. Sexual health is defined as “the ongoing process 
towards physical, psychic and socio-cultural well-being connected with 
sexuality” (World Health Organization and Sexology, 2000). Sexuality and 
sexual functioning are closely related to each other. Different types of cancer 
could cause sexual dysfunction. It is also a common adverse effect of cancer 
treatments, with an estimate of 40% to 100% after various cancer therapies 
(Derogatis and Kourlesis, 1981).  
Breasts are considered as erogenous part of the body and play an 
essential role in the female sexuality. The diagnosis of breast cancer threatened 
women’s normal femininity by affecting their sense of self, body image and 
emotional health (Gibert, Ussher, and Perz, 2010; Spence, 1995; Young, 1992). 
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Patients with breast cancer and its treatment alone could have a tremendous 
influence on woman’s sexuality. The changes to sexual function and health can 
potentially be the most troublesome areas of life after breast cancer even 
following successful treatment of the disease (Anderson, 2009; Bertero et al, 
2007; Burwell et al, 2006). It is also often associated with serious physical and 
psychological consequences (Langellier and Sullivan, 1998). Women with 
breast cancer have reduced sexual satisfaction and struggled to maintain their 
sexual life when compared to their same-aged healthy counterparts (Speer et al, 
2005).  
The specific sexual well-being disturbances experienced by breast cancer 
survivors are pain, fatigue, reduced vaginal lubrication, nausea, hot flushes, 
night sweats, vomiting, vaginal irritation, painful sexual intercourse, reduced 
sexual libido, vaginal atrophy, reduced sexual arousal, numbness in previously 
sensitive breasts and problems with orgasm (Avis, Crawford and Manuel, 2004; 
Fobair et al, 2006; Ganz et al, 1998; Ganz et al, 2003; Knobf, 2001; Wilmoth, 
2001). Archibald et al (2006) found that some survivors of breast cancer had 
positive changes with regards to their sexuality after the disease. On the contrary 
to this finding, most literature concluded that women with breast cancer 
experience a spectrum of psychological adverse effects, such as depression and 
anxiety (Garussi and Faezee, 2008). These women also experience changes in 
their sexual self (Wilmorth, 2001). In an online survey conducted in Australia, 
1259 women with breast cancer participated by answering an open-ended 
question asking about subjective experience of alterations to sexual health after 
breast cancer. The commonest concerns identified are those related to 
psychological disturbances, physical changes, perceptions of themselves as 
being unattractive or less feminine, self- acceptance of changes, concerns related 
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to spouse or relationship, and spousal support and relationship improvement 
(Ussher, Perz and Gilbert, 2012). 
 
2.4 PREVALENCE OF SEXUAL DYSFUNCTION IN BREAST CANCER 
SURVIVORS 
 
 Sexual dysfunction is commonly related to different types of cancer and 
cancer treatments. Sexual dysfunction is defined as “a lack of healthy/ expected/ 
normal, sexual response/ interest where psychological, biological, 
interpersonal, and contextual factors may contribute” (Basson et al, 2003). 
Sexual dysfunction after various cancer therapies is estimated to be in the range 
of 40% to 100% across sites (Derogatis and Kourlesis, 1981). Surgery, 
chemotherapy, radiotherapy and hormonal therapy are treatment modalities 
available for breast cancer. Sexual dysfunction is a recognized complication of 
breast cancer therapy that can affect women regardless of their menopausal 
status and their quality of life. Sexual function can be affected by consequences 
of breast cancer therapies such as sex hormone deficiency (Buijs et al, 2008; 
Joly et al, 2000; Meyerowitz et al, 1999; Schover, 2008) or by changes in body 
image (Arora et al, 2001; Janz et al, 2005).  The commonest sexual problems 
experienced by women with cancer are decreased sexual desire, painful sexual 
intercourse, changes in genital sensation secondary to pain or loss of sensation 
and numbness, and difficulties in achieving orgasm (Schover, Montague and 
Lakin, 1997). These problems can cause sexual dissatisfaction secondary to pain 
and frustration, also leading to decreased frequency of sexual activity (Bre´dart 
et al, 2011). Even though it is considered as a common adverse effect of the 
disease itself and its different treatment modalities, sexual dysfunction is among 
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the least talked about issues in cancer survivors (Dizon, 2009). Sexual disorders 
do not only occur during treatment of breast cancer but also persist after 
completion of treatment (Katz, 2011). Hence, this could possibly explain the 
high prevalence (90%) of sexual dysfunction observed in women with breast 
cancer, with some studies reporting that almost all women experience some 
form of sexual complaints after therapy of breast cancer (Krychman, 2006). 
 In a survey conducted involving 509 women with breast cancer at 
different stage of the disease and receiving therapy, 76% of the respondents 
experienced sexual dysfunction attributed to breast cancer or its therapies, 
defined as a Female Sexual Function Index (FSFI) score < 26. Majority of these 
patients (79%) perceived their sexual symptoms to be bothersome. 51% reported 
moderate or severe levels of bother with a FSFI score of 5 and less (Goldfarb et 
al, 2009). In a separate study conducted in France involving 378 breast cancer 
survivors (BCS), the prevalence of sexual problems were found to be 
significantly higher in BCS than the adjusted data from a French female 
representative sample (p< 0.0001). These include differences in frequency of 
sexual intercourses in the past month, dyspareunia, problems with sexual libido, 
and difficulty with regards in reaching orgasm (Bre´dart et al, 2011). 
Based on another research done, long-term sexual dysfunction is seen in 
about 50% of women with breast cancer (Ganz et al, 1998). The similar 
proportion was also observed in women who have had gynaecological cancer 
(Andersen, 1995). In a prospective cohort study carried out in Seoul National 
University Bundang Hospital (SNUBH) involved 191 breast cancer patients who 
had undergone surgery, more moderate to severe problems with sexual desire 
(30.1%, 27.7%, and 26.0% vs. 17.5%) and sexual activity (13.3%, 12.7%, and 
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11.4% vs. 6.0%) at 3, 6, and 12 months following breast cancer surgery were 
reported among these women compared with the pre-treatment levels. Sexual 
interest or desire, that was assessed by the Beck Depression Inventory item 21 
(BDI 21), and also sexual activity, as assessed by the Disability of the Arm, 
Shoulder, and Hand item 21 (DASH 21) demonstrated significant deterioration 
at each follow up post-surgery compared with pre-treatment data (p<0.001 in all 
cases for both) (Yang et al, 2011).  
A cross-sectional survey of breast cancer outpatients was conducted in 
Japan in 2005. The data from 85 patients, who were sexually active before breast 
cancer operation and were without recurrence were analysed. Although 73 
patients had resumed sexual activity after surgery, 43 recorded a decrease in the 
frequency of sexual activity. Majority (72 women) reported at least one sexually 
related changes, which includes decreased sexual interest, hesitation to be naked 
in front of partner, reduced sexual pleasure, physical distress described as 
pressure to the chest during sexual intercourse, dyspareunia, and uncomfortable 
sensation when touched at the surgical scar (Takashi et al, 2008).  A qualitative 
and quantitative online survey conducted in Australia found that the majority of 
the 1956 participants with breast cancer (98% were women) recorded a 
reduction in frequency of sex (78%), energy for sex (76%), sexual arousal 
(74%), feeling desirable (73%), sexual libido (71%), sexual pleasure (64%), 
sexual satisfaction (62%), and intimacy (60%). The same study also identified 
fatigue (71%), vaginal dryness (63%), hot flushes (51%), and feeling 
unattractive (51%) were the most frequent areas of breast cancer or breast cancer 
therapies that were thought to have an impact on sexual health (Ussher, Perz and 
Gilbert, 2012). 
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2.5 FACTORS ASSOCIATED WITH SEXUAL DYSFUNCTION IN BREAST 
CANCER SURVIVORS 
 
2.5.1 PATIENT’S AGE 
 
A French study involving 378 breast cancer survivors reported that 29% 
(109) of the subjects had absence of sexual activity at the time of the survey. 
Age more than 55 years was identified as a factor associated with no sexual 
activity or sexual dissatisfaction based on univariate analysis conducted on the 
total sample in the same study. Age of greater than 50 years was also associated 
with reduced frequency of sexual activity, reduced sexual pleasure (Sexual 
Activity Questionnaire (SAQ)- Pleasure sub-scale), or greater sexual discomfort 
(SAQ- Discomfort sub-scale) in 268 women reporting current sexual activity 
(Bre´dart et al, 2011).  
Speer and colleagues conducted a study among 55 breast cancer 
survivors (BCS) who were not having recurrence and who had completed their 
initial breast cancer therapy, which found that women who were more than 70 
years old have very low sexual functioning scores based on the Female Sexual 
Function Index (FSFI) used. The amount of lubrication and sexual pain 
experienced by BCSs were related to age (Speer et al, 2005).  
Another study done in Sudan looked at sexual health issues involving 
100 breast cancer patients and 100 controls. The patients were at different stages 
of breast cancer and had undergone different cancer treatment options. Out of 
the 100 patients, 60 patients had received hormonal therapy and were in the 
follow-up period, and 40 patients had yet to receive hormonal therapy and were 
having chemotherapy and/ or radiation therapy. Watts Sexual Function 
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Questionnaire was used in the outcome assessment.  A negative correlation (r= -
0.188, df= 98, p= 0.03) was found between sexual function and patients’ age 
(Abasher, 2009).  
 
2.5.2 STAGE OF CANCER 
 
A longitudinal study was conducted to look at the variations in sexual 
problems over time comparing women with early stage breast cancer and 
healthy controls. This study had involved 1033 participants of which, 17.3% was 
Stage 0, 33.4% was Stage I or IIA and 49.3% was healthy women. Four 
interviews were carried out at 4-6 months (T1), 6 months (T2), 1 year (T3), and 
2 years (T4) after surgery for breast cancer patients or a negative/ benign 
screening mammogram for the control group. This study reported that women 
with early stage breast cancer are more likely to experience problems related to 
sexual attractiveness compared to their healthy counterparts at the initial phase 
of the disease (4-6 months). Problems related to sexual attractiveness were 
reported less by these women as the time progresses (Pérez et al, 2010). 
In a different study, involving 191 newly diagnosed breast cancer 
patients, 60% of the sample indicated interruption in their sexual quality of life. 
Advanced stage of the disease was among the factors reported to lead to 
disruption in sexual quality of life among these women during breast cancer 
therapy (Beckjord and Campas, 2007). 
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2.5.3 MEDICAL COMORBIDITY 
 
Sexual functioning can be affected by chronic medical illness. 
Neurological, vascular, endocrinological, musculoskeletal, or psychological are 
the mechanism that maybe involved in the disturbances of sexual functioning 
(Nusbaum, Hamilton and Lenehan, 2003). Few, if any, chronic illnesses require 
limitation of sexual activity, even though sexual activity involves high physical 
demands (Kaplan, 1974; Kolodny, Masters and Johnson, 1979). Nevertheless, 
changes to sexual activity to accommodate physiological or mechanical 
limitations may be carried out by couples (Nusbaum, Hamilton and Lenehan, 
2003). Patients with chronic illness may not be interested in sex or may become 
sexually inactive because of misunderstandings about their capability to have 
sex or the safety of having sexual relations, or due to body image worries or 
grief related to the diagnosis of their illness (Carter, 1990). Treatments for 
chronic illnesses such as medications and surgery can also cause disruption in 
sexual functioning (Nusbaum, Hamilton and Lenehan, 2003) 
Bre´dart and colleagues (2011) had carried out a research to examine the 
prevalence and determinants of sexual activity, sexual difficulties, and sexual 
satisfaction in French breast cancer survivors (BCSs). The participants consisted 
of 378 women, with early-stage breast cancer, post-treatment of 6 months to 5 
years, aged 18-70 years, and they were randomly chosen from an appointment 
list. They filled in questionnaires assessing the quality of life (EORTC QLQ-
C30 and QLQ-BR23), body image scale, and sexuality (Sexual Activity 
Questionnaire- SAQ, Relationship and Sexuality Scale, and French Sexual 
Behaviour Scale- CSF). Presence of concomitant disease(s) was among the 
factors identified to be associated with no sexual activity or sexual 
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dissatisfaction in BCSs who participated in the research using univariate 
analysis (Bre´dart et al, 2011).  
 
2.5.4 SURGICAL INTERVENTIONS 
 
Surgery is one of the treatment modalities available for treatment of 
breast cancer. In a prospective study carried out in Morocco, 120 patients who 
were diagnosed with breast cancer from a medical oncology department at 
University Military Hospital of Instruction at Rabat were enrolled into the study. 
Female Sexual Function Index (FSFI) was used to examine sexual functioning in 
the subjects. A total of 80 patients (66.5%) had undergone radical mastectomy 
and 40 patients (33.5%) had breast conserving surgery (BCS).  Majority of the 
subjects (91.5%) reported an absence of sexual dysfunction before the diagnosis 
and therapy of breast cancer. However, of these, 100% indicated deterioration of 
the symptomatology after various treatment modalities. In this sub-sample, 78% 
has reported that they had no previous history of sexual dysfunction prior to the 
cancer treatment. Of the sexual dysfunctions, 9% was observed after surgery 
(Sbitti et al, 2011). 
Of 186 women with Stage I or II breast cancer who have had 
lumpectomy, 57% reported lubrication disorder, 53.8% were dissatisfied with 
their sexual health, desire disorder in 42.5%, and arousal disorder in 37.0% (all 
patients vs. 204 healthy controls p< 0.01). This study indicated that 
lumpectomized breast cancer women experienced significantly marked 
difficulties in their sexual functioning (Safarinejad, Shafiei and Safarinejad, 
2013). 
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Biglia and colleagues (2010) conducted a study involving 35 women 
with a premenopausal diagnosis of breast cancer who are waiting for adjuvant 
treatment. They were assessed at baseline which is during first follow up post-
surgery (T0), then post chemotherapy or at least 6 months of hormonal therapy 
(T1), and after a year (T2). The participants completed validated scales on 
menopausal symptoms, sexuality, partner relationship, depression, body image, 
and cognitive functions. The types of surgery that the participants had 
undergone are lumpectomy (91.4%), mastectomy (8.6%), sentinel lymph node 
(51.4%), and axillary dissection (48.6%). Half of the participants had McCoy 
Female Sexuality Questionnaire (MFSQ) scores below the normal range already 
at baseline. The mean score related to the sexuality domain was significantly 
impaired after 1 year of follow-up (-12.7, p= 0.022) (Biglia et al, 2010). 
In a study carried out by Pérez and colleagues,  patients with mastectomy 
(35.7%) have 2.7 times greater odds to report sexual difficulties on the 9 items 
measuring sexual interest, sexual attractiveness, and ability to enjoy sexual 
relations (arousal, dyspareunia/ discomfort, orgasm, and satisfaction) at 2-year 
follow-up compared to baseline (p= 0.0339) (Pérez et al, 2010). Patients who 
had undergone mastectomy also were reported to have low sexual desire and 
were only slightly satisfied with their sex life in a different study involving 123 
Turkish patients who had mastectomy (Karabulut, 2009). 
A prospective study involving 223 women with early-stage breast 
cancer, found that on average, women who had undergone breast conserving 
therapy (BCT), had lower quality of sexual life (QOSL) scores compared to 
those who had mastectomy. Women who had mastectomy also had higher 
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sexual functioning (SF) scores than to those who had undergone BCT (Den 
Oudsten et al, 2010). 
On a contrary, a study conducted in Turkey involving 75 breast cancer 
survivors (50 patients received total mastectomy alone and 25 had total 
mastectomy and breast reconstruction surgery), and 50 healthy controls, found 
that the type of surgery has no effect on sexual satisfaction as indicated by 
similar mean scores of the Golombok Rust Inventory of Sexual Satisfaction 
(GRISS) between the three groups (Elbi Mete, Noyan and Alper, 2004). This 
finding is further supported by another study done in Korea involving 191 
women diagnosed with breast cancer who were interviewed at baseline (prior to 
surgery), and then at 3, 6, and 12 months follow up post-surgery. Among the 
domains assessed in the survey are sexual desire, sexual activity, sexual 
satisfaction, sexual attractiveness, body image, medical illness, symptoms of 
upper limb dysfunction, and socio-demographic data. 60.2% (115 patients) had 
undergone conservative surgery (CS), whilst 39.8% (76 patients) had undergone 
extensive surgery (ES). The type of surgery had no significant effect on the 
sexual health (Burwell et al, 2006; Ganz et al, 1992; Yang et al, 2010). 
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2.5.5 CHEMOTHERAPY 
 
A woman’s physical and psychological health can be seriously affected 
by chemotherapy, which may affect the quality of life (Arora et al, 2001; Kaplan 
1992; Lindley et al, 1998; Makar et al, 1997). Longstanding impairments in 
sexual functioning have been associated with chemotherapy (Dorval et al, 1998; 
Dow et al, 1996; Ganz et al, 1998; Ganz et al, 1996; Young et al, 1996). 
Sexuality can be affected by chemotherapy directly, through gonadal and 
hormonal changes, or indirectly, by inducing feelings of fatigue, apathy, nausea, 
vomiting and malaise, and sleep or appetite changes that lead to interruption of 
sexual libido (Kaplan, 1992). 
Researches that investigated the effects of adjuvant chemotherapy on the 
quality of life have reported significant impacts on sexual dysfunction (Alfonso 
et al, 1997; Arora et al, 2001; Dorval et al, 1998; Dow et al, 1996; Ganz et al, 
1998; Ganz et al, 1996; Kaplan, 1992; Lindley et al, 1998; Makar et al, 1997; 
Rose and Davis, 1980; Wilmoth and Ross, 1996; Young, 1996). These include 
dyspareunia, vaginal dryness, impaired sexual activity, and reduced libido 
(Lindley et al, 1998; Makar et al, 1996; Wilmoth and Ross, 1996; Young, 1996).  
Previous literature had identified that between 50-60% of women with 
breast cancer who had completed chemotherapy experienced sexual dysfunction 
past 12 months post treatment (Curran et al, 1998; Lindley et al, 1998). In a 
separate study involving 120 Moroccan women with breast cancer, as high as 
90% of the participants reported sexual dysfunction after chemotherapy (Sbitti et 
al, 2011). 
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A longitudinal Korean study involving 191 women with breast cancer 
found that chemotherapy cause changes in sexual desire and sexual activity only 
at the early stage post therapy (p <0.05) (Yang et al, 2011). A recent systemic 
review of literature investigating the changes in sexuality after breast cancer 
reported that women who had undergone adjuvant chemotherapy are at 
increased risk for sexual dysfunction compared to those who had not received 
such treatment. Disorders of arousal, lubrication, orgasm, and dyspareunia were 
most significantly associated with the sexual dysfunction observed (Emilee, 
Ussher and Perz, 2010).  
A study observed that patients who undergone surgery (lumpectomy or 
mastectomy) followed by chemotherapy had higher rates of reporting an adverse 
effect on their sex life, with 48% for lumpectomy and 51% for mastectomy. The 
patients who had surgery only, reported rates of 18% and 25% for lumpectomy 
and mastectomy respectively (Ganz et al, 2004 and 2005). 
Women who received high doses of chemotherapy are at greater risk of 
developing sexual dysfunction compared to those who received conventional 
doses (Arora et al, 2001; Makar et al, 1997). Women who became menopausal 
secondary to chemotherapy experienced more prominent changes in sexual 
functioning after chemotherapy (Curran et al, 1998; Ganz et al, 1998; Young, 
1996). 
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2.5.6 RADIOTHERAPY 
 
Among short-term side effects of adjuvant radiotherapy to the breast are 
breast tenderness and skin redness. These side effects have no significant impact 
on sexual functioning in breast cancer patients (Kissane et al, 2004). Sexual 
function was significantly less affected by radiotherapy as the primary adjuvant 
treatment when compared to adjuvant chemotherapy as reported by multiple 
studies (Beckmann et al, 1983; Carroll, 1991; Cohen, Kahn and Steeves, 1998; 
Dunn et al, 1998; Greer and White, 1977; Lasry et al, 1987; Meyer and 
Aspegren, 1988; Morris et al, 1980; Rosenqvist, Sandelin and Wickman, 1996; 
Steginga et al, 1998; Wellisch et al, 1989). 
There were no literature found that indicated extensive increases in 
psychosexual problems after radiation therapy (Kissane et al, 2004). A study 
reported 75% of women who chose primary radiation therapy before surgery had 
unchanged or good sexual quality of life (Lasry et al, 1987).  
In another study involving 120 Moroccan diagnosed with breast cancer, 
dyspareunia (65%) is the commonest sexual dysfunction reported. Problems 
with lubrication are seen in 54% of women and the absence or reduction of 
sexual libido (48% and 64%, respectively).Orgasmic problems (40%), sexual 
dissatisfaction (37%), short duration of intercourse and arousal (38%) were seen 
in about one third of the participants. Before the diagnosis and treatment of 
breast cancer, sexual dysfunction were absent in 91.5% of women and 
worsening of the symptoms after breast cancer therapies were seen in all of these 
patients. Sexual dysfunction was reported in only 3% of the women receiving 
radiotherapy (Sbitti, 2011). The incidence of sexual dysfunction after 
radiotherapy was also reported being as low as 6% (Barni and Mondin, 1997). 
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2.5.7 HORMONAL TREATMENT 
 
Hormonal treatment are divided into non-steroidal anti-oestrogens 
(tamoxifen, toremifene, droloxifene, and raloxifene), steroidal anti-oestrogens 
(faslodex), luteinizing hormone-releasing hormone agonists (goserelin), 
selective aromatase inhibitors (anastrozole, letrozole, vorozole, formestane, and 
fadrozole), progestins (medroxyprogesterone acetate), and androgens/ 
antiandrogens (Buzdar and Hortobagyi, 1998). The most common side effects 
observed are hot flushes, increased weight, nausea, fatigue, and vaginal 
bleeding, discharge or irritation. Rate of thromboembolic events is 1% and the 
risk for endometrial cancer is 2 cases per 1000 patients yearly with tamoxifen 
(Buzdar and Hortobagyi, 1998). 
Tamoxifen has been the most frequently researched. Although anecdotal 
reports describe tamoxifen both increases and decreases sexual desire, these are 
very rare events occurring (Barni and Ardizzoia, 1998; Leonard, Lee and 
Harrison, 1996). The National Cancer Institute (NCI) conducted a large survey 
on sexual functioning involving American breast cancer survivors with an 
average of three years post diagnosis. Nearly half of the participants were 
presently on tamoxifen. Tamoxifen did not significantly affect sexual 
functioning (Ganz et al, 1998). 
A cross-sectional study involving 85 Japanese women with breast cancer 
also found that there were no statistically significant correlations between 
having a history of hormonal therapy with reduced sexual libido, reduced sexual 
pleasure, and dyspareunia (Takahashi et al, 2007). This finding was further 
supported by a Moroccan study where none of the subjects on hormonal therapy 
reported problem in their sexual function (Sbitti, 2011). 
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2.5.8 BODY IMAGE 
 
“Body image is deﬁned as the mental picture of one’s body, an attitude 
about the physical self, appearance, and state of health, wholeness, normal 
functioning, and sexuality. Body image is a component of a larger concept of 
self that for women includes feeling feminine and attractive (Carver et al, 1998; 
Cohen et al, 1998; Hopwood, 1993; Mock, 1993; White, 2000) enjoying one’s 
body as a symbol of social expression, and as a way of being in the world” 
(Cohen et al., 1998). Higher levels of self-confidence in coping with breast 
cancer are seen in women with positive body image perceptions (Pikler and 
Winterowd, 2003). Sexual function can also be affected by psychological 
responses to cancer through mood and body image changes and disturbances in 
established patterns of achieving physical pleasure and intimacy (Fobair et al, 
2006; Frierson et al, 2006).  
Lam and colleague (2012) conducted a study to examine the degree and 
factors associated with change in body image and sexuality throughout the first 
year after breast cancer diagnosis. A total of 363 Chinese women undergoing 
surgery for breast cancer were assessed at baseline, 1 month, 4 months, and 8 
months post-surgery. The modalities that were assessed at baseline were 
psychological disturbances, treatment decision making (TDM) difficulties, 
satisfaction with outcome of therapy, optimism, and self-efficacy. Self-image 
and sexuality was assessed at every follow-up. A total of 211 out of the 363 
original participants were successfully traced and assessed 6 years later. High-
stable, recovery, and high-deteriorating were the different trajectories of self-
image and sexuality recognized from the study. Stable levels of self-image and 
sexuality scores were seen in most women (64% self-image; 58% sexuality). 
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Those with high-stable level of self-image had the best 6-year self-image and 
sexuality. High and stable self-image and sexuality were indicated by low TDM 
difficulties and high treatment outcome satisfaction. 
In a Danish study involving a total of 214 patients who were treated with 
breast conserving therapy (BCT), among the participants, 15% reported 
reduction in femininity, 25% experience reduction in sexual attractiveness, and 
28% of patients had changed their dressing habits secondary to the disease or 
breast cancer therapy (Lyngholm et al, 2013). 
Fobair and colleagues (2006) carried out a study involving a sample of 
549 women who were assessed seven months of diagnosis with breast cancer (in 
situ, local, or regional). The study observed that half of the participants reported 
body image issues, with 33% had two or more body image issues some of the 
time, and 17% at least one problem much of the time. Out of the 360 sexually 
active women, half (52%) experienced a little problem in two or more areas of 
sexual functioning (24%), or a definite or serious problem in at least one area 
(28%). This study also showed the association between body image problems 
and sexual difficulties faced by women with breast cancer (Fobair et al, 2006). A 
Korean study also identified that low perceived sexual attractiveness early post-
surgery was associated with higher overall sexual problems (Yang et al, 2011). 
Similar finding was also observed in the research conducted by Bre´dart and 
colleagues (2012). 
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2.5.9 MENOPAUSE 
 
Menopause is a sequel of surgical removal of the ovaries or the adverse 
effect of chemotherapy, which can disrupt ovarian function, leading to 
anovulation and impairment in fertility (Kissane et al, 2004). Reduction in 
oestrogen levels and the classical symptoms of vaginal dryness, and painful 
sexual intercourse are experienced by postmenopausal women, which may 
possibly lead to reduction of sexual activity (Hentschel, 2001), also seen in 
women treated for breast cancer (Couzi, Helzlsouer and Fetting, 1995).   
Women who do not experience pre-mature menopause post therapy for 
breast cancer were found to have better sexual functioning, with the presence of 
normal libido, sexual satisfaction and better marital adjustment (Ghizzani et al, 
1995). Interruption of normal ovarian function affects body image and sexual 
adjustment after adjuvant chemotherapy (Bines, Oleske and Cobleigh, 1996). 
Premature menopause was also the main association between chemotherapy and 
sexual dysfunction in other studies (Burwell et al, 2006; Schover, 1994). 
Based on a study conducted online involving young Dutch women (45 
years of age and less) with breast cancer, premature menopause has been found 
to have led to the occurrence of genital arousal disorder in the samples (Kedde et 
al, 2013). 
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2.5.10 MARITAL RELATIONSHIP 
 
Interruptions and changes in the daily living resulting from breast cancer 
diagnosis were described in a growing literature (Rowland and Massie, 2009). 
Marriage is an important element in the woman’s adaptation process to the 
diagnosis and therapy of breast cancer (Bloom et al, 2001). Treatment phase is a 
period when patients are at increased risk to develop psychological distress and 
in great need of support. A study suggests that the relationship with their spouse 
is a very important source of support during this phase. Hence this provides a 
probable explanation for the strong associations observed between marital 
quality, intimacy, and women’s psychological quality of life (PQoL) (Moreira et 
al, 2011). 
Majority of women with breast cancer experienced body image and 
sexual problems at the initial phase after the diagnosis of the disease, with 
greater sexual and body image problems were associated with the partner’s 
difficulty in understanding the patient’s feelings (Fobair et al, 2006). 
Bre´dart and colleagues (2011) identified that no, and reduced frequency 
of sexual activity, sexual dissatisfaction, reduced sexual pleasure, and higher 
sexual discomfort were all associated with perceived emotional separation in the 
spouse or spousal fear of sexual intercourse among breast cancer survivors. 
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2.5.11 PSYCHOLOGICAL STATUS 
 
The diagnosis of cancer and its treatment do not only have physical 
impacts but also psychosocial and financial consequences surrounding it (Pumo 
et al, 2012). Patients diagnosed with cancer commonly experienced anxiety and 
depression, with double the risk of psychological problems compared to the 
general population (Hinz et al, 2010). Interruption in all angles of life, reduction 
in the patient’s coping capability to their illness, and interference with 
relationships, rehabilitation, and enjoyment of their remaining life span are 
among the consequences of untreated anxiety, depression, and sexual disorders 
(Pumo et al, 2012). 
Out of 167 breast cancer survivors enrolled in their study, Pumo and 
colleagues (2012) found that 72.4% of the participants reported psychological 
effects and sexual problems were identified in 65.9% of the participants. This 
study also noted an association between frequency of psychological problems 
and seriousness of sexual difficulties. Anxiety, depression, fear, and cognitive 
and affective disorders were the psychological problems experienced by the 
samples in this study. Young patients, those who were married, and those with 
low education were the factors associated with high psychological disorders 
(Pumo et al, 2012). 
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2.6 CONCEPTUAL FRAMEWORK 
 Figure 2.1 Conceptual framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sexual dysfunction 
Socio-demographic 
factors: Age, race, 
religion, education level, 
employment status, total 
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Disease factors: Age of 
illness onset, duration of 
illness, metastatic status, 
treatment modalities- 
surgery, chemotherapy, 
radiotherapy, hormonal 
therapy 
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Age of partner, 
duration of 
relationship 
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Menopausal 
status, medical 
comorbidity, 
body mass index 
(BMI), waist 
circumference 
BREAST CANCER 
Body image distress, marital 
dissatisfaction, psychological disorders 
(depression & anxiety) & health-related 
quality of life 
Socio-demographic, 
disease, clinical and 
marital factors (as 
listed above)  
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CHAPTER THREE 
 
RATIONALE AND OBJECTIVES 
 
3.1 RATIONALE OF THE STUDY 
 
Sexual well-being is a vital component of quality of life. Thus, its assessment is 
vital in order to be able to provide a holistic care for patients with breast cancer. 
History taking process should incorporate a short enquiry about sexual function 
for both, women who are newly diagnosed with breast cancer and also those 
who are attending regular follow ups. Time restrictions, deficiency in the health 
care providers’ training with regards to assessment of sexual function and issues 
related to it, or the uncomfortable feeling associated with discussing sexual 
issues commonly hinder both the physician and the patient in doing so. As a 
result, sexual problems amongst breast cancer survivors are often neglected even 
though it is a recognized adverse effect of the disease itself and also treatments 
for breast cancer.  
In Malaysia, there is lack of published data regarding sexual dysfunction among 
breast cancer survivors (BCS). We only have published data from other 
countries. As sexual satisfaction may be influenced by socio-religious values, 
this study is very important in providing the much needed baseline information 
regarding sexual dysfunction in BCS. This study will also determine the 
associated factors related to sexual dysfunction that will provide clues to those 
survivors who are at risk of sexual dysfunction. This study serves as a stepping 
stone towards a more relevant planning of an intervention program in order to 
provide a more comprehensive care for BCS. 
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3.2 GENERAL OBJECTIVE 
 
The aim of the study is to determine the prevalence of sexual dysfunction in 
breast cancer patients who are in remission attending follow-up at the breast 
clinic at the Department of Surgery in University Malaya Medical Centre 
(UMMC). 
 
3.3 SPECIFIC OBJECTIVES 
 
1. To determine the severity of marital dissatisfaction experienced by the 
survivors and its relationship with sexual dysfunction. 
 
2. To determine the severity of body image distress experienced by the 
survivors and its relationship with sexual dysfunction. 
 
3. To determine the significant associations of biological factors, psychosocial 
factors, disease-related factors, depression, anxiety, body image distress, 
marital dissatisfaction, and health related quality of life with sexual 
dysfunction in breast cancer survivors. 
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3.4 RESEARCH QUESTIONS 
 
  
1. What is the prevalence of sexual dysfunction in breast cancer survivors 
attending the outpatient follow-up at the breast clinic in UMMC? 
 
2. What are the factors associated with sexual dysfunction in breast cancer 
survivors attending the outpatient follow-up at the breast clinic in UMMC? 
 
3. What is the level of body image distress in these breast cancer survivors? 
 
4. What is the severity of marital dissatisfaction among these breast cancer 
survivors? 
 
5. What is the interaction between sexual dysfunction, body image distress and 
marital dissatisfaction in these breast cancer survivors?  
 
 
3.5 RESEARCH HYPOTHESES 
 
 
1. There is a difference of sexual function between breast cancer survivors 
(BCS) with body image distress and those without body image distress. 
 
2. There is a difference of sexual function between BCS experiencing marital 
dissatisfaction and those without marital dissatisfaction. 
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CHAPTER FOUR 
 
METHODOLOGY 
 
4.1 STUDY SETTING 
 
This study was conducted at the breast clinic in the Department of Surgery of 
University Malaya Medical Centre (UMMC). UMMC is a tertiary hospital and 
one of the organizations under the Ministry of Higher Education. UMMC is part 
of the University of Malaya (UM). It was founded in 1962 and is the first 
teaching hospital in the country which provides teaching and training of medical 
and paramedic staff to cater the health demands of the local population. Health 
services, learning, and research are the main objectives of UMMC. The hospital 
has 1200 beds equipped with modern medical facilities and is rapidly expanding 
to meet the health demands of the Klang Valley area. The Breast Unit in UMMC 
was started in 1993 which provides clinical services, teaching and training, and 
also conducts research activities. The breast clinic in UMMC provides 
multidisciplinary clinical services involving staff from various medical 
departments such as surgery, radiology, oncology, psycho-oncology, palliative 
medicine, pathology, breast care nurse, and rehabilitative medicine. Since it 
started in 1993, there were nearly 4000 patients who were registered in the 
UMMC Breast Cancer Database in the year 2009. 
UMMC is situated at the border of Kuala Lumpur and one of the densely 
populated town in the state of Selangor called Petaling Jaya. Kuala Lumpur is 
the capital of Malaysia with a population of 1.67 million people (Department of 
Statistics, 2010). Petaling Jaya is a city comprising mostly of residential areas 
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and some industrial areas with a population exceeding 600,000 people in 2010. 
Half of the population are Chinese, and this is followed by the Malays, and the 
Indians. UMMC serves as a health centre for both Kuala Lumpur and Selangor, 
especially for the community of Petaling Jaya. 
 
4.2 STUDY DESIGN 
 
This is a cross-sectional study involving patients who have been diagnosed with 
breast cancer and attended the follow-up at the breast clinic in UMMC. 
Convenience sampling was used in this study where every patient that fulfilled 
the inclusion criteria during the study period was invited to participate. 
 
4.3 PERIOD OF STUDY 
 
This study was conducted from August 2012 until December 2012 for the period 
of 4 months. 
 
4.4 STUDY POPULATION 
 
The subjects were the patients, diagnosed with breast cancer who attended 
follow-up at the breast clinic in UMMC during the study period. 
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4.5 INCLUSION CRITERIA 
 
1. Female breast cancer patients who attended breast outpatient clinics in 
UMMC. 
2. Patients aged 65 and below. 
3. Patients had a living spouse during enrolment into the study. 
4. Three months after any active treatment (surgery, chemotherapy, or 
radiotherapy) other than hormonal therapy. 
5. Patients who were able to give informed consent. 
6. Patients who were able to understand, read and communicate in English 
adequately well. 
 
4.6 EXCLUSION CRITERIA 
 
1. Patients who were single or spouse not staying together. 
2. Patients who were on chemotherapy or radiotherapy during enrolment into 
the study. 
 
4.7 DATA COLLECTION 
 
The patients with breast cancer were identified in the breast clinic at the 
Department of Surgery. Their medical notes were screened. Those who were 
qualified for the study will be approached to participate in the study. The 
selected patients were taken into a consultation room in the breast clinic 
individually to ensure their privacy as sexual matter is considered to be a private 
and sensitive matter to discuss. An explanation about the study was then given 
to the patients. Patients were reassured of the confidentiality of the information 
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given in this study. The Research Information and Patient Consent Form sheets 
were given to the patients. Informed consent was obtained if the patient agreed 
to be enrolled in the study. The socio-demographic data was recorded by the 
investigator based on the data sheets prepared. Her height, weight, and waist 
circumference were measured. The readings were than recorded on the Patient 
Data sheet. 
The patients were then given self-rated questionnaires- Female Sexual Function 
Index (FSFI), Breast Impact of Treatment Scale (BITS), Golombok Rust 
Inventory of Marital State (GRIMS), Hospital Anxiety and Depression Scale 
(HADS), and Psychological General Well-being Index (PGWBI). The 
questionnaires were all in English language to standardize the scoring of each 
scale. They were requested to answer the questionnaires independently. They 
were given privacy to answer the questionnaires and in their own time. The 
patients were allowed to ask clarification from the investigator when the 
language is a problem. The investigator provided assisted guidance on 
answering the questionnaire that would not in any way influence the patient’s 
selection of answers and introduce bias. Care was also taken not to cause much 
embarrassment to the patients and thus, prevented dishonesty in their answers. 
During the data collection, every patient who participated in the study was also 
given information about the walk-in psychiatry clinic that is available daily from 
Monday to Friday mornings. This was done as the investigator did not know 
which of these participants is experiencing difficulties in their marriage, sexual 
relationship or psychological problems, especially anxiety or depression that 
could possibly have detrimental effect on them. Apart from the participants, the 
doctors in the breast clinic were also reminded to routinely enquire about these 
issues during their consultation. All patients who were suspected to experience 
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difficulties were advised to be referred for expert assessment and further 
management. The doctors were also provided with the information about the 
walk-in psychiatry clinic available in UMMC. The clinical information was 
obtained by tracing the patients’ medical notes.  
Figure 4.1 below illustrated the flow chart of the subject recruitment process for 
the study. 
Figure 4.1 Flow chart of the subject recruitment process for the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The investigator screened the medical notes for 
eligibility. 
 
Explanation was given by the investigator and 
patients were provided with the Patient 
Information Sheet. Consent was obtained from the 
patients who agreed.  
Socio-demographic data and topometric 
measurements were taken by the investigator 
using the socio-demographic and clinical data 
sheet. 
Patients were given time and privacy to answer the 
questionnaires (FSFI, BITS, GRIMS, HADS & PGWBI) 
in a consultation room at the breast clinic 
individually. 
The investigator obtained the clinical information 
required from the medical notes. 
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4.8 SAMPLE SIZE 
 
The sample size for research question 1 was calculated by using the Sample Size 
Calculator for Prevalence Studies (Naing, Winn and Rusli. Sample Size 
Calculator for Prevalence Studies, Version 1.0.01): 
  Level of confidence = 95%      
  Expected prevalence, P = 0.75     
  Population size, N = 96      
  Precision, d = 0.05 
There is no published local study on sexual dysfunction in breast cancer 
survivors. In this study, the prevalence rate was taken as 76% based on a study 
conducted by Goldfarb and colleagues (2009). 
 Thus form the Sample Size Table: 
  Sample size, n = 73 (with Finite Population Correction)       
  An additional of 20% was added for non-respondents:  
  n = 73 + (0.2 x 73)       
  So, n = 88 breast cancer patients. 
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The sample size for research question 2 was calculated using the two proportion 
formula as below: 
n = P1(1 - P1) + P2(1 - P2)  (Zα + Zβ)
2
     
          (P1 - P2)
2
  
Where,           
P1 = 0.68 i.e. expected proportion of  females who have sexual 
difficulties (Philips, 2000)       
P2 = 0.30 i.e. proportion of females who have sexual difficulties in the 
general population (Philips, 2000)      
Zα = 1.96        
Zβ = 0.84 
Therefore, 
n = 0.68(0.32) + 0.30(0.70) (2.8)
2
 = 24    
         0.38
2
       
An additional of 20% was added for non-respondents:   
n = 24 + (0.2 x 24) = 28         
So, n = 28 x 2 = 56 breast cancer patients 
  For this study, a sample of 100 breast cancer survivors was taken. 
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4.9 INSTRUMENTS 
 
4.9.1 SOCIO-DEMOGRAPHIC AND CLINICAL DATA 
 
A set of data sheet was devised to collect information from the patients. The data 
sheet is divided into four parts. 
The first part is to obtain the identification and socio-demographic information 
such as the registration number, age, race, religion, employment status, 
educational background, and monthly household income. The second part of the 
data sheet is to gather marital information such as the partner’s age, duration of 
marriage, and presence of any marital problems.  
The third part is for the clinical information like the age at the onset of illness, 
duration of illness, clinical stage of the disease, treatment(s) that the patients has 
had or is having at the point of the study (surgery, chemotherapy, radiotherapy, 
or hormonal therapy), presence of any other medical comorbidity, presence of 
any metastasis of the disease itself, and menopausal status. The last part is to 
record the patients’ weight, height, body mass index, and abdominal 
circumference. 
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4.9.2 FEMALE SEXUAL FUNCTION INDEX (FSFI) 
 
The FSFI is a 19 self-administered items multidimensional scale for examining 
sexual function in women (Wiegel, Meston and Rosen, 2005). In a study 
conducted by Rosen and colleagues (2000), the scale was given to 131 normal 
controls and 128 age-matched subjects with female sexual arousal disorder 
(FSAD) involving five research centres. A total of 6 domains were identified, 
which consisted desire, subjective arousal, lubrication, orgasm, satisfaction, and 
pain. The scale recorded a high general test-retest reliability coefficients for each 
separate domains (r= 0.79 to 0.86). It also has a good internal consistency 
(Cronbach’s alpha values of 0.82 and higher). The scale also has good construct 
validity. In addition, divergent validity with a scale of marital satisfaction 
(Locke-Wallace Marital Adjustment Test) was also observed. These findings 
indicated that the FSFI is a valid and reliable clinical instrument in assessing 
female sexual dysfunction and also the specific domains related to it (Rosen et 
al, 2000). 
The scale has been cross-validated in 568 samples of women with mixed sexual 
dysfunctions. Out of the 568 participants, a total of 307 women has a mixed of 
sexual dysfunction diagnoses and 261 women were non-dysfunctional controls. 
The internal reliability for the total score and the six individual domain scores 
were found to be between good to excellent, with Cronbach’s alpha of > 0.9 for 
the combined sample and above 0.8 for the sexually dysfunction and non-
dysfunctional women. Discriminant validity testing concluded that the FSFI 
total score and the scores of its individual domains were able to differentiate 
those with female sexual dysfunction and those with normal sexual function. A 
total score of 26.55 on the FSFI scale were found to be the optimal cut-off 
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indicating the presence of female sexual dysfunction. This study identified that 
70.7% of women has sexual dysfunction based on this cut-off score and 88.1% 
of women with normal sexual function in the cross-validation sample were 
correctly identified (Wiegel, Meston and Rosen, 2005). 
Baser and colleagues (2012) have also conducted a study of psychometric 
validation of the FSFI in cancer survivors. The data from 3 separate institutional 
review board-approved studies of the psychosexual adjustment of women cancer 
survivors carried out at the Memorial Sloan-Kettering Cancer Center were 
combined. Psychometric analysis was done to the FSFI responses from 181 
women consisting of 4 cohorts, including survivors of gynaecological cancer (all 
types; 2 cohorts), malignancies requiring bone-marrow/ stem cell transplantation 
and early stage cervical cancer. The internal consistency reliability was 0.94 for 
the FSFI total score and ranged from 0.85 to 0.94 for the domain scores. The 
total score recorded a range from 0.44 to 0.79 and the domain scores recorded a 
range from 0.62 to 0.88 for the corrected item-total correlations. The FSFI 
exhibited strong psychometric properties and was a useful tool for evaluating 
sexual dysfunction, and cancer-related dysfunction in sexually active women 
with cancer (Baser, Li and Carter, 2012). 
The FSFI is divided into six domains, including desire, arousal, lubrication, 
orgasm, satisfaction, and pain. The scoring for the separate domains of the FSFI 
and full scale score is illustrated in Table 4.1 below. Attention should be given 
that within the separate domains, a domain score of zero indicates that the 
subject reported the absence of sexual activity during the past month. In this 
study, the cut-off total score of 26.6 (rounded to one decimal point) based on the 
study done by Wiegel and colleagues (2005), was taken to differentiate breast 
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cancer survivors (BCS) with sexual dysfunction and those without sexual 
dysfunction.   
FSFI has been translated to Malay language and its psychometric properties 
have been explored (Sidi et al, 2007). They found that for the Malay version of 
the FSFI, the cut-off score for a ‘case’ of female sexual dysfunction was 55 
which is not similar to the original version. Hence, this study intents to use the 
original FSFI. 
 Table 4.1 Domains, item cluster, and scoring of the FSFI 
Domain Item 
cluster 
Score 
range 
Factor Minimum 
score 
Maximum 
score 
Desire 
Arousal 
Lubrication 
Orgasm 
Satisfaction 
Pain 
1, 2 
3, 4, 5, 6 
7, 8, 9, 10 
11, 12, 13 
14, 15, 16 
17, 18, 19 
1-5 
0-5 
0-5 
0-5 
0(or 1)-5 
0-5 
0.6 
0.3 
0.3 
0.4 
0.4 
0.4 
1.2 
0 
0 
0 
0.8 
0 
6.0 
6.0 
6.0 
6.0 
6.0 
6.0 
  Full scale score 
range 
 2.0 36.0 
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4.9.3 BREAST IMPACT OF TREATMENT SCALE (BITS) 
 
The BITS was constructed from previous breast cancer studies examining the 
worries of women post breast cancer surgery (Frierson, Thiel and Andersen, 
2006). The authors offered a different conceptualization called the body change 
stress. Body change stress is defined as the subjective psychological distress, 
thoughts, and behaviours experienced by women following breast cancer and/ or 
breast surgeries. Body change stress is directly correlated to body dissatisfaction 
and the magnitude of body image (Zainal et al, 2013). Evaluation of more than 
50 items from various scales used in previous studies had generated the 13 items 
in the BITS. The BITS can be considered as a ‘gold standard’ tool as it includes 
body image satisfaction, sexual behaviour, sexual affects, and cancer-related 
thoughts and behaviour in respond to traumatic stress (Frierson, Thiel and 
Andersen, 2006). 
The BITS was translated to the Malay language. The Malay version of the BITS 
(MVBITS) was validated in a study involving 70 women with breast cancer who 
undergone chemotherapy in the Oncology Clinic of University Malaya Medical 
Centre (UMMC). The MVBITS has good reliability with internal consistency, 
Cronbach’s alpha of 0.945. The test-retest reliability after the 3-weeks interval 
was still high and stable (Zainal et al, 2013). However, the original English 
version of the BITS was used in this study. 
The BITS entails of 13 items, each item is scored in 4 points scale (0= not at all, 
1= rarely, 3= sometimes, and 5= often). The total score ranges from 0 to 65 with 
the cut-off point of 26. Higher score indicated more body change stress as the 
following: 0 to 25- mild, 26 to 43- moderate, and 44 and above- severe. The 
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internal consistency was between 0.84 to 0.91, and it has good validity 
(Frierson, Thiel and Andersen, 2006; Yurek, Farrar and Andersen, 2000). 
Table 4.2 Score range of the BITS and its interpretation 
Score range Interpretation 
0 to 25 
26 to 43 
44 and above 
Mild body change stress 
Moderate body change stress 
Severe body change stress 
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4.9.4 GOLOMBOK RUST INVENTORY OF MARITAL STATE (GRIMS) 
 
The GRIMS was developed based on the conceptual blueprint of marital 
discord. It assesses the overall quality of a couple’s relationship (Rust et al, 
1990). The items were generated based on specific areas of distress identified by 
both marital therapists and their clients (Rust et al, 1986). This was conducted 
among 57 couples who participated in a marital therapy study (Bennun, 1985). 
At the beginning, 183 items were generated, and this was narrowed down to 28 
items after a pilot study was conducted involving 60 couples (120 subjects) who 
attended marital therapy and marriage guidance clinic. The mean score on the 
scale for men was 46.88 (SD= 10.99), and for women was 42.66 (SD= 11.26). 
The scale has split half reliability of 0.92 for men, and 0.90 for women. Both, 
the content and face validity were also high (Rust et al, 1986).  
The English version of the GRIMS in examining marital satisfaction was 
validated in our local population by Quek and colleagues (2002). The study was 
done in University Malaya Medical Centre (UMMC) involving 60 respondents 
with benign prostatic hyperplasia (BPH). The validity and reliability of the scale 
were studied in two different groups of the subjects, one without lower urinary 
tract symptoms (LUTS) which is the control group (N= 30), and one group with 
LUTS who were admitted for transurethral resection of the prostate (TURP) 
which represents the surgical group (N= 30). Most of the items in the scale had 
high internal consistency, which indicated a high level of homogeneity between 
them. Test-retest reliability was assessed in 30 patients following a 12-week 
period. The intra-class correlation coefficient (ICC) and Pearson’s product 
moment correlation of the total GRIMS score was 0.87 (p< 0.001) and 0.78 (p≤ 
0.01) respectively, in the assessment of the test-retest reliability conducted in 30 
 50 
 
patients after a 12-week interval. The study also found that all items in the scale 
have high sensitivity and specificity to the effects of treatment. The scale also 
has good discriminant validity (Quek et al, 2002). 
Quek and colleagues (2001) also conducted a study to validate the Malay 
version of the GRIMS (Mal-GRIMS) involving 37 urological patients. The scale 
recorded an excellent internal consistency with the Cronbach’s alpha value of 
0.43 to 1.00. It also have highly significant test-retest coefficient and ICC (ICC= 
0.51 and above) in most of the items. The total scores of the Mal-GRIMS also 
showed high sensitivity and specificity (Quek et al, 2001). 
The GRIMS consists of 28 items, of which 14 items are reversely scored, and 14 
are directly scored. The reversed items of the GRIMS are 3, 6, 7, 8, 11, 13, 16, 
18, 19, 21, 23, 24, 26, and 28. Each item is scored on a 4-point scale, ranging 
from ‘strongly disagree’ to ‘strongly agree.’ Higher total score of the GRIMS 
indicates the more severe the relationship problem (Rust et al, 1988). 
Table 4.3 Item cluster and scoring of the GRIMS 
Item cluster Scoring 
3, 6, 7, 8, 11, 13, 16, 18, 19, 21, 23, 24, 26, 28 
1, 2, 4, 5, 9, 10, 12, 14, 15, 17, 20, 22, 25, 27 
Reversely scored 
Directly score 
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Table 4.4 Total score range and interpretation of the GRIMS 
Total score range Interpretation 
16 or less 
17-21 
22-25 
26-29 
30-33 
34-37 
38-41 
42-46 
47 and above 
Undefined 
Very good 
Good 
Above average 
Average 
Poor 
Bad 
Severe 
Very severe 
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4.9.5 HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS) 
 
The HADS is a self-administered questionnaire that provides a reliable and valid 
assessment of anxiety and depression in medical outpatient clinics (Herrmann, 
1997; Zigmond and Snaith, 1983). It is not a diagnostic scale, and is best used 
for screening purposes of general hospital patients who need further psychiatric 
assessment and further intervention (Herrmann, 1997). They measure the 
severity of symptoms that suggest the likelihood that a patient may have the 
disorder (Zainal et al, 2007; Zigmond and Snaith, 1983). 
Kjaergaard and colleagues (2013) conducted a study to evaluate the 
psychometric properties of the Beck Depression Inventory-II (BDI), the 
Montgomery and Åsberg Depression Rating Scale (MADRS), and the Hospital 
Anxiety and Depression Scale (HADS) in a sample from a healthy population 
for screening of Major Depressive Episode (MDE). MDE was diagnosed using 
the Structured Clinical Interview for Diagnostic and Statistical Manual of 
Mental Disorders (DSM)-IV Axis I Disorders-Clinician Version (SCID-CV). 
Out of the 357 subjects, a current MDE was diagnosed in 20 subjects (6%). High 
area under the receiver operating characteristics curve (ROC) was recorded by 
all the three scales including the depression domain for the HADS (AUC 0.84-
0.87). All scales also had high internal consistency (0.75-0.89). The optimal cut-
off score for MDE was ≥ 12 for BDI-II, MADRS ≥ 8, total HADS ≥ 9, and 
HADS-D ≥ 4, with sensitivities of 0.85 and specificity of 0.75. All depressions 
scales had low diagnostic accuracy (Cohen’s kappa= 0.20-0.40), which indicated 
that these scales are acceptable as screening instruments (Kjaedgaard, 
Arfwedson Wang and Waterloo, 2013). 
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A cross-sectional survey was conducted in Norway involving 1,781 patients 
attending 41 general practitioner practices to assess the usefulness of the HADS 
for general practitioners (GPs). The study found that the HADS-A had optimal 
cut-off ≥ 8 (sensitivity 0.89; specificity 0.75), area under the curve (AUC) of 
0.88. 76% of the patients were correctly identified in relation to generalized 
anxiety disorder (GAD). The HADS-D had optimal cut-off ≥ 8 (sensitivity 0.80; 
specificity 0.88), AUC of 0.93. 87% of the patients were correctly identified in 
relation to Major Depressive Episode (MDE) (Olssøn, Mykletun and Dahl, 
2013). In a different study done to examine the psychometric properties of the 
HADS in a large population, Mykletun and colleagues (2001) concluded that the 
basic psychometric properties of the HADS are quite good in terms of factor 
structure, inter-correlation, homogeneity, and internal consistency. Both 
domains (anxiety and depression) were found to have good internal consistency, 
with Cronbach’s alpha of 0.80 and 0.76 respectively (Mykletun, Stordal and 
Dahl, 2001). 
The English version of the HADS was validated in the Malaysian population in 
a study conducted by Fatt and colleagues (2007). A total of 267 participants 
were involved in the study. They were recruited from urological (those presented 
with pre-mature ejaculation (PE)) and primary care (those presented with other 
medical symptoms- controls) clinics. All the items in the HADS recorded good 
internal consistency and this observation was made in both groups, those with 
PE and those without PE (Cronbach’s alpha > 0.800). Both groups also had 
intraclass correlation coefficient (ICC) of > 0.800. These observations indicated 
that the items in the HADS have high reliability and consistency. A significant 
difference was recorded for the scores of all the items of both sub-domains 
(anxiety and depression) when comparison was made between the 2 groups 
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involved in the study. This indicated that the HADS has good discriminant 
validity. 
It is divided into 2 domains, which are the anxiety and depression domain. The 
HADS consisted of seven questions that evaluate anxiety and seven questions 
that evaluate depression. It is rated on a four-point Likert scale (0 to 3). The 
minimum score of ‘0’ indicates the lowest stress while the maximum score of 
‘3’ indicates the maximum stress for that particular question in the scale. The 
score of the individual domain ranges from 0 to 21. The sum of the ratings for 
the 7 questions that assess anxiety and depression separately will give the score 
for the individual domain. Presence of problems was indicated by higher scores. 
Patients who scored more than 7 on the anxiety domain would be categorized as 
‘anxious’ while those who scored more than 7 on the depression domain would 
be categorized as ‘depressed.’ The total HADS score was obtained by summing 
the ratings for all the 14 questions (Zigmond and Snaith, 1983).  An indication 
that the patient may have anxiety or depressive disorder is when a total score of 
15 or more, or a score of 8 or more is obtained on the domain(s). The two 
domains have been found to be independent measures. The scale has been 
suggested for use in cancer research because it did not include items on physical 
aspects of psychiatric disorder (eg. fatigue) (Maguire and Selby, 1989). 
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Table 4.5 Domains and item cluster of the HADS 
Domain Item cluster Score range 
Anxiety 
Depression 
1, 3, 5, 7, 9, 11, 13 
2, 4, 6, 8, 10, 12, 14 
0-3 
0-3 
 
Table 4.6 Scoring of the individual domain of the HADS and its 
interpretation 
Domain Score Interpretation 
Anxiety 
Depression 
8 and above (≥ 8) 
8 and above (≥ 8) 
Anxious 
Depressed 
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4.9.6 PSYCHOLOGICAL GENERAL WELL-BEING INDEX (PGWBI) 
 
The PGWBI questionnaire is a 22 self-administered items validated Health 
Related Quality of Life (HRQoL) measure, commonly used in medical-related 
studies and epidemiological researches to provide an overall assessment of self-
perceived psychological health and well-being (Boman et al, 2001; Havelund et 
al, 1999; Hunt and McKenna, 1992; Omvik et al, 1993; Rasmussen, Norholm, 
and Bech, 1999; Reddy et al, 2000; Walle et al, 1994; Wilkund and Kalrberg, 
1991; Wilkund et al, 1992). The Psychological General Well-Being Schedule, a 
scale consisting of 68 questions was developed by Harold Dupuy, a psychologist 
at the National Centre of Health Statistics in the late sixties, to assess the degree 
of ‘happiness’ of the American population or the probability of psychological 
distress (Grossi et al, 2006). It was considered to be one of the earliest generic 
assessments for health-related quality of life with particular attention to mental 
health (Grossi et al, 2006). A revision of the scale and a final version of 22 
selected items were validated under the name of PGWBI by Dupuy and John E 
some years later. An extensive reference data of this version were generated in 
the US general population and was published in 1984 (Dupuy, 1984). 
A database that consist the observations on 8536 patients from 11 studies 
conducted in 19 countries and 16 languages were compiled by investigators 
working with the MAPI Research Institute as part of the International Health-
Related Quality of Life Outcomes Database (IQOD). These can be used as 
reference values that can help the interpretation of scores in other studies 
(Chassany et al, 2004).  
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Lundgren-Nilsson and colleagues (2013) conducted a study to evaluate the 
construct validity of the PGWBI. The study involved 179 patients who attended 
a tertiary stress clinic. These patients were treated for stress-related exhaustion. 
The PGWBI was administered as part of the routine clinical assessment at 
baseline and 3 months. After 3 months, a vast improvement in well-being was 
reported among the participants. This study concluded that the PGWBI 
questionnaire has satisfactory internal construct validity (Lundgren-Nilsson et al, 
2013). 
It is assessed on a 6-point scale, which examine the psychological health and 
general well-being of the respondents. It is divided into six HRQoL domains: 
anxiety, depressed mood, positive well-being, self-control, general health, and 
vitality.  Each item was scored in between 0 to 5, with the lowest value (0) 
indicating the most distress and the highest value (5) indicating the highest level 
of well-being. Hence, the total score of the PGWBI ranged from 0 to 110 
(Chassany et al, 2004). 
Table 4.7 Dimensions and item cluster of the PGWBI 
Dimensions Item cluster Range 
Anxiety 
Depressed mood 
Positive well-being 
Self-control 
General health 
Vitality 
5, 8, 17, 19, 22 
3, 7, 11 
1, 9, 15, 20 
4, 14, 18 
2, 10, 13 
6, 12, 16, 21 
0-25 
0-15 
0-20 
0-15 
0-15 
0-20 
Global score  0-110 
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4.9.7 WEIGHT, HEIGHT, WAIST CIRCUMFERENCE, AND BODY MASS 
INDEX (BMI) 
 
 
The patients’ weight was measured and recorded in kilograms (kg) to the nearest 
0.1kg and the height recorded in meters (m) to the nearest 0.01m. The BMI will 
be calculated as: 
 
BMI = Weight (kg)         
 Height
2
 (m
2
) 
 
The waist circumference was obtained using a standard measuring tape. It was 
taken at the mid-point between the rib cage and the iliac crest. Both the waist 
circumference and BMI were classified according to the Malaysia Clinical 
Practice Guideline (CPG) in Management of Obesity (2004). 
 
Table 4.8 Waist circumference classification for Asian populations 
(WHO, 2004) 
 
Gender Waist circumference (cm) 
Male 
Female 
≥ 90 cm- high risk 
≥ 80 cm- high risk 
 
 
Table 4.9 Classification of weight by BMI for Asian populations (WHO, 
2004) 
BMI range (kg/m
2
) Classification 
≤ 18.4 
18.5-22.9 
23.0-27.4 
≥ 27.5 
Underweight 
Normal weight 
Overweight 
Obese 
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These classifications were adopted because Asian populations are at higher risk 
of developing medical comorbidities at a lower BMI and the Asians also have a 
higher body fat percentage compared to non-Asians (Malaysia CPG on 
Management of Obesity, 2004). 
 
 
4.10 STATISTICAL ANALYSIS 
 
 
The data was analysed using the Statistical Package for Social Sciences (SPSS) 
version 21.0. 
 
Descriptive analysis was conducted for socio-demographic, clinical, disease and 
marital variables. Descriptive analysis was also done for sexual dysfunction, 
body image distress, marital dissatisfaction, depressive, and anxiety symptoms 
and quality of life. The prevalence for sexual dysfunction, body image distress, 
marital dissatisfaction, possible depression, and anxiety cases were obtained. 
Severity of body image distress and marital dissatisfaction experienced by breast 
cancer patients recruited in the study were also analysed. The cut-off scores for 
sexual dysfunction, body image distress, marital dissatisfaction, probable 
depression, and anxiety cases were used to examine the correlation with socio-
demographic, clinical, disease and marital variables. For quality of life, the 
median score was used to assess correlation. Variables such as age, race, 
religion, educational level, total monthly household income, age of disease 
onset, duration of illness, body mass index, waist circumference, partner’s age 
and duration of relationship were re-categorised. Chi square test and Fisher’s 
exact test, wherever appropriate was used. 
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The correlation between dependent and independent variables were obtained. 
Further multivariate analysis was conducted between sexual dysfunction as the 
dependent variable and significant independent variables from the univariate 
analysis using multivariate linear regression analysis.   
 
 
4.11 ETHICAL CONSIDERATION 
 
 
This study was approved by the Research Committee, Department of 
Psychological Medicine in July 2011 and the Ethics Committee, University 
Malaya Medical Centre in September 2011. An informed and written consent 
was obtained from all of the study participants. 
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CHAPTER FIVE 
  
RESULTS 
 
This was a cross-sectional study of sexual dysfunction, body image distress, and marital 
dissatisfaction in breast cancer survivors attending follow up at the breast clinic in 
University Malaya Medical Centre (UMMC). It was conducted over a four-month 
period, starting from August 2012 to December 2012. During this study period, a total 
of 136 breast cancer patients were approached to participate in the study. However, 35 
patients refused to participate, with 14 patients refused to give consent, and the other 21 
could not speak and read English. All the remaining 101 patients managed to complete 
the questionnaires required in the study, but 1 patient was found to be single. Therefore, 
a total of 100 breast cancer patients were included in the data analysis. Figure 5.1 
illustrated the flow chart of the study participants. 
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Figure 5.1 Flow chart of the study participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Written consent obtained 
from participants     
(n=101) 
Refused to participate    
(n= 14) 
Could not speak or read 
English                               
(n= 21) 
Analysed                            
(n= 100) 
Single participant missed 
during screening were 
excluded from analysis      
(n= 1) 
Breast cancer patients that 
fulfilled the criteria for 
enrolment                         
(n= 136) 
 
Socio-demographic data & 
questionnaires (FSFI, BITS, 
GRIMS, HADS & PGWBI) 
completed                            
(n= 101) 
Explanation and Patient 
Information Sheet given   
(n= 136) 
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5.1 DESCRIPTIVE STATISTICS 
 
5.1.1 DESCRIPTIVE STATISTICS OF PATIENTS’ SOCIO-DEMOGRAPHIC 
CHARACTERISTICS 
 
Table 5.1 describes the descriptive statistics of the patients’ socio-demographic 
characteristics. The mean age for the subjects was 52.64 years with a standard 
deviation of 7.54 years. Of all the participants 43.0% were Chinese. This is 
followed by Malay and Indian, with 37.0% and 20.0% respectively. More than 
half of these women had a minimum of secondary education (61.0%). Almost 
half of them were working either part time or full time (46.0%). The participants 
mostly had a household income of RM 3000 and below per month with 55.0%. 
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Table 5.1 Socio-demographic characteristics of the breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Socio-demographic characteristics Frequency (%) 
 
 
Age (years) 
≤ 50 
> 50 
Minimum 33 
Maximum 65 
Mean ± sd (52.64 ± 7.54) 
 
Race 
Malay  
Chinese 
Indian 
 
 
Religion 
Islam 
Buddhism 
Hinduism 
Christianity 
 
Education level 
No formal education 
Primary education 
Secondary education 
Tertiary education 
 
Employment status 
Unemployed/ housewives 
Working part time/ full time 
Pensioner/ retiree 
 
Household income range (per month) 
≤ RM 3000 
> RM 3000  
 
 
 
 
 
40 (40.0) 
60 (60.0) 
 
 
 
 
 
37 (37.0) 
43 (43.0) 
20 (20.0) 
 
 
 
37 (37.0) 
33 (33.0) 
12 (12.0) 
18 (18.0) 
 
 
3 (3.0) 
6 (6.0) 
61 (61.0) 
30 (30.0) 
 
 
37(37.0) 
46 (46.0) 
17 (17.0) 
 
 
55 (55.0) 
45 (45.0) 
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5.1.2 DESCRIPTIVE STATISTICS OF PATIENTS’ DISEASE 
CHARACTERISTICS 
 
Table 5.2 shows the disease profile of the subjects. Most of the women had 
onset of breast cancer at the age of 50 years and below with 59.0%. The mean 
age of onset of the disease was 47.77 years, with a standard deviation of 7.93 
years. Majority of these participants had duration of illness of 5 years and below 
(70.0%). The mean time of diagnosis to their enrolment in the study was 4.99 
years, with the standard deviation of 4.73 years. Majority of the participants 
(49.0%) were diagnosed with Stage II breast cancer at first consultation with the 
breast team. This is followed by Stage I (38.0%), Stage III (11.0%) and Stage IV 
(2.0%). Only 3.0% of these women had distant metastasis of the disease at the 
point of enrolment into the study. More than half of the women had undergone 
mastectomy 64.0% as compared to lumpectomy 35.0% and 1 patient did not 
have any surgical intervention. 75.0% of these patients had chemotherapy and 
hormonal therapy while 72% had radiotherapy therapy. 
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Table 5.2 Disease characteristics of breast cancer patients attending 
follow up at the breast clinic in UMMC 
 
Disease characteristics Frequency (%) 
 
 
Age of onset (years) 
≤ 50 
> 50 
Mean ± sd (47.77 ± 7.93) 
Median 48.50 
Minimum 32 
Maximum 63 
 
Duration of illness (years) 
(From diagnosis to enrolment into the study) 
≤ 5 
> 5 
Mean ± sd (4.99 ± 4.73) 
Median 3.00 
 
Stage of cancer at first consultation 
Stage I 
Stage II 
Stage III 
Stage IV 
 
Distant metastatic status 
(At the enrolment into the study) 
Metastasis 
Non-metastasis 
 
Breast cancer surgery 
Mastectomy 
Lumpectomy 
No 
 
Chemotherapy 
Yes 
No 
 
Chemotherapy regime 
FEC regime 
TAC regime 
Others 
 
Radiotherapy 
Yes 
No 
 
 
  
 
 
 
59 (59.0) 
41 (41.0) 
 
 
 
 
 
 
 
70 (70.0) 
30 (30.0) 
 
 
 
 
38 (38.0) 
49 (49.0) 
11 (11.0) 
2 (2.0) 
 
 
   
3(3.0) 
97 (97.0) 
 
 
64 (64.0) 
35 (35.0) 
1 (1.0) 
 
 
75 (75.0) 
25 (25.0) 
 
 
66 (88.0) 
1 (1.3) 
8 (10.7) 
 
 
72 (72.0) 
28 (28.0) 
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 Table 5.2 Continued 
Disease characteristics Frequency (%) 
 
 
Hormonal therapy 
Yes 
No 
 
Current hormonal therapy 
Tamoxifen 
Femara (Letrozole) 
Aromasin (Exemastane) 
Others 
 
 
 
 
 
75 (75.0) 
25 (25.0) 
 
 
68 (90.7) 
4 (5.3) 
1(1.3) 
2 (2.7) 
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5.1.3 DESCRIPTIVE STATISTICS OF THE PATIENTS’ CLINICAL 
CHARACTERISTICS 
 
Table 5.3 shows the clinical characteristics of the participants enrolled in the 
study. Most of the participants were menopausal with 77.0% compared to those 
who were non-menopausal (23.0%). The mean duration of menopause was 7.38 
years, with a standard deviation of 5.40 years. A high proportion of these 
women had no underlying medical illness (67.0%). More than half of them were 
within the overweight and obese category in terms of their body mass index 
(BMI) with 67.0%. The mean weight and height of the participants was 61.70 kg 
and 1.55 m respectively. A total of 58.0% of these women with breast cancer 
had a waist circumference of 80 cm and above. 
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Table 5.3 Clinical characteristics of breast cancer patients attending 
follow up at the breast clinic in UMMC 
 
 Clinical characteristics Frequency (%) 
 
Menopausal status 
Yes 
No 
 
Duration of menopause (years) 
(From the onset to enrolment in the study) 
Mean ± sd (7.38 ± 5.40) 
 
Medical comorbidity 
Yes 
No 
 
Body mass index (kg/m
2
) 
Underweight 
Normal weight 
Overweight 
Obese 
Mean weight (kg) ± sd (61.70 ± 10.72) 
Mean height (m) ± sd (1.55 ± 0.06) 
 
Waist circumference (cm) 
< 80 
≥ 80 
Mean ± sd (81.40 ± 9.68) 
 
 
 
                              77 (77.0) 
23 (23.0) 
 
 
 
 
 
 
33 (33.0) 
67 (67.0) 
 
 
5 (5.0) 
28 (28.0) 
39 (39.0) 
28 (28.0) 
 
 
 
 
42 (42.0) 
58 (58.0) 
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5.1.4 DESCRIPTIVE STATISTICS OF PATIENTS’ MARITAL PROFILES 
 
Table 5.4 shows the marital profiles of the breast cancer participants. Most 
(69.0%) of the partners were above 50-years of age. Majority of the patients 
have a long duration of relationship (> 20 years) with 73 out of 100 patients. The 
mean duration of relationship was 27.37 with a standard deviation of 8.75. 
Table 5.4 Marital profiles of breast cancer patients attending follow up 
at the breast clinic in UMMC 
 
Marital profiles Frequency (%) 
 
Age of partner (years) 
≤ 50 
> 50 
Mean ± sd (56.44 ± 9.04) 
Minimum 37 
Maximum 75 
 
Duration of relationship (years) 
≤ 20 
> 20 
Mean ± sd (27.37 ± 8.75) 
 
 
 
 
31 (31.0) 
69 (69.0) 
 
 
 
 
 
27 (27.0) 
73 (73.0) 
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5.1.5 DESCRIPTIVE STATISTICS OF SCORE FOR SEXUAL 
DYSFUNCTION 
 
Figure 5.2 illustrate the descriptive statistics of score for sexual dysfunction as 
assessed by the Female Sexual Function Index (FSFI). A total of 90 out of 100 
women reported sexual dysfunction as indicated by total FSFI scores of ≤ 26.6. 
Therefore, the prevalence of sexual dysfunction among breast cancer survivors 
who participated in this study was 90.0%. 
Figure 5.2 Descriptive statistics of sexual dysfunction in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
 
  
 
 
 
 
 
 
90.00% 
10.00% 
Sexual dysfunction 
Sexual dysfunction
No sexual dysfunction
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Figure 5.3 showed the distribution of the total FSFI scores among the 
participants. The participants had a mean total FSFI score of 15.90 with a 
standard deviation of 9.54. The median score was 19.05. 
Figure 5.3 Distribution of total FSFI scores of breast cancer patients 
attending follow up at the breast clinic in UMMC 
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5.1.6 DESCRIPTIVE STATISTICS OF DOMAINS OF SEXUAL FUNCTION  
 
Table 5.5 shows the mean score of specific domains of sexual function as 
assessed by the FSFI reported by women who participated in this study.  
 
Table 5.5 Mean score of specific domains of sexual function as assessed 
by the FSFI in breast cancer patients attending follow up at the breast clinic 
in UMMC 
 
Domains of sexual function Mean ± sd 
 
 
Sexual desire 
 
Sexual arousal 
 
Lubrication  
 
Orgasm 
 
Sexual satisfaction 
 
Pain 
 
 
 
 
2.54 ± 1.01 
 
2.30 ± 1.42 
 
2.46 ± 1.99 
 
2.58 ± 2.07 
 
3.15 ± 1.80 
 
2.87 ± 2.13 
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5.1.7 DESCRIPTIVE STATISTICS FOR BODY IMAGE DISTRESS 
 
Figure 5.4 illustrates the descriptive statistics for body image distress 
experienced by the participants as assessed by the Breast Impact of Treatment 
Scale (BITS). The cut-off point of 26 and above indicated body image distress. 
Among the 100 participants in the study, a total of 9 patients did not complete 
the entire questionnaire. A total of 39 (42.9%) women reported body image 
distress and 52 (57.1%) patients did not have body image distress. The mean 
total score for the BITS was 21.96 with a standard deviation of 15.78. Therefore, 
the prevalence of body image distress experienced by the breast cancer survivors 
included in this study was 42.9%.  
Figure 5.4 Descriptive statistics for body image distress among breast 
cancer patients attending follow up at the breast clinic in UMMC 
 
 
 
 
 
 
42.90% 
57.10% 
Body image distress 
Body image distress
No body image distress
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Figure 5.5 shows the histogram of the BITS total score among the participants of 
the study. 
 
Figure 5.5 Distribution of the BITS total score in breast cancer patients 
attending follow up at the breast clinic in UMMC 
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Figure 5.6 illustrates the severity of body image distress experienced by the 
breast cancer survivors in the study. 30.8% of these women experienced 
moderate severity of body image distress, while 12.1% had severe body image 
distress. 
 
Figure 5.6 Descriptive statistics of the severity of body image distress in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57.10% 
30.80% 
12.10% 
Severity of body image distress 
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5.1.8 DESCRIPTIVE STATISTICS FOR THE HOSPITAL ANXIETY AND 
DEPRESSION SCALE (HADS) SCORE 
 
Figure 5.7 and 5.8 represent the descriptive statistics of the HADS sub-scales 
score. Figure 5.7 indicated that 9 out of 100 patients with breast cancer scores ≥ 
8 on the HADS depression sub-scale. The prevalence of these women that may 
have had depression was 9.0%. Figure 5.8 showed that 27 out of 100 patients 
who participated in this study had scores of ≥ 8 on the HADS anxiety sub-scale, 
indicating the prevalence of 27.0% that may possibly have had anxiety. For both 
depression and anxiety sub-scales, 7 out of 100 patients scored ≥ 8. 
Figure 5.7 Possible cases of depression in breast cancer patients 
attending follow up at the breast clinic in UMMC 
 
 
 
 
 
 
 
9.00% 
91.00% 
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Depressed
Not depressed
 78 
 
Figure 5.8 Possible cases of anxiety in breast cancer patients attending 
follow up at the breast clinic in UMMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27.00% 
73.00% 
Anxiety 
Anxious
Not anxious
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Figure 5.9 and 5.10 showed the distribution of depression and anxiety sub-scale 
scores respectively. 
 
Figure 5.9 Distribution of the depression sub-scale scores in breast 
cancer patients attending follow up at the breast clinic in UMMC 
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Figure 5.10 Distribution of the anxiety sub-scale scores in breast cancer 
patients attending follow up at the breast clinic in UMMC 
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5.1.9 DESCRIPTIVE STATISTICS FOR THE GOLOMBOK-RUST 
INVENTORY OF MARITAL STATE (GRIMS) SCORE 
 
Table 5.6 describes the descriptive statistics of marital satisfaction among the 
participants based on the GRIMS total score. Poor marital satisfaction was 
reported by 22 out of the 100 women who participated in the study. Half of these 
women, which is 55.0% had at least poor to very severe marital problems. 
 
Table 5.6 Descriptive statistics of marital satisfaction in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Independent variables Frequency (%) 
Marital satisfaction 
 
Undefined 
 
Very good 
 
Good  
 
Above average 
 
Average 
 
Poor 
 
Bad 
 
Severe 
 
Very severe 
 
 
5 (5.0) 
 
8 (8.0) 
 
8 (8.0) 
 
10 (10.0) 
 
14 (14.0) 
 
22 (22.0) 
 
15 (15.0) 
 
11 (11.0) 
 
7 (7.0) 
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Figure 5.11 illustrates the descriptive statistics for marital dissatisfaction in 
breast cancer participants based on the total GRIMS score. Marital 
dissatisfaction was considered if the total GRIMS score was ≥ 34. A total of 55 
out of the 100 women reported marital dissatisfaction. The mean total GRIMS 
score was 33.39 with a standard deviation of 10.06. Therefore, the prevalence of 
marital dissatisfaction reported by the participants in this study was 55.0%. 
 
Figure 5.11 Descriptive statistics for marital dissatisfaction in breast 
cancer patients attending follow up at the breast clinic in UMMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55.00% 
45.00% 
Marital dissatisfaction 
Marital dissatisfaction
Non-marital
dissatisfaction
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Figure 5.12 shows the distribution of the GRIMS total score among the 
participants which was rather normally distributed. 
 
Figure 5.12 Distribution of the GRIMS total score in breast cancer 
patients attending follow up at the breast clinic in UMMC 
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5.1.10 DESCRIPTIVE STATISTICS OF THE PSYCHOLOGICAL GENERAL 
WELL BEING INDEX (PGWBI) SCORE 
 
 
Table 5.7 shows the descriptive statistics for specific domains and total score of 
the PGWBI. 
 
Table 5.7 Descriptive statistics of specific domains and total score of the 
PGWBI in breast cancer patients attending follow up at the breast clinic in 
UMMC 
 
Domains Minimum 
score 
Maximum 
score 
Median Mean Standard 
deviation 
Anxiety 
 
Depressed 
mood 
 
Positive well-
being 
 
Self-control 
 
General health 
 
Vitality 
 
Total score 
5 
 
7 
 
 
2 
 
 
5 
 
3 
 
5 
 
38 
25 
 
15 
 
 
20 
 
 
15 
 
15 
 
20 
 
110 
19.00 
 
12.00 
 
 
13.00 
 
 
11.00 
 
10.00 
 
14.00 
 
76.00 
17.91 
 
12.05 
 
 
12.51 
 
 
11.00 
 
9.75 
 
13.39 
 
76.61 
4.00 
 
2.04 
 
 
3.67 
 
 
2.66 
 
2.38 
 
3.14 
 
15.09 
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Figure 5.13 shows the distribution of the total PGWBI score of the participants 
which was more or less normally distributed. The mean of the total PGWBI 
score was 76.61 with standard deviation of 15.09. 
 
Figure 5.13 Distribution of the total PGWBI score in breast cancer 
patients attending follow up at the breast clinic in UMMC 
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5.2 ASSOCIATION AND REGRESSION 
 
 
5.2.1 UNIVARIATE ANALYSIS OF SEXUAL DYSFUNCTION AND STUDY 
VARIABLES 
 
 
Table 5.8 Socio-demographic profiles with sexual dysfunction in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Sexual 
dysfunction 
(n= 90) 
No sexual 
dysfunction 
(n= 10) 
x
2
 
value 
OR 95% CI p value 
 
Age (years) 
≤ 50 (%) 
> 50 (%) 
 
Race 
Malay (%) 
Non-Malay 
(%) 
 
Religion 
Muslim (%) 
Non-Muslim 
(%) 
 
Education  
level 
Secondary and 
below (%) 
Tertiary (%) 
 
Employment 
Employed (%) 
Unemployed 
(%) 
 
Household 
income (per 
month) 
≤ RM 3000 
(%) 
> RM 3000 
(%) 
 
 
 
35 (87.5) 
55 (91.7) 
 
 
35 (94.6) 
55 (87.3) 
 
 
 
35 (94.6) 
55 (87.3) 
 
 
 
 
63 (90.0) 
 
27 (90.0) 
 
 
40 (87.0) 
50 (92.6) 
 
 
 
 
 
52 (94.5) 
 
38 (84.4) 
 
 
5 (12.5) 
5 (8.3) 
 
 
2 (5.4) 
8 (12.7) 
 
 
 
2 (5.4) 
8 (12.7) 
 
 
 
 
7 (10.0) 
 
3 (10.0) 
 
 
6 (13.0) 
4 (7.4) 
 
 
 
 
 
3 (5.5) 
 
7 (15.6) 
 
 
¥ 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
 
 
¥ 
 
 
1.571 
 
 
 
0.393 
 
 
 
 
0.393 
 
 
 
 
 
1.000 
 
 
 
 
1.875 
 
 
 
 
 
 
0.313 
 
 
0.424-  
5.824 
 
 
0.079-
1.958 
 
 
 
0.079-
1.958 
 
 
 
 
0.240-
4.161 
 
 
 
0.495-
7.102 
 
 
 
 
 
0.076-
1.290 
 
 
0.515 
 
 
 
0.315 
 
 
 
 
0.315 
 
 
 
 
 
1.000 
 
 
 
 
0.506 
 
 
 
 
 
 
0.108 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
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Table 5.8 shows the socio-demographic profiles with sexual dysfunction. None 
of the socio-demographic variables were found to be significantly associated 
with sexual dysfunction.  Breast cancer patients who are 50-years and below, 
and those who are employed appear to have higher odds of experiencing sexual 
dysfunction. However these associations are not statistically significant. 
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Table 5.9 Clinical and disease profiles with sexual dysfunction in breast 
cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Sexual 
dysfunction 
(n= 90) 
No sexual 
dysfunction 
(n= 10) 
x
2
 
value 
OR 95% CI p value 
 
Age of onset 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
illness (years) 
≤ 5 (%) 
> 5 (%) 
 
Surgery 
Yes (%) 
No (%) 
 
Chemotherapy 
Yes (%) 
No (%) 
 
Radiotherapy 
Yes (%) 
No (%) 
 
Hormonal 
therapy 
Yes (%) 
No (%) 
 
 
 
 
50 (84.7) 
40 (97.6) 
 
 
 
63 (90.0) 
27 (90.0) 
 
 
89 (89.9) 
1 (100.0) 
 
 
66 (88.0) 
24 (96.0) 
 
 
66 (91.7) 
24 (85.7) 
 
 
 
67 (89.3) 
23 (92.0) 
 
 
 
 
9 (15.3) 
1 (2.4) 
 
 
 
7 (10.0) 
3 (10.0) 
 
 
10 (10.1) 
0 (0.0) 
 
 
9 (12.0) 
1 (4.0) 
 
 
6 (8.3) 
4 (14.3) 
 
 
 
8 (10.7) 
2 (8.0) 
 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
¥ 
 
 
 
¥ 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
7.200 
 
 
 
 
1.000 
 
 
 
 
 
 
 
3.273 
 
 
 
0.545 
 
 
 
 
1.373 
 
 
 
 
0.875-
59.233 
 
 
 
0.240-
4.161 
 
 
 
 
 
 
0.394-
27.215 
 
 
0.142-
2.101 
 
 
 
0.272-
6.940 
 
 
 
 
0.044* 
 
 
 
 
1.000 
 
 
 
1.000 
 
 
 
0.444 
 
 
 
0.460 
 
 
 
 
1.000 
 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
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Table 5.9 Continued 
 
Variables Sexual 
dysfunction 
(n= 90) 
No sexual 
dysfunction 
(n= 10) 
x
2
 
value 
OR 95% CI p value 
 
Distant 
metastasis  
Metastasis (%) 
Non-
metastasis (%) 
 
Medical 
comorbidity 
Yes (%) 
No (%) 
 
Menopausal 
status 
Yes (%) 
No (%) 
 
BMI (kg/m
2
) 
Underweight/ 
normal weight 
(%) 
Overweight/ 
obese (%) 
 
Waist circum-
ference (cm) 
< 80 cm (%) 
≥ 80 cm (%) 
 
 
 
3 (100.0) 
87 (89.7) 
 
 
 
 
32 (97.0) 
58 (86.6) 
 
 
 
71 (92.2) 
19 (82.6) 
 
 
31 (93.9) 
 
 
59 (88.1) 
 
 
 
 
36 (85.7) 
54 (93.1) 
 
 
 
0 (0.0) 
10 (10.3) 
 
 
 
 
1 (3.0) 
9 (13.4) 
 
 
 
6 (7.8) 
4 (17.4) 
 
 
2 (6.1) 
 
 
8 (11.9) 
 
 
 
 
6 (14.3) 
4 (6.9) 
 
 
 
 
 
¥ 
 
 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
¥ 
 
 
 
 
 
 
 
¥ 
 
 
 
 
 
 
 
 
 
 
0.201 
 
 
 
 
0.401 
 
 
 
0.476 
 
 
 
 
 
 
 
2.250 
 
 
 
 
 
 
 
 
 
0.024-
1.662 
 
 
 
0.103-
1.568 
 
 
0.095-
2.379 
 
 
 
 
 
 
0.593-
8.538 
 
 
 
 
1.000 
 
 
 
 
 
0.159 
 
 
 
 
0.232 
 
 
 
0.490 
 
 
 
 
 
 
 
0.314 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.9 shows the clinical and disease profiles with sexual dysfunction. 
Based on this table, there was significant association between younger age of 
disease onset (≤ 50 years) with sexual dysfunction, with an odds ratio of 
7.200, p= 0.044. This would indicate that younger women diagnosed with 
breast cancer were at greater odds of experiencing sexual dysfunction compared 
to older women diagnosed with breast cancer. 
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Women who has had chemotherapy, hormonal therapy and those with waist 
circumference of less than 80 cm appear to have greater odds of experiencing 
sexual dysfunction but these associations are not statistically significant. 
 
Table 5.10 Marital profiles with sexual dysfunction in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Variables Sexual 
dysfunction 
(n= 90) 
No sexual 
dysfunction 
(n= 10) 
x
2
 
value 
OR 95% CI p value 
 
Partner’s age 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
relationship 
(years) 
≤ 20 (%) 
> 20 (%) 
 
 
 
 
 
26 (83.9) 
64 (92.8) 
 
 
 
 
23 (85.2) 
67 (91.8) 
 
 
 
5 (16.1) 
5 (7.2) 
 
 
 
 
4 (14.8) 
6 (8.2) 
 
 
 
¥ 
 
 
 
 
 
¥ 
 
 
 
 
2.462 
 
 
 
 
 
1.942 
 
 
 
0.657-
9.221 
 
 
 
 
0.503-
7.498 
 
 
 
0.277 
 
 
 
 
 
0.452 
 
 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.10 shows the marital profiles with sexual dysfunction. From this table, 
women with younger partner (≤ 50-years of age) and those with shorter duration 
of relationship (≤ 20 years) appeared to have higher odds of experiencing sexual 
dysfunction. However, the associations were not statistically significant. 
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5.2.2 UNIVARIATE ANALYSIS OF BODY IMAGE DISTRESS AND STUDY 
VARIABLES 
 
Table 5.11 Socio-demographic profiles with body image distress in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Body image 
distress  
(n= 39) 
No body 
image 
distress 
 (n= 52) 
x
2
 value OR 95% 
CI 
p value 
       
Age (years) 
≤ 50 (%) 
> 50 (%) 
 
Race 
Malay (%) 
Non- Malay (%) 
 
Religion 
Muslim (%) 
Non-Muslim 
(%) 
 
Education level 
No formal 
education/ 
primary/ 
secondary (%) 
Tertiary (%) 
 
Employment 
Employed (%) 
Unemployed 
(%) 
 
Household 
income (per 
month) 
≤ RM 3000 (%) 
> RM 3000 (%) 
 
 
 
 
18 (48.6) 
21 (38.9) 
 
 
12 (36.4) 
27 (46.6) 
 
 
12 (36.4) 
27 (46.6) 
 
 
 
26 (40.6) 
 
 
 
13 (48.1) 
 
 
19 (45.2) 
20 (40.8) 
 
 
 
 
 
23 (45.1) 
16 (40.0) 
 
19 (51.4) 
33 (61.1) 
 
 
21 (63.6) 
31 (53.4) 
 
 
21 (63.6) 
31 (53.4) 
 
 
 
38 (59.4) 
 
 
 
14 (51.9) 
 
 
23 (54.8) 
29 (59.2) 
 
 
 
 
 
28 (54.9) 
24 (60.0) 
 
0.854 
 
 
 
0.891 
 
 
 
0.891 
 
 
 
 
0.439 
 
 
 
 
 
 
0.181 
 
 
 
 
 
 
0.238 
 
0.672 
 
 
 
1.524 
 
 
 
1.524 
 
 
 
 
1.357 
 
 
 
 
 
 
0.835 
 
 
 
 
 
 
0.812 
 
0.288-
1.565 
 
 
0.634-
3.664 
 
 
0.634-
3.664 
 
 
 
0.549-
3.354 
 
 
 
 
 
0.363-
1.920 
 
 
 
 
 
0.351-
1.879 
 
0.355 
 
 
 
0.345 
 
 
 
0.345 
 
 
 
 
0.508 
 
 
 
 
 
 
0.671 
 
 
 
 
 
 
0.626 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
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Only 91 out of the 100 participants completed the BITS questionnaire entirely. 
When the BITS total score ≥ 26 was used, none of the socio-demographic 
variables were found to be associated with body image distress as shown in 
Table 5.11. Malay, Muslim and those with lower education level (secondary or 
primary or no formal education) were found to have higher odds to develop 
body image distress. However, these associations were not statistically 
significant. 
 
Table 5.12 Clinical and disease profiles with body image distress in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Body image 
distress  
(n= 39) 
 
No body 
image 
distress 
 (n= 52) 
x
2
 value OR 95% CI p value 
 
Age of onset 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
illness (years) 
≤ 5 (%) 
> 5 (%) 
 
Surgery 
Yes (%) 
No (%) 
 
Chemotherapy 
Yes (%) 
No (%) 
 
Radiotherapy 
Yes (%) 
No (%) 
 
Hormonal 
therapy 
Yes (%) 
No (%) 
 
 
 
 
24 (45.3) 
15 (39.5) 
 
 
 
31 (47.7) 
8 (30.8) 
 
 
39 (43.3) 
0 (0.0) 
 
 
31 (45.6) 
8 (34.8) 
 
 
28 (43.1) 
11 (42.3) 
 
 
 
31 (45.6) 
8 (34.8) 
 
 
 
 
29 (54.7) 
23 (60.5) 
 
 
 
34 (52.3) 
18 (69.2) 
 
 
51 (56.7) 
1 (100.0) 
 
 
37 (54.4) 
15 (65.2) 
 
 
37 (56.9) 
15 (57.7) 
 
 
 
37 (54.4) 
15 (65.2) 
 
 
 
 
0.305 
 
 
 
 
2.172 
 
 
 
¥ 
 
 
 
0.819 
 
 
 
0.004 
 
 
 
 
0.819 
 
 
 
 
0.788 
 
 
 
 
0.487 
 
 
 
 
 
 
 
0.637 
 
 
 
0.969 
 
 
 
 
0.637 
 
 
 
0.338-
1.836 
 
 
 
0.186-
1.279 
 
 
 
 
 
 
0.238-
1.699 
 
 
0.386-
2.432 
 
 
 
0.238-
1.699 
 
 
 
0.581 
 
 
 
 
0.141 
 
 
 
1.000 
 
 
 
0.365 
 
 
 
0.947 
 
 
 
 
0.365 
 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
 93 
 
Table 5.12 Continued 
 
Variables Body image 
distress  
(n= 39) 
No body 
image 
distress 
 (n= 52) 
x
2
 value OR 95% CI p value 
 
Distant 
metastasis  
Metastasis (%) 
Non-
metastasis (%) 
 
Medical 
comorbidity 
Yes (%) 
No (%) 
 
Menopausal 
status 
Yes (%) 
No (%) 
 
BMI (kg/m
2
) 
Underweight/ 
normal weight 
(%) 
Overweight/ 
obese (%) 
 
Waist circum-
ference (cm) 
< 80 cm (%) 
≥ 80 cm (%) 
 
 
 
1 (50.0) 
38 (42.7) 
 
 
 
 
11 (34.4) 
28 (47.5) 
 
 
 
30 (42.9) 
9 (42.9) 
 
 
13 (46.4) 
 
 
26 (41.3) 
 
 
 
 
17 (44.7) 
22 (41.5) 
 
 
 
1 (50.0) 
51 (57.3) 
 
 
 
 
21 (65.6) 
31 (52.5) 
 
 
 
40 (57.1) 
12 (57.1) 
 
 
15 (53.6) 
 
 
37 (58.7) 
 
 
 
 
21 (55.3) 
31 (58.5) 
 
 
 
 
 
¥ 
 
 
 
 
 
1.450 
 
 
 
 
0.000 
 
 
 
0.811 
 
 
 
 
 
 
 
0.094 
 
 
 
0.745 
 
 
 
 
 
1.724 
 
 
 
 
1.000 
 
 
 
1.426 
 
 
 
 
 
 
 
0.877 
 
 
 
0.045-
12.295 
 
 
 
 
0.708-
4.202 
 
 
 
0.373-
2.679 
 
 
0.331-
1.987 
 
 
 
 
 
 
0.378-
2.033 
 
 
 
1.000 
 
 
 
 
 
0.229 
 
 
 
 
1.000 
 
 
 
0.646 
 
 
 
 
 
 
 
0.759 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.12 shows the clinical and disease profiles with body image distress. 
From this table, none of the clinical and disease profiles had statistically 
significant association with body image distress. 
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Table 5.13 Marital profiles with body image distress in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Variables Body image 
distress 
 (n= 39) 
No body 
image 
distress 
(n= 52) 
x
2
 value OR 95% 
CI 
p value 
       
Partner’s age 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
relationship 
(years) 
≤ 20 (%) 
> 20 (%) 
 
 
15 (53.6) 
24 (38.1)  
 
 
 
 
10 (41.7) 
29 (43.3) 
 
 
13 (46.4) 
39 (61.9) 
 
 
 
 
14 (58.3) 
38 (56.7) 
 
 
1.896 
 
 
 
 
 
0.019 
 
 
0.533 
 
 
 
 
 
1.068 
 
 
 
0.217-
1.312 
 
 
 
 
0.415-
2.747 
 
 
0.169 
 
 
 
 
 
0.891 
 
 
      
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.13 illustrates the marital profiles with body image distress. Even though 
breast cancer patients with shorter duration of relationship (≤ 20 years) have 
higher odds of developing body image distress, none of the marital profiles were 
significantly associated with body image distress. 
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5.2.3 UNIVARIATE ANALYSIS OF MARITAL DISSATISFACTION AND 
STUDY VARIABLES 
 
 
Table 5.14 Socio-demographic profiles with marital dissatisfaction in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Marital 
dissatisfaction  
(n= 55) 
No marital 
dissatisfaction 
(n= 45) 
x
2
 
value 
OR 95% CI p 
value 
       
Age (years) 
≤ 50 (%) 
> 50 (%) 
 
Race 
Malay (%) 
Non- Malay 
(%) 
 
Religion 
Muslim (%) 
Non-Muslim 
(%) 
 
Education 
level 
No formal 
education/ 
primary/ 
secondary 
(%) 
Tertiary (%) 
 
Employment 
Employed 
(%) 
Unemployed 
(%) 
 
Household 
income (per 
month) 
≤ RM 3000 
(%) 
> RM 3000 
(%) 
 
 
25 (62.5) 
30 (50.0) 
 
 
17 (45.9) 
38 (60.3) 
 
 
 
17 (45.9) 
38 (60.3) 
 
 
 
 
40 (57.1) 
 
 
 
 
15 (50.0) 
 
 
26 (56.5) 
 
29 (53.7) 
 
 
 
 
 
32 (58.2) 
 
23 (51.1) 
 
15 (37.5) 
30 (50.0) 
 
 
20 (54.1) 
25 (39.7) 
 
 
 
20 (54.1) 
25 (39.7) 
 
 
 
 
30 (42.9) 
 
 
 
 
15 (50.0) 
 
 
20 (43.5) 
 
25 (46.3) 
 
 
 
 
 
23 (41.8) 
 
22 (48.9) 
 
1.515 
 
 
 
1.945 
 
 
 
 
1.945 
 
 
 
 
 
0.433 
 
 
 
 
 
 
 
0.080 
 
 
 
 
 
 
 
0.500 
 
0.600 
 
 
 
1.788 
 
 
 
 
1.788 
 
 
 
 
 
0.750 
 
 
 
 
 
 
 
0.892 
 
 
 
 
 
 
 
0.751 
 
0.265-
1.357 
 
 
0.787-
4.061 
 
 
 
0.787-
4.061 
 
 
 
 
0.318-
1.769 
 
 
 
 
 
 
0.404-
1.968 
 
 
 
 
 
 
0.340-
1.660 
 
0.218 
 
 
 
0.163 
 
 
 
 
0.163 
 
 
 
 
 
0.511 
 
 
 
 
 
 
 
0.778 
 
 
 
 
 
 
 
0.480 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
 
 
 
 96 
 
Table 5.14 shows the socio-demographic profiles with marital dissatisfaction. 
Malay patients and those practising Islam have greater odds of having marital 
dissatisfaction compared to the non-Malays and non-Muslim devotees. 
However, these associations are not statistically significant. There are no 
significant differences in marital dissatisfaction with regards to the socio-
demographic profiles (age, race, religion, employment status, education level, 
and household income) of the participants in the study. 
 
Table 5.15 Clinical and disease profiles with marital dissatisfaction in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Marital 
dissatisfaction  
(n= 55) 
No marital 
dissatisfaction 
(n= 45) 
x
2
 
value 
OR 95% 
CI 
p 
value 
 
Age of 
onset 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
illness 
(years) 
≤ 5 (%) 
> 5 (%) 
 
Surgery 
Yes (%) 
No (%) 
 
Chemo-
therapy 
Yes (%) 
No (%) 
 
Radio-
therapy 
Yes (%) 
No (%) 
 
Hormonal 
therapy 
Yes (%) 
No (%) 
 
 
 
 
 
35 (59.3) 
20 (48.8) 
 
 
 
 
42 (60.0) 
13 (43.3) 
 
 
55 (55.6) 
0 (0.0) 
 
 
 
42 (56.0) 
13 (52.0) 
 
 
 
44 (61.1) 
11 (39.3) 
 
 
 
41 (54.7) 
14 (56.0) 
 
 
 
 
24 (40.7) 
21 (51.2) 
 
 
 
 
28 (40.0) 
17 (56.7) 
 
 
44 (44.4) 
1 (100.0) 
 
 
 
33 (44.0) 
12 (48.0) 
 
 
 
28 (38.9) 
17 (60.7) 
 
 
 
34 (45.3) 
11 (44.0) 
 
 
 
 
1.086 
 
 
 
 
 
2.357 
 
 
 
¥ 
 
 
 
 
0.121 
 
 
 
 
3.880 
 
 
 
 
0.013 
 
 
 
 
0.653 
 
 
 
 
 
0.510 
 
 
 
 
 
 
 
 
0.851 
 
 
 
 
0.412 
 
 
 
 
1.055 
 
 
 
 
0.293-
1.458 
 
 
 
 
0.214-
1.212 
 
 
 
 
 
 
 
0.343-
2.109 
 
 
 
0.168-
1.007 
 
 
 
0.424-
2.625 
 
 
 
 
0.297 
 
 
 
 
 
0.125 
 
 
 
0.450 
 
 
 
 
0.728 
 
 
 
 
0.049* 
 
 
 
 
0.908 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
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Table 5.15 Continued 
 
Variables Marital 
dissatisfaction  
(n= 55) 
No marital 
dissatisfaction 
(n= 45) 
x
2
 
value 
OR 95% 
CI 
p 
value 
 
Distant 
metastasis 
Metastasis 
(%) 
Non-
metastasis 
(%) 
 
Medical 
comorbidity 
Yes (%) 
No (%) 
 
Menopausal 
status 
Yes (%) 
No (%) 
 
BMI (kg/m
2
) 
Under-
weight/ 
normal 
weight (%) 
Overweight/ 
obese (%) 
 
Waist 
circum-
ference (cm) 
< 80 cm (%) 
≥ 80 cm (%) 
 
 
 
2 (66.7) 
 
53 (54.6) 
 
 
 
 
 
16 (48.5) 
39 (58.2) 
 
 
 
40 (51.9) 
15 (65.2) 
 
 
20 (60.6) 
 
 
 
35 (52.2) 
 
 
 
 
 
23 (54.8) 
32 (55.2) 
 
 
 
1 (33.3) 
 
44 (45.4) 
 
 
 
 
 
17 (51.5) 
28 (41.8) 
 
 
 
37 (48.1) 
8 (34.8) 
 
 
13 (39.4) 
 
 
 
32 (48.8) 
 
 
 
 
 
19 (45.2) 
26 (44.8) 
 
 
 
¥ 
 
 
 
 
 
 
 
0.845 
 
 
 
 
1.260 
 
 
 
0.625 
 
 
 
 
 
 
 
 
 
0.002 
 
 
 
0.602 
 
 
 
 
 
 
 
1.480 
 
 
 
 
1.734 
 
 
 
0.711 
 
 
 
 
 
 
 
 
 
1.017 
 
 
 
0.053-
6.865 
 
 
 
 
 
 
0.640-
3.420 
 
 
 
0.659-
4.564 
 
 
0.305-
1.658 
 
 
 
 
 
 
 
 
0.458-
2.259 
 
 
 
 
1.000 
 
 
 
 
 
 
 
0.358 
 
 
 
 
0.262 
 
 
 
0.429 
 
 
 
 
 
 
 
 
 
0.968 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.15 shows the clinical and disease profiles with marital dissatisfaction. 
Women who had hormonal therapy, menopause, presence of medical 
comorbidity, and have a smaller waist circumference (< 80cm) have greater 
odds of having marital dissatisfaction, but these associations are not statistically 
significant. Those who were diagnosed with breast cancer at a younger age (≤ 50 
years), and shorter duration of illness (≤ 5 years) have lower odds of 
experiencing marital dissatisfaction. However, these associations are also 
statistically insignificant. Women who had radiotherapy have lower odds of 
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experiencing marital dissatisfaction and this association is statistically 
significant with p= 0.049. 
 
Table 5.16 Marital profiles with marital dissatisfaction in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Variables Marital 
dissatisfaction  
(n= 55) 
No marital 
dissatisfaction 
(n= 45) 
x
2
 
value 
OR 95% CI p 
value 
       
Partner’s 
age (years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
relationship 
(years) 
≤ 20 (%) 
> 20 (%) 
 
 
19 (61.3) 
36 (52.2) 
 
 
 
 
16 (59.3) 
39 (53.4) 
 
 
12 (38.7) 
33 (47.8) 
 
 
 
 
11 (40.7) 
34 (46.6) 
 
 
0.689 
 
 
 
 
 
0.271 
 
 
0.291 
 
 
 
 
 
0.789 
 
 
0.291-
1.634 
 
 
 
 
0.322-
1.930 
 
 
0.397 
 
 
 
 
 
0.603 
       
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.16 shows the marital profiles with marital dissatisfaction. There are no 
differences with marital dissatisfaction with regards to the partners’ age and the 
duration of the relationship. 
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5.2.4 UNIVARIATE ANALYSIS OF HADS-D AND STUDY VARIABLES 
 
Table 5.17 Socio-demographic profiles with depressive symptoms in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Depressed  
(n= 9) 
Not depressed 
 (n= 91 ) 
x
2
 value OR 95% 
CI 
p value 
       
Age (years) 
≤ 50 (%) 
> 50 (%) 
 
Race 
Malay (%) 
Non- Malay 
(%) 
 
Religion 
Muslim (%) 
Non-Muslim 
(%) 
 
Education level 
No formal 
education/ 
primary/ 
secondary (%) 
Tertiary (%) 
 
Employment 
Employed (%) 
Unemployed 
(%) 
 
Household 
income (per 
month) 
≤ RM 3000 
(%) 
> RM 3000 
(%) 
 
 
 
4 (10.0) 
5 (8.3) 
 
 
2 (5.4) 
7 (11.1) 
 
 
 
2 (5.4) 
7 (11.1) 
 
 
 
9 (12.9) 
 
 
 
0 (0.0) 
 
 
4 (8.7) 
5 (9.3) 
 
 
 
 
 
6 (10.9) 
 
3 (6.7) 
 
36 (90.0) 
55 (91.7) 
 
 
35 (94.6) 
56 (88.9) 
 
 
 
35 (94.6) 
56 (88.9) 
 
 
 
61 (87.1) 
 
 
 
30 (100.0) 
 
 
42 (91.3) 
49 (90.7) 
 
 
 
 
 
49 (89.1) 
 
42 (93.3) 
 
¥ 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
 
 
¥ 
 
 
 
 
 
 
¥ 
 
0.818 
 
 
 
2.188 
 
 
 
 
2.188 
 
 
 
 
 
 
 
 
 
 
 
1.071 
 
 
 
 
 
 
0.583 
 
0.206-
3.253 
 
 
0.430-
11.134 
 
 
 
0.430-
11.134 
 
 
 
 
 
 
 
 
 
 
0.270- 
4.250 
 
 
 
 
 
0.137- 
2.477 
 
1.000 
 
 
 
0.478 
 
 
 
 
0.478 
 
 
 
 
0.054 
 
 
 
 
 
 
1.000 
 
 
 
 
 
 
0.508 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.17 describes the socio-demographic data with depressive symptoms 
based on the HADS-D score of ≥ 8. Women who are working have higher odds 
of developing depressive symptoms, but this association is not statistically 
significant. Being Malay and practising Islam were also noted to have higher 
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odds of developing depressive symptoms. However, these associations are not 
statistically significant too. There are no differences in depressive symptoms 
with regards to the participants’ age, educational level and the monthly 
household income. 
 
Table 5.18 Clinical and disease profiles with depressive symptoms in 
breast cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Depressed  
(n= 9) 
Not depressed 
(n= 91) 
x
2
 
value 
OR 95% 
CI 
p 
value 
 
Age of 
onset 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
illness 
(years) 
≤ 5 (%) 
> 5 (%) 
 
Surgery 
Yes (%) 
No (%) 
 
Chemo-
therapy 
Yes (%) 
No (%) 
 
Radio-
therapy 
Yes (%) 
No (%) 
 
Hormonal 
therapy 
Yes (%) 
No (%) 
 
 
 
 
 
6 (10.2) 
3 (7.3) 
 
 
 
 
7 (10.0) 
2 (6.7) 
 
 
9 (9.1) 
0 (0.0) 
 
 
 
7 (9.3) 
2 (8.0) 
 
 
 
6 (8.3) 
3 (10.7) 
 
 
 
8 (10.7) 
1 (4.0) 
 
 
 
 
 
53 (89.8) 
38 (92.7) 
 
 
 
 
63 (90.0) 
28 (93.3) 
 
 
90 (90.9) 
1 (100.0) 
 
 
 
68 (90.7) 
23 (92.0) 
 
 
 
66 (91.7) 
25 (89.3) 
 
 
 
67 (89.3) 
24 (96.0) 
 
 
 
 
 
¥ 
 
 
 
 
 
¥ 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
 
0.697 
 
 
 
 
 
0.643 
 
 
 
 
 
 
 
 
0.845 
 
 
 
 
1.320 
 
 
 
 
0.349 
 
 
 
 
0.164-
2.965 
 
 
 
 
0.126-
3.292 
 
 
 
 
 
 
 
0.164-
4.359 
 
 
 
0.306-
5.686 
 
 
 
0.041-
2.938 
 
 
 
 
0.733 
 
 
 
 
 
0.720 
 
 
 
1.000 
 
 
 
 
1.000 
 
 
 
 
0.707 
 
 
 
 
0.444 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
 
 
 
 
 
 
 
 101 
 
Table 5.18 Continued 
 
Variables Depressed  
(n= 9) 
Not depressed 
(n= 91) 
x
2
 
value 
OR 95% 
CI 
p 
value 
 
Distant 
metastasis 
Metastasis 
(%) 
Non-
metastasis 
(%) 
 
Medical 
comorbidity 
Yes (%) 
No (%) 
 
Menopausal 
status 
Yes (%) 
No (%) 
 
BMI (kg/m
2
) 
Under-
weight/ 
normal 
weight (%) 
Overweight/ 
obese (%) 
 
Waist 
circum-
ference (cm) 
< 80 cm (%) 
≥ 80 cm (%) 
 
 
 
 
0 (0.0) 
 
9 (9.3) 
 
 
 
 
 
3 (9.1) 
6 (9.0) 
 
 
 
9 (11.7) 
0 (0.0) 
 
 
3 (9.1) 
 
 
 
6 (9.0) 
 
 
 
 
 
3 (7.1) 
6 (10.3) 
 
 
 
3 (100.0) 
 
88 (90.7) 
 
 
 
 
 
30 (90.9) 
61 (91.0) 
 
 
 
68 (88.3) 
23 (100.0) 
 
 
30 (90.9) 
 
 
 
61 (91.0) 
 
 
 
 
 
39 (92.9) 
52 (89.7) 
 
 
 
¥ 
 
 
 
 
 
 
 
¥ 
 
 
 
 
¥ 
 
 
 
¥ 
 
 
 
 
 
 
 
 
 
¥ 
 
 
 
 
 
 
 
 
 
 
 
0.984 
 
 
 
 
 
 
 
 
0.984 
 
 
 
 
 
 
 
 
 
1.500 
 
 
 
 
 
 
 
 
 
 
 
0.230-
4.207 
 
 
 
 
 
 
 
0.230-
4.207 
 
 
 
 
 
 
 
 
0.353-
6.374 
 
 
 
1.000 
 
 
 
 
 
 
 
1.000 
 
 
 
 
0.113 
 
 
 
1.000 
 
 
 
 
 
 
 
 
 
0.730 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.18 shows the clinical and disease profiles with depressive symptoms. 
Women who had radiotherapy and those with waist circumference of < 80cm 
have greater odds of developing depressive symptoms, but these associations are 
not statistically significant. There are no differences in depressive symptoms in 
terms of both the clinical and disease profiles of the participants. 
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Table 5.19 Marital profiles with depressive symptoms in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Variables Depressed 
 (n= 9) 
Not 
depressed 
(n= 91) 
x
2
 value OR 95% 
CI 
p value 
       
Partner’s age 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
relationship 
(years) 
≤ 20 (%) 
> 20 (%) 
 
 
2 (6.5) 
7 (10.1)  
 
 
 
 
1 (3.7) 
8 (11.0) 
 
 
29 (93.5) 
62 (89.9) 
 
 
 
 
26 (96.3) 
65 (89.0) 
 
 
¥ 
 
 
 
 
 
¥ 
 
 
1.637 
 
 
 
 
 
3.200 
 
 
0.320- 
8.374 
 
 
 
 
0.381-
26.874 
 
 
0.717 
 
 
 
 
 
0.438 
 
 
      
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.19 shows the marital profiles with depressive symptoms. When the total 
HADS-D was taken at ≥ 8, there are no differences in depressive symptoms with 
regards to the participants’ marital profiles. 
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5.2.5 UNIVARIATE ANALYSIS OF HADS-A AND STUDY VARIABLES 
 
 
Table 5.20 Socio-demographic profiles with anxiety symptoms in breast 
cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Anxious  
(n= 27) 
Not anxious 
 (n= 73) 
x
2
 value OR 95% 
CI 
p value 
       
Age (years) 
≤ 50 (%) 
> 50 (%) 
 
Race 
Malay (%) 
Non- Malay 
(%) 
 
Religion 
Muslim (%) 
Non-Muslim 
(%) 
 
Education level 
No formal 
education/ 
primary/ 
secondary (%) 
Tertiary (%) 
 
Employment 
Employed (%) 
Unemployed 
(%) 
 
Household 
income (per 
month) 
≤ RM 3000 
(%) 
> RM 3000 
(%) 
 
 
 
16 (40.0) 
11 (18.3) 
 
 
7 (18.9) 
20 (31.7) 
 
 
 
7 (18.9) 
20 (31.7) 
 
 
 
19 (27.1) 
 
 
 
8 (26.7) 
 
 
17 (37.0) 
10 (18.5) 
 
 
 
 
 
14 (25.5) 
 
13 (28.9) 
 
24 (60.0) 
49 (81.7) 
 
 
30 (81.1) 
43 (68.3) 
 
 
 
30 (81.1) 
43 (68.3) 
 
 
 
51 (72.9) 
 
 
 
22 (73.3) 
 
 
29 (63.0) 
44 (81.5) 
 
 
 
 
 
41 (74.5) 
 
32 (71.1) 
 
5.716 
 
 
 
1.946 
 
 
 
 
1.946 
 
 
 
 
0.002 
 
 
 
 
 
 
4.284 
 
 
 
 
 
 
0.148 
 
0.337 
 
 
 
1.993 
 
 
 
 
1.993 
 
 
 
 
0.976 
 
 
 
 
 
 
0.388 
 
 
 
 
 
 
1.190 
 
0.136- 
0.836 
 
 
0.749- 
5.305 
 
 
 
0.749- 
5.305 
 
 
 
0.372- 
2.563 
 
 
 
 
 
0.156- 
0.964 
 
 
 
 
 
0.491- 
2.883 
 
0.017* 
 
 
 
0.163 
 
 
 
 
0.163 
 
 
 
 
0.961 
 
 
 
 
 
 
0.038* 
 
 
 
 
 
 
0.700 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.20 shows the socio-demographic data with anxiety symptoms. When the 
total HADS-A was taken at ≥ 8, younger breast cancer patients (≤ 50 years) are 
at lower odds of experiencing depressive symptoms compared to older patients, 
with an odds ratio of 0.337, p= 0.017. Those who are employed are also at lower 
odds of developing anxiety symptoms compared to those who are not working, 
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with an odds ratio of 0.388, p= 0.038. None of the other socio-demographic 
variables were significant with anxiety symptoms. 
 
Table 5.21 Clinical and disease profiles with anxiety symptoms in breast 
cancer patients attending follow up at the breast clinic in UMMC 
 
Variables Anxious  
(n= 27) 
Not anxious 
(n= 73) 
x
2
 
value 
OR 95% 
CI 
p 
value 
 
Age of 
onset 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
illness 
(years) 
≤ 5 (%) 
> 5 (%) 
 
Surgery 
Yes (%) 
No (%) 
 
Chemo-
therapy 
Yes (%) 
No (%) 
 
Radio-
therapy 
Yes (%) 
No (%) 
 
Hormonal 
therapy 
Yes (%) 
No (%) 
 
 
 
 
 
19 (32.2) 
8 (19.5) 
 
 
 
 
20 (28.6) 
7 (23.3) 
 
 
27 (27.3) 
0 (0.0) 
 
 
 
21 (28.0) 
6 (24.0) 
 
 
 
23 (31.9) 
4 (14.3) 
 
 
 
20 (26.7) 
7 (28.0) 
 
 
 
 
40 (67.8) 
33 (80.5) 
 
 
 
 
50 (71.4) 
23 (76.7) 
 
 
72 (72.7) 
1 (100.0) 
 
 
 
54 (72.0) 
19 (76.0) 
 
 
 
49 (68.1) 
24 (85.7) 
 
 
 
55 (73.3) 
18 (72.0) 
 
 
 
 
1.977 
 
 
 
 
 
0.292 
 
 
 
¥ 
 
 
 
 
0.152 
 
 
 
 
3.190 
 
 
 
 
0.017 
 
 
 
 
0.510 
 
 
 
 
 
0.761 
 
 
 
 
 
 
 
 
0.812 
 
 
 
 
0.355 
 
 
 
 
1.069 
 
 
 
 
0.198-
1.314 
 
 
 
 
0.282-
2.052 
 
 
 
 
 
 
 
0.285-
2.314 
 
 
 
0.110-
1.143 
 
 
 
0.389-
2.942 
 
 
 
 
0.160 
 
 
 
 
 
0.589 
 
 
 
1.000 
 
 
 
 
0.696 
 
 
 
 
0.074 
 
 
 
 
0.897 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
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Table 5.21 Continued 
 
Variables Anxious  
(n= 27) 
Not anxious 
(n= 73) 
x
2
 
value 
OR 95% 
CI 
p 
value 
 
Distant 
metastasis 
Metastasis 
(%) 
Non-
metastasis 
(%) 
 
Medical 
comorbidity 
Yes (%) 
No (%) 
 
Menopausal 
status 
Yes (%) 
No (%) 
 
BMI (kg/m
2
) 
Under-
weight/ 
normal 
weight (%) 
Overweight/ 
obese (%) 
 
Waist 
circum-
ference (cm) 
< 80 cm (%) 
≥ 80 cm (%) 
 
 
 
1 (33.3) 
 
26 (26.8) 
 
 
 
 
 
7 (21.2) 
20 (29.9) 
 
 
 
20 (26.0) 
7 (30.4) 
 
 
7 (21.2) 
 
 
 
20 (29.9) 
 
 
 
 
 
9 (21.4) 
18 (31.0) 
 
 
 
2 (66.7) 
 
71 (73.2) 
 
 
 
 
 
26 (78.8) 
47 (70.1) 
 
 
 
57 (74.0) 
16 (69.6) 
 
 
26 (78.8) 
 
 
 
47 (70.1) 
 
 
 
 
 
33 (78.6) 
40 (69.0) 
 
 
 
¥ 
 
 
 
 
 
 
 
0.837 
 
 
 
 
0.179 
 
 
 
0.837 
 
 
 
 
 
 
 
 
 
1.140 
 
 
 
0.732 
 
 
 
 
 
 
 
1.581 
 
 
 
 
1.247 
 
 
 
1.581 
 
 
 
 
 
 
 
 
 
1.650 
 
 
 
 
 
 
0.064-
8.421 
 
 
 
 
 
 
0.590-
4.233 
 
 
 
0.448-
3.471 
 
 
0.590-
4.233 
 
 
 
 
 
 
 
 
0.655-
4.154 
 
 
 
1.000 
 
 
 
 
 
 
 
0.360 
 
 
 
 
0.672 
 
 
 
0.360 
 
 
 
 
 
 
 
 
 
0.286 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.21 illustrates the clinical and disease profiles with anxiety symptoms. 
Breast cancer patients who have had hormonal therapy, medical comorbidity, 
menopausal, under or normal weight and those with waist circumference < 80 
cm are at greater odds to develop anxiety symptoms compared to those who did 
not undergo radiation therapy. However these associations are not statistically 
significant. None of the clinical and disease profiles are statistically significant 
with anxiety symptoms, when the total HADS-A score was taken at ≥ 8. 
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Table 5.22 Marital profiles with anxiety symptoms in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Variables Anxious 
 (n= 27) 
Not anxious 
(n= 73) 
x
2
 value OR 95% 
CI 
p value 
       
Partner’s age 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
relationship 
(years) 
≤ 20 (%) 
> 20 (%) 
 
 
10 (32.3) 
17 (24.6) 
 
 
 
 
10 (37.0) 
17 (23.3) 
 
 
21 (67.7) 
52 (75.4) 
 
 
 
 
17 (63.0) 
56 (76.7) 
 
 
0.630 
 
 
 
 
 
1.890 
 
 
0.687 
 
 
 
 
 
0.516 
 
 
0.271-
1.742 
 
 
 
 
0.199-
1.336 
 
 
0.427 
 
 
 
 
 
0.169 
 
 
      
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.22 shows the marital profiles with anxiety symptoms. Breast cancer 
patients with younger partners (≤ 50 years) and those with the duration of 
relationship of 20 years and less have lower odds of experiencing anxiety 
symptoms. However, these associations are not statistically significant. 
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5.2.6 UNIVARIATE ANALYSIS OF TOTAL PGWBI SCORE AND STUDY 
VARIABLES 
 
 
The PGWBI has no cut-off point, hence the median score (76.00) was used in 
the analysis. 
   
Table 5.23 Socio-demographic profiles with total PGWBI score in breast 
cancer patients attending follow up at the breast clinic in UMMC 
 
Variables PGWBI ≥ 76  
(n= 52) 
PGWBI < 76 
 (n= 48) 
x
2
 
value 
OR 95% 
CI 
p value 
       
Age (years) 
≤ 50 (%) 
> 50 (%) 
 
Race 
Malay (%) 
Non-Malay 
(%) 
 
Religion 
Muslim (%) 
Non-Muslim 
(%) 
 
Education level 
No formal 
education/ 
primary/ 
secondary (%) 
Tertiary (%) 
 
Employment 
Employed (%) 
Unemployed 
(%) 
 
Household 
income (per 
month) 
≤ RM 3000 
(%) 
> RM 3000 
(%) 
 
 
 
15 (37.5) 
37 (61.7) 
 
 
26 (70.3) 
26 (41.3) 
 
 
 
26 (70.3) 
26 (41.3) 
 
 
 
39 (55.7) 
 
 
 
13 (43.3) 
 
 
19 (41.3) 
33 (61.1) 
 
 
 
 
 
30 (54.5) 
 
22 (48.9) 
 
25 (62.5) 
23 (38.3) 
 
 
11 (29.7) 
37 (58.7) 
 
 
 
11 (29.7) 
37 (58.7) 
 
 
 
31 (44.3) 
 
 
 
17 (56.7) 
 
 
27 (58.7) 
21 (38.9) 
 
 
 
 
 
25 (45.5) 
 
23 (51.1) 
 
5.616 
 
 
 
7.854 
 
 
 
 
7.854 
 
 
 
 
1.290 
 
 
 
 
 
 
3.904 
 
 
 
 
 
 
0.317 
 
 
 
 
2.681 
 
 
 
0.297 
 
 
 
 
0.297 
 
 
 
 
0.608 
 
 
 
 
 
 
2.233 
 
 
 
 
 
 
0.797 
 
1.175- 
6.118 
 
 
0.125- 
0.706 
 
 
 
0.125- 
0.706 
 
 
 
0.257- 
1.440 
 
 
 
 
 
1.001- 
4.982 
 
 
 
 
 
0.362- 
1.755 
 
 
 
 
0.018* 
 
 
 
0.005** 
 
 
 
 
0.005** 
 
 
 
 
0.256 
 
 
 
 
 
 
0.048* 
 
 
 
 
 
 
0.573 
*   Significance level: p < 0.05 
** Significance level: p < 0.01  
¥   Fisher’s Exact Test 
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Table 5.23 shows the socio-demographic profiles with the total PGWBI score. 
Younger women (≤ 50 years of age) and those who are working have greater 
odds of obtaining higher PGWBI total score, with odds ratio of 2.681 and 2.233 
respectively. These associations are statistically significant, with p= 0.018 and 
p= 0.048 respectively. Whereas Malay and Muslim women have lower odds of 
obtaining higher PGWBI total score, with odds ratio of 0.297 and p= 0.005. 
 
Table 5.24 Clinical and disease profiles with total PGWBI score in breast 
cancer patients attending follow up at the breast clinic in UMMC 
 
Variables PGWBI ≥ 
76  
(n= 52) 
PGWBI < 
76 
(n= 48) 
x
2
 value OR 95% CI p value 
 
Age of 
onset 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
illness 
(years) 
≤ 5 (%) 
> 5 (%) 
 
Surgery 
Yes (%) 
No (%) 
 
Chemo-
therapy 
Yes (%) 
No (%) 
 
Radio-
therapy 
Yes (%) 
No (%) 
 
Hormonal 
therapy 
Yes (%) 
No (%) 
 
 
 
 
 
25 (42.4) 
27 (65.9) 
 
 
 
 
35 (50.0) 
17 (56.7) 
 
 
51 (51.5) 
1 (100.0) 
 
 
 
42 (56.6) 
10 (40.0) 
 
 
 
36 (50.0) 
16 (57.1) 
 
 
 
40 (53.3) 
12 (48.0) 
 
 
 
 
34 (57.6) 
14 (34.1) 
 
 
 
 
35 (50.0) 
13 (43.3) 
 
 
48 (48.5) 
0 (0.0) 
 
 
 
33 (44.0) 
15 (60.0) 
 
 
 
36 (50.0) 
12 (42.9) 
 
 
 
35 (46.7) 
13 (52.0) 
 
 
 
 
5.343 
 
 
 
 
 
0.374 
 
 
 
¥ 
 
 
 
 
1.923 
 
 
 
 
0.412 
 
 
 
 
0.214 
 
 
 
 
2.623 
 
 
 
 
 
1.308 
 
 
 
 
 
 
 
 
0.524 
 
 
 
 
1.333 
 
 
 
 
0.808 
 
 
 
 
1.148-
5.995 
 
 
 
 
0.553-
3.093 
 
 
 
 
 
 
 
0.209-
1.316 
 
 
 
0.553-
3.213 
 
 
 
0.326-
1.999 
 
 
 
 
0.021* 
 
 
 
 
 
0.541 
 
 
 
1.000 
 
 
 
 
0.166 
 
 
 
 
0.521 
 
 
 
 
0.644 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
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Table 5.24 Continued 
 
Variables PGWBI ≥ 
76  
(n= 52) 
PGWBI < 
76 
(n= 48) 
x
2
 value OR 95% CI p value 
 
Distant 
metastasis 
Metastasis 
(%) 
Non-
metastasis 
(%) 
 
Medical 
comorbidity 
Yes (%) 
No (%) 
 
Menopausal 
status 
Yes (%) 
No (%) 
 
BMI (kg/m
2
) 
Under-
weight/ 
normal 
weight (%) 
Overweight/ 
obese (%) 
 
Waist 
circum-
ference (cm) 
< 80 cm (%) 
≥ 80 cm (%) 
 
 
 
1 (33.3) 
 
51 (52.6) 
 
 
 
 
 
19 (57.6) 
33 (49.3) 
 
 
 
43 (55.8) 
9 (39.1) 
 
 
13 (39.4) 
 
 
 
39 (58.2) 
 
 
 
 
 
16 (38.1) 
36 (62.1) 
 
 
 
 
2 (66.7) 
 
46 (47.4) 
 
 
 
 
 
14 (42.4) 
34 (50.7) 
 
 
 
34 (44.2) 
14 (60.9) 
 
 
20 (60.6) 
 
 
 
28 (41.8) 
 
 
 
 
 
26 (61.9) 
22 (37.9) 
 
 
 
¥ 
 
 
 
 
 
 
 
0.613 
 
 
 
 
1.982 
 
 
 
3.136 
 
 
 
 
 
 
 
 
 
5.609 
 
 
 
2.217 
 
 
 
 
 
 
 
0.715 
 
 
 
 
0.508 
 
 
 
2.143 
 
 
 
 
 
 
 
 
 
2.659 
 
 
 
0.195-
25.271 
 
 
 
 
 
 
0.309-
1.657 
 
 
 
0.196-
1.315 
 
 
0.915-
5.016 
 
 
 
 
 
 
 
 
1.173-
6.026 
 
 
 
0.606 
 
 
 
 
 
 
 
0.433 
 
 
 
 
0.159 
 
 
 
0.077 
 
 
 
 
 
 
 
 
 
0.018* 
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.24 shows the clinical and disease profiles with the total PGWBI score. 
Breast cancer patients with younger age of disease onset (≤ 50 years of age) and 
waist circumference < 80 cm were at greater odds of obtaining higher total 
PGWBI score and these associations are statistically significant, with p= 0.021 
and p= 0.018 respectively. 
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Table 5.25 Marital profiles with the total PGWBI score in breast cancer 
patients attending follow up at the breast clinic in UMMC 
 
Variables PGWBI ≥ 76  
(n= 52) 
PGWBI < 76 
(n= 48) 
x
2
 value OR 95% 
CI 
p value 
       
Partner’s age 
(years) 
≤ 50 (%) 
> 50 (%) 
 
Duration of 
relationship 
(years) 
≤ 20 (%) 
> 20 (%) 
 
 
12 (38.7) 
40 (58.0) 
 
 
 
 
10 (37.0) 
42 (57.5) 
 
 
19 (61.3) 
29 (44.0) 
 
 
 
 
17 (63.0) 
31 (42.5) 
 
 
3.179 
 
 
 
 
 
3.318 
 
 
2.184 
 
 
 
 
 
2.303 
 
 
0.918-
5.195 
 
 
 
 
0.928-
5.714 
 
 
0.075 
 
 
 
 
 
0.069 
       
* Significance level: p < 0.05  
¥ Fisher’s Exact Test 
 
 
Table 5.25 illustrates the marital profiles with the total PGWBI score. The 
participants’ marital profiles are not significantly associated with the total 
PGWBI score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
 
5.2.7 CORRELATION BETWEEN DEPENDENT MEASURE AND 
INDEPENDENT MEASURES 
  
 
Table 5.26 Correlation between body image distress (BITS), marital 
dissatisfaction (GRIMS), depressive symptoms (HADS-D), anxiety 
symptoms (HADS-A), and quality of life (PGWBI) with sexual dysfunction 
(FSFI) 
 
  BITS GRIMS HADS-
D 
HADS-A PGWBI 
Sexual 
dysfunction 
(FSFI) 
Correlation 
co-efficient, 
r 
p value 
-0.13 
 
 
0.226 
-0.49 
 
 
< 0.001*** 
-0.34 
 
 
0.001** 
-0.10 
 
 
0.301 
0.24 
 
 
0.140 
       
 **   Significance level: p < 0.01 
 *** Significance level: p < 0.001 
 
 
 Table 5.26 shows the correlation between body image distress, marital 
dissatisfaction, depressive, and anxiety symptoms and quality of life with sexual 
dysfunction. There is significant correlation between measures of marital 
dissatisfaction and depressive symptoms with the primary outcome measure of 
sexual dysfunction, with p< 0.001 and p= 0.001 respectively. Body image 
distress (r= -0.13), marital dissatisfaction (r= -0.49), anxiety, and depressive 
symptoms (r= -0.10, -0.34 respectively) scores are inversely correlated with 
sexual dysfunction. 
 
Table 5.27 Correlation between sexual dysfunction (FSFI), marital 
dissatisfaction (GRIMS), depressive symptoms (HADS-D), anxiety 
symptoms (HADS-A), and quality of life (PGWBI) with body image distress 
(BITS) 
 
  FSFI GRIMS HADS-D HADS-A PGWBI 
Body image 
distress 
(BITS) 
Correlation 
co-efficient, 
r 
p value 
-0.13 
 
 
0.226 
0.34 
 
 
0.001** 
0.37 
 
 
<0.001*** 
0.45 
 
 
<0.001*** 
-0.41 
 
 
<0.001*** 
       
 **   Significance level: p < 0.01 
 *** Significance level: p < 0.001 
 
 
 112 
 
 Table 5.27 shows the correlation between sexual dysfunction, marital 
dissatisfaction, depressive, and anxiety symptoms and quality of life with body 
image distress. Measures of marital dissatisfaction, depressive, and anxiety 
symptoms and quality of life showed significant correlation with body image 
distress. 
 
Table 5.28 Correlation between sexual dysfunction (FSFI), body image 
distress (BITS), depressive symptoms (HADS-D), anxiety symptoms 
(HADS-A), quality of life (PGWBI) with marital dissatisfaction (GRIMS) 
 
  FSFI BITS HADS-D HADS-A PGWBI 
Marital 
dis-
satisfaction 
(GRIMS) 
Correlation 
co-efficient, 
r 
p value 
-0.49 
 
<0.001*** 
0.34 
 
 
0.001** 
0.39 
 
 
<0.001*** 
0.38 
 
 
<0.001*** 
-0.40 
 
 
<0.001*** 
       
**   Significance level: p < 0.01 
*** Significance level: p < 0.001 
 
 
Table 5.28 shows the correlation between sexual dysfunction, body image 
distress, depressive and anxiety symptoms, and quality of life with marital 
dissatisfaction. Measures of sexual dysfunction, body image distress, depressive 
and anxiety symptoms, and quality of life are significantly correlated with 
marital dissatisfaction. 
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Figure 5.14 Summary of correlation between dependent measures and 
independent measures 
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5.2.8 MULTIVARIATE LINEAR REGRESSION ANALYSIS BETWEEN 
SEXUAL DYSFUNCTION AND INDEPENDENT MEASURES 
 
 
Table 5.29 Multivariate linear regression analysis of independent 
variables with sexual dysfunction 
 
Variables Unstandardized 
coefficients, B  
Standardized 
coefficients, 
Beta 
p value 95% CI 
     
     
Age of disease 
onset 
-0.423 -0.351 < 0.001*** -0.616 to -0.231 
     
Total GRIMS 
score 
 
HADS-D 
subscale score 
 
 
R = 0.623 
R
2 
= 0.388 
Adjusted R
2
 = 
0.368 
 
-0.353 
 
 
-0.669 
-0.371 
 
 
-0.202 
 
 
 
< 0.001*** 
 
 
0.022* 
 
 
 
-0.518 to -0.189 
 
 
-1.240 to -0.098 
 
 
 
*     Significance level: p < 0.05 
*** Significance level: p < 0.001 
 
 
 From the univariate analysis conducted, the patients who experienced sexual 
dysfunction showed significant association with age of disease onset, the total 
GRIMS score and HADS-D sub-scale score, with p< 0.05. Multivariate linear 
regression was conducted as shown in Table 5.29 above. For every year increase 
in the age of disease onset, the total FSFI score was expected to decrease by -
0.423 point, holding all other variables constant, with p< 0.001. The coefficient 
for the total GRIMS score was -0.353, which indicated that for every point 
increase in the total GRIMS score, the total FSFI score was expected to decrease 
by -0.353 point, with p< 0.001. For every 1 point increase in the HADS-D sub-
scale, the total FSFI score was expected to decrease by -0.669, with p= 0.022. 
All the independent variables (age of disease onset, GRIMS total score and 
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HADS-D score) were statistically significant with total FSFI score. The adjusted 
R
2
 is 0.368, which indicated that 37% of the total variability of the FSFI total 
score is explained by age of disease onset, GRIMS total score and HADS-D 
score. 
 
Table 5.30 Stepwise multivariate linear regression analysis of 
independent variables with sexual dysfunction 
 
 
Model Summary 
Model R R 
Square 
Adjusted R 
Square 
Std. Error 
of the 
Estimate 
Change Statistics 
R Square 
Change 
F 
Change 
df1 df2 Sig. F 
Chang
e 
1 .489
a
 .239 .231 8.3664 .239 30.812 1 98 .000 
2 .594
b
 .353 .340 7.7541 .114 17.089 1 97 .000 
3 .623
c
 .388 .368 7.5838 .034 5.405 1 96 .022 
a. Predictors: (Constant), GRIMS total 
b. Predictors: (Constant), GRIMS total, Actual age of onset 
c. Predictors: (Constant), GRIMS total, Actual age of onset, HADS depression 
Coefficients
a
 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
1 
(Constant) 31.392 2.914 
 
10.772 .000 25.608 37.175 
GRIMS total -.464 .084 -.489 -5.551 .000 -.630 -.298 
2 
(Constant) 49.759 5.200 
 
9.570 .000 39.439 60.079 
GRIMS total -.429 .078 -.452 -5.505 .000 -.584 -.274 
Actual age of 
onset 
-.409 .099 -.340 -4.134 .000 -.605 -.213 
3 
(Constant) 50.257 5.090 
 
9.874 .000 40.154 60.361 
GRIMS total -.353 .083 -.372 -4.260 .000 -.518 -.189 
Actual age of 
onset 
-.423 .097 -.351 -4.366 .000 -.616 -.231 
HADS 
depression 
-.669 .288 -.202 -2.325 .022 -1.240 -.098 
a. Dependent Variable: FSFI total 
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Table 5.30 showed the stepwise multivariate linear regression that was carried 
out for the independent variables with sexual dysfunction. Model 1 which 
included only the GRIMS total score for 23% of the variance (adjusted R
2
= 
0.231). The inclusion of actual age of disease onset in model 2 resulted in 
additional 11% of the variance being explained (R
2
 change= 0.114). The final 
model 3 also included HADS-D sub-scale score, and this model accounted for 
37% of the variance (adjusted R
2
= 0.368). Hence using the stepwise method, a 
significant model emerged, with adjusted R
2
= 0.368. Significant variables are 
GRIMS total score (B= -0.372, p< 0.001), actual age of disease onset (B= -
0.351, p< 0.001) and HADS-D sub-scale score (B= -0.202, p= 0.022). 
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CHAPTER SIX 
 
DISCUSSION 
 
This is a cross-sectional study examining the prevalence of sexual dysfunction amongst 
breast cancer survivors attending follow up at the breast clinic in University Malaya 
Medical Centre (UMMC) from August 2012 to December 2012. Other aims were to 
determine the severity of body image distress and marital dissatisfaction amongst the 
participants and their associations with sexual dysfunction as well as the associated 
socio-demographic and clinical variables. 
 
6.1 SOCIO-DEMOGRAPHIC, CLINICAL, DISEASE AND MARITAL 
CHARACTERISTICS OF THE STUDY PARTICIPANTS 
 
 In this study, Table 5.1 showed that the majority of the participants were 
more than 50 years of age (60%) and the mean of age was 52.64 with a standard 
deviation of 7.54. This finding was similar to a study done on the survival 
analysis of women with breast cancer in Malaysia which was based in UMMC 
by Taib et al, (2003). Out of the 413 breast cancer survivors that were included 
in the study, 241 women (58%) were between 41 to 59 years of age and 95 
women (23%) were 60 years of age and above. 
 More Chinese breast cancer survivors were noted from the study with 
43%, and this was followed by the Malays and the Indians, with 37% and 20% 
respectively. This was surprising as the Malay ethnic origin usually makes up 
the majority of the population in the country. The possible explanation for this 
observation is that the Chinese has the highest incidence of breast cancer, with 1 
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in 16 Chinese women will develop breast cancer during their lifetime, followed 
by 1 in 16 Indian women and 1 in 28 Malay women (Lim and Halimah, 2004). 
Similar findings were also reported in the National Cancer Statistics 2007. 
Chinese women with breast cancer were also found to have higher 5-year 
survival probability of 0.635 compared to the Indian and Malay women, with 
0.574 and 0.475 respectively (Taib, Yip and Mohamed, 2003). Having said that, 
according to the hospital statistics, Chinese patient attendees are over-
represented in UMMC. 
 Religion is still an important aspect of most Malaysians regardless of 
their ethnicity.  In this study, the majority of the participants were Muslims with 
37%, and this was followed by Buddhism (33%), Christianity (18%) and 
Hinduism (12%). This finding correlates with Islam as being the largest religion 
in Malaysia. It was also noted that in this study, there were 43 Chinese patients 
but only 33 patients who were Buddhist devotees. The explanation to this 
disparity observed could be the fact that occasionally Chinese may have other 
religious practise such as Christianity. 
 Amongst the breast cancer survivors that were included in this study, 
61% had completed secondary education while 30% had tertiary education. A 
low percentage of these women (3%) had no formal education and only 6% had 
only completed primary education. Even though the 2 participants have never 
had formal schooling, they were still able to understand and read English 
language. Thus, they were still able to complete the questionnaires which were 
self-administered scales.  
 Almost half (46%) of the breast cancer patients in this study were either 
working full time or part time. Out of the 100 participants, 37 were either 
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unemployed or a housewife. Pensioner or retiree made up 17% of the 
participants. Majority of these women had a low total household income of 
RM3000 and below per month (55%). 
 In the study population, majority (59%) of these women were 50 years 
and younger at the onset of breast cancer. The mean for age of onset was 47.77 
years with a standard deviation of 7.93. This was higher compared to the 
findings in an epidemiological study conducted by Yip and colleagues (2003) 
which reported that out of 3738 cases of breast cancer seen in Malaysia that 
year, about 50% were below the age of 50 years. The mean age of onset of 47.77 
years was also younger compared to the mean age of onset of 51 years in a study 
conducted by Taib and colleagues (2008). Majority of these women had duration 
of illness of 5 years and below (70%). The mean duration of breast cancer from 
the time of diagnosis to their recruitment into the study was 4.99 years with 
median of 3.00 years and standard deviation of 4.73. 
 Only 3 out of the 100 breast cancer survivors had distant metastasis of 
the disease at the point of enrolment into the study. This could be due to public 
awareness campaign through the mass media. The early screening programs 
which allow for detection of the disease at an early stage, and also advances in 
the treatment modalities of breast cancer is accessible to most Malaysians. 99 
out of the 100 breast cancer patients in this study had breast cancer surgery, of 
which 64 had a mastectomy and the remaining 35 had lumpectomy. 75% of the 
women had chemotherapy, 72% had radiotherapy, and 75% had hormonal 
therapy. Of those that were still on hormonal therapy during participation in the 
study, 68 (90.7%) were on Tamoxifen. 
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 Majority of these women with breast cancer were menopausal (77%). 
The mean duration from the onset of menopause to their participation into the 
study was 7.38 years with a standard deviation of 5.40. Only a minority of them 
(33%) had other medical comorbidity which was mainly a history of diabetes 
mellitus or hypertension. With regards to the body mass index (BMI) of the 
participants, only 28% had normal BMI compared to 39% who were considered 
overweight and 28% who were in the obese category. The mean weight of the 
participants was 61.70kg with a standard deviation of 10.72. 58% of these 
women had waist circumference of 80cm and above with the mean of 81.40cm 
and standard deviation of 9.68. 
 In this study, Table 5.4 illustrated the marital profiles of the participants 
which indicated that majority (69%) of the partners were above 50 years of age 
with the mean of 56.44 years and standard deviation of  9.04. The youngest 
partner was 37 years of age, and the oldest partner was 75 years of age. 
 
6.2 SEXUAL DYSFUNCTION AND SOCIO-DEMOGRAPHIC VARIABLES 
 
 The prevalence of sexual dysfunction amongst breast cancer survivors in 
this study was 90% with the total FSFI score of ≤ 26.6 taken as an indication of 
the presence of sexual dysfunction. This was higher compared to the 75% 
prevalence of sexual dysfunction in breast cancer patients reported in a study 
done in the United States by Goldfarb et al (2009). In their cross-sectional study, 
Goldfarb and colleagues (2009) had recruited 100 women with breast cancer 
from an outpatient clinic of a breast centre. The subjects had mean age of 52 
(range 26-75 years of age) and the FSFI with a cut-off score of less than 26 was 
also used to assess for sexual dysfunction. In a different survey also conducted 
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in the United States by Raggio and colleagues (2014), 83 breast cancer survivors 
with a median of 7 years post diagnosis were included in the study. 77% of all 
the subjects were found to have sexual dysfunction as identified also by the 
FSFI. In another cross-sectional study conducted by Capodice and colleagues 
(2008), the prevalence of sexual dysfunction as assessed by using the FSFI was 
reported to be at 57%. This particular study had recruited a total of 117 women 
with breast cancer, with the median age of 52 years (range 29-82 years of age). 
Kedde and colleagues (2013) carried out a cross sectional study looking at 
sexual dysfunction amongst Dutch women with breast cancer and found that the 
prevalence of sexual dysfunction to be 64% in those still receiving treatment for 
cancer and 45% in those who had completed their treatment. 
 The possible reason for the discrepancy observed in the prevalence of 
sexual dysfunction in this current study compared to previous papers would be 
the difference in the study population. All the above cited studies were 
conducted in Western countries. In Asian countries like Malaysia, female sexual 
dysfunction is rarely talked about amongst the general public and considered 
relatively new (Sidi el at, 2007). Hence, the awareness about this issue amongst 
the general public especially Malaysian women might be scarce as compared to 
their Western counterparts. This could be a contributing factor to explain the 
high prevalence of sexual dysfunction observed in this study compared to the 
ones involving Western populations. 
Higher number of Malay women with breast cancer and thus Muslim 
women (94.6%) were found to have sexual dysfunction compared to their non-
Malay and non-Muslim counterparts (87.3%) based on this study. The cultural 
and religious beliefs amongst these women could also be a probable contributing 
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factor to the high prevalence of sexual dysfunction observed. Muslim women 
are not encouraged to talk about their sexual relationship with other people 
except with their husband. Women might feel uneasy and uncomfortable 
discussing their sexual difficulties with their husband, fearing that the issue 
could jeopardize their relationship. They might also perceived that the 
difficulties that they are facing is normal, thus preventing them from consulting 
about the sexual problems. Also it is not an uncommon practise amongst 
Malaysian, particularly in the Malays, to seek traditional methods of treatment 
for sexual problems, either by visiting traditional healers or by consuming 
traditional medications or preparations. This cultural belief and practise could 
also provide a possible explanation for the high prevalence rate of sexual 
dysfunction amongst Malaysian women with breast cancer that was recruited in 
this study. 
The observation made in this study was similar to the findings of a study 
conducted on sexual dysfunction amongst Malaysian women by Sidi et al 
(2007). In this study involving a total of 230 married women, the authors found 
that amongst the risk factors significantly associated with female sexual 
dysfunction was Malay ethnicity. 61.8% of the Malay women recruited in the 
study were found to have sexual dysfunction. Yusoff and colleagues (2012) had 
done a qualitative study on 10 husbands of breast cancer women, of whom 7 
were Malays. Amongst the marital challenges narrated by the 3 Malay husbands 
were their wives’ perception of being unattractive post-surgery, feelings of 
insecurity, not wanted and unappreciated. These women were also described to 
feel inadequate and unworthy for not being able to fulfil their husband’s needs. 
In other instances, the husbands found them to be overly sensitive and jealous. 
Husband’s engagement in extra-marital affair after the wife was diagnosed with 
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breast cancer was also described as part of the marital challenges faced. The 
challenges encountered by the Malay couples described in this study could lead 
to strain in their relationship and could also possibly have implication to their 
sexual relationship. These marital adversities could provide a possible 
explanation to the higher number of observed cases of sexual dysfunction in 
Malay women with breast cancer compared to the non-Malays in this study. 
The menopause rate amongst the subjects of this study was considerably 
high at 77% which could also contribute to the high prevalence of sexual 
dysfunction observed. Pre-mature menopause secondary to breast cancer 
treatment could result in sexual dysfunction in women with breast cancer. Post-
menopausal status either early or late onset has been found to be strongly 
associated with sexual dysfunction in breast cancer survivors (Capodice et al, 
2008). 
“Female sexual dysfunction (FSD) is characterized by disturbances in 
the process of a normal sexual response cycle or dyspareunia” (Mat Napes et al, 
2013). “A normal sexual response cycle includes stages of desire, arousal/ 
excitement, orgasm and resolution” as described by Masters and Johnson (1966) 
and revised by Kaplan (1969). In FSD, one or more stages of the sexual 
response cycle can be disturbed (Basson, 2005). The diagnosis and treatment of 
breast cancer can have tremendous effects on women sexuality and sexual 
function. Breast cancer patients may experience fatigue, decreased sexual desire, 
reduced physiological arousal in response to sexual stimuli, dyspareunia as a 
result of vaginal dryness secondary to reduced oestrogen levels during the 
treatment of breast cancer and at times persisted across the trajectories of the 
disease (Katz, 2011). Concerns about cancer recurrence and potential result of 
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breast cancer treatment are often the main priorities in many women compared 
to potential changes in sexuality and sexual function (Anllo, 2000). However, it 
is detrimental that breast cancer survivors recognize that the disease and the 
treatment modalities can have a tremendous impact on their sexual relationship 
that may persist for long duration of time (Katz, 2011). 
Sexual dysfunction was also found to be greater in the older age group (> 
50 years of age) with 91.7% compared to younger patients (≤ 50 years of age) 
with 87.5%. A possible explanation to this observation is that the frequency of 
sexual activity declines as the age progresses amongst Malaysian couples. 
Chronic medical comorbidity, side effects of medications and physical 
limitations could also be contributing factors to sexual dysfunction experienced 
by older patients with breast cancer. This observation was similar to the finding 
in a study conducted in France by Bre´dart and colleagues (2011) where 
amongst sexually active women with breast cancer, age of above 50 years was 
associated with lower frequency of sexual activity, reduced sexual pleasure or 
greater sexual discomfort. 
Higher sexual dysfunction was reported amongst those who were 
unemployed (92.6%) compared to those who are working with only 87%. Those 
with lower economic status (total household income of ≤ RM 3000 per month) 
had higher sexual dysfunction with 94.5% compared to those with high monthly 
total household income with only 84.4%. Lower socio-economic status and 
financial difficulties can put these women at risk for developing psychological 
distress. Financial problems could also lead to strain in the relationship between 
the woman with breast cancer and her spouse, thus affecting the sexual function 
and relationship. The similar finding was observed in a study on depression and 
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sexual adjustment following breast cancer in low income Hispanic and non-
Hispanic White (Christie, Meyerowitz and Maly, 2010). Hispanic women had 
poorer sexual function compared to the non-Hispanic, even after controlling for 
significant covariates. They had significantly lower sexual libido, more 
difficulty relaxing and enjoying sex, and more difficulties in sexual arousal and 
orgasms compared to the non-Hispanic White women. 
 
6.3 SEXUAL DYSFUNCTION AND CLINICAL, AND DISEASE 
VARIABLES 
 
 In this study, Table 5.9 showed the analysis of clinical and disease 
variables with sexual dysfunction. Young age of breast cancer onset (≤ 50 years 
of age) was found to be significantly associated with sexual dysfunction with p= 
0.044. Sexual dysfunction was 7 times more common in younger women 
diagnosed with breast cancer with an odds ratio of 7.200. 84.7% of women from 
this age group reported sexual dysfunction. This was higher compared to the 
findings of a study conducted by Kedde et al (2013) which reported the 
prevalence of sexual dysfunction amongst women with breast cancer who were 
45 years of age or younger to be 64% in those still receiving treatment for the 
disease and 45% in those who had completed their treatment. 
 The diagnosis of breast cancer is more distressing for young women 
compared to older women because of more severe psychosocial worries 
secondary to the negative reproductive effects of the treatment modalities 
(Bakewell and Volker, 2005; Ganz et al, 2003). Women younger than 45 years 
of age experienced pre-mature menopause secondary to the adjuvant 
chemotherapy or hormonal therapy, which in turn led to disturbances in sexual 
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functioning and infertility problems that may induce additional psychological 
distress (Arora et al, 2001; Bardwell et al, 2006; Ganz et al, 2003; Hopwood et 
al, 2007). 
 Sexual dysfunction between women with short duration of illness (≤ 5 
years) and those with longer duration of illness (> 5 years) was noted to be equal 
(90%). Amongst breast cancer participants who had undergone surgery, sexual 
dysfunction was reported to be 89.9%.  
Sexual dysfunction was observed in 67 out of 75 (89.3%) participants 
who have had hormonal therapy. Majority of them (90.7%) were on Tamoxifen. 
Tamoxifen is the most frequently used anticancer agent globally (Mortimer et al, 
1999). The agent led to hot flushes and night sweats in acute toxicities, which 
also suggests that Tamoxifen produces symptoms of menopause (Fisher et al, 
1989). Reduction of oestrogen level after menopause resulted in the decrease of 
vaginal lubrication and vaginal dryness, which can lead to pain during sexual 
intercourse (Leiblum et al, 1983; Semmens & Wegner; 1982). These symptoms 
could possibly have negative impacts on sexual function of women with breast 
cancer. In a study conducted by Mortimer and colleagues (1999) which involved 
a total of 57 women with breast cancer who received Tamoxifen between 2 to 24 
months period, the authors found that 54% of the patients experienced pain, 
burning, or discomfort during sexual intercourse. The finding of this study 
confers with the observation made by Mortimer and colleagues (1999). 
 Majority (97%) of those participants with medical comorbidity 
experienced sexual dysfunction compared to only 86.6% of those without any 
comorbid medical illness. This finding was in keeping with the observation 
made in a study done by Bre’dart and colleagues (2011) which found that the 
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absence of sexual activity and sexual dissatisfaction were associated with 
comorbidities in breast cancer patients. Menopausal women were also noted to 
have higher sexual dysfunction cases with 92.2% compared to non-menopausal 
women with 82.6%. However, this was not statistically significant difference. 
Pre-mature menopause can be a complication of breast cancer treatment which 
leads to vaginal dryness, an important cause for sexual functioning problems in 
women with breast cancer (Bloom, Peterson and Kang, 2007; Ganz et al, 1998; 
Kornblith and Ligibel, 2003). Nonetheless, in this study menopausal stage per se 
was not associated with sexual dysfunction. There must be other factors which 
influence the high prevalence of sexual dysfunction in these women. 
 
6.4 SEXUAL DYSFUNCTION AND MARITAL VARIABLES 
 
 Older spousal age (> 50 years) was noted to have higher cases of sexual 
dysfunction with 92.8% compared to those with younger spouse with 83.9%. 
This could possibly be due to reduction in sexual activity as the couple grew 
older. Presence of medical comorbidity in the spouse and some of its treatment 
could also contribute to sexual problems amongst older couples.  
 Those with longer duration of relationship (> 20 years) recorded more 
cases of sexual dysfunction compared to participants with shorter duration of 
relationship (≤ 20 years), with 91.8% and 85.2% respectively.  
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6.5 ASSOCIATION OF BODY IMAGE DISTRESS WITH SEXUAL 
DYSFUNCTION 
 
 
 The Breast Impact of Treatment Scale (BITS) was used to assess body 
image distress in this study. The cut-off point of ≥ 26 indicated the presence of 
body image distress. Higher total score also indicated a greater degree of body 
image distress. 
In this study, the prevalence of body image distress amongst breast 
cancer participants was 42.9%. The prevalence in this study was lower 
compared to the finding of a study conducted by Fobair and colleagues (2006) 
where half of the 546 women were reported to experience two or more body 
image problems some of the time (33%), or at least one problem much of the 
time (17%). In a different study conducted amongst breast cancer patients who 
had undergone breast conserving therapies, assessment of body image found that 
15% felt less feminine, 25% felt less sexually attractive, and 28% of these 
women had changed their clothing habits secondary to the disease or treatment 
(Lyngholm et al, 2013). 
 Women with better body image were found to have a higher level of 
confidence and were able to cope better with cancer (Pikler and Winterowd, 
2003). Perceived loss of femininity and body integrity, hesitance to look at one’s 
self naked, feeling sexually unattractive, self-consciousness about appearance, 
and dissatisfaction with surgical scars are negative perceptions of body image 
that might be experienced by breast cancer survivors (Bartelink et al, 1985; 
Beckmann et al, 1983; Cohen et al, 1998; de Haes et al, 1986; Ganz et al, 1992 
& 2003; Hopwood, 1993; Kemeny et al, 1988; Lasry et al, 1987; Pozo et al, 
1992; Sanger and Reznikoff, 1981; Steinberg et al, 1985; Wellisch et al, 1989). 
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 From multivariate linear regression analysis conducted in this study, 
body image distress was not significantly associated with sexual dysfunction. 
The observation made in this study replicated the findings from previous 
literature (Ashcroft et al, 1985; Ganz et al, 1987; Goldberg et al, 1992; Penman 
et al, 1986). 
 
 
6.6 ASSOCIATION OF MARITAL DISSATISFACTION WITH SEXUAL 
DYSFUNCTION  
 
 
 In this study, marital satisfaction was measured by using the Golombok 
Rust Inventory of Marital State (GRIMS) with a higher score indicating greater 
degree of marital dissatisfaction.  
 
Spouses are often considered as the primary sources of support after the 
diagnosis of life threatening illness (Lasry et al, 2003). The disease does not 
only affect the women diagnosed with breast cancer but also involves the 
partners and other family members as a whole. The marital relationship plays a 
vital part in the woman’s adaptation process to the diagnosis and therapy of 
breast cancer (Bloom et al, 2001). Literature have illustrated that the quality of 
the marital relationship is significantly associated with the women’s 
psychological adaptation to the illness (Giese-Davis et al, 2000; Manne and 
Glassman, 2000; O’Mahoney and Carroll, 1997).  The illness experience and 
treatment regime are strong enough to bring about these emotional disturbances 
(Iqbal et al, 2001). Both cross-sectional and longitudinal studies have reported 
increased levels of spousal distress such as anxiety and depressed mood, and 
difficulties in marital communication (Baider et al, 2003; Carlson et al, 2000; 
Foy and Rose, 2001; Lewis, 1997; Lewis and Deal, 1995; Northouse and Swain, 
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1987; Omne-Poten et al, 1993; Ptacek el at, 1994; Toseland et al, 1995). In 
another study conducted by Rodrigue and Hoffman (1994), as high as 29% of 
sampled couples who had been receiving cancer therapies showed clinically high 
levels of psychological distress. Couples battling with breast cancer also 
reported more strain and conflict in their relationship (Carter et al, 1993; 
Northouse et al, 1998; Wai Ming, 2002). Couples with pre-existing marital 
problems were at increased risk of marital breakdown when faced with the 
illness due to greater demands and strain added on to their relationship (Carter et 
al, 1993; Lewis and Hammond, 1992; Litchman et al, 1987; Morris et al, 1977; 
Northouse, 1989).  
 
Marriage may protect from increased social isolation, psychological 
disturbances, and pain following the diagnosis of cancer in a woman (Katz et al, 
2005). Emotional support includes empathising, listening, comforting and 
communicating with the loved ones. While informational support involves 
giving advice, guidance and feedback about a problem. Instrumental support 
entails physical aids such as helping with house chores, managing the bills or 
finances and transportation (Kinsinger et al, 2011). The association between 
partner’s emotional support and adjustment to cancer is well-recognised in the 
literature (Alferi et al, 2001; Helgeson, 2003; Helgeson and Cohen, 1996). A 
study conducted by Pistrang and Barker (1995) showed that support from other 
sources from the patient’s social network could not replace for the loss of 
support from a spouse.  
 
Slower recovery process, worse health condition and performance status 
are associated with marital distress (Yang and Schuler, 2009). Among a sample 
of high risk women awaiting genetic testing for hereditary breast and ovarian 
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cancer, unhappily married women were found to have experienced more distress 
than either unmarried or happily married women (Coyne and Anderson, 1999). 
Couples struggling with the disease were found to experience marital distress, 
which is than expressed in sexual relationships and their communication forms 
(Northouse, Cracchiolo-Caraway and Appel, 1991). Studies also found that, the 
diagnosis of breast cancer can lead to disturbances in marital intimacy and 
reduction in frequency, and enjoyment of sexual activity (Hughes, 1996; 
Kadmon et al, 2008). Greater spousal distress is also associated with higher 
distress levels in women with breast cancer (Kim et al, 2008; Segrin et al, 2007).  
 
Sexual difficulties are experienced by women with breast cancer up to 3 
years following the diagnosis (Ganz et al, 1996). Factors that play important role 
in women’s psychosexual functioning include medical factors (surgical 
disfigurement and adverse effects of adjuvant therapies), psychological factors 
(body image, psychological problems) and relationship variables (spouse’s 
reaction to illness and its therapy) (Kinsinger et al, 2011). A husband’s 
supportive response to the disease can protect against relationship difficulties 
(Ghizzani et al, 1995; Holmberg et al, 2001; Manne et al, 2004; Skerrett, 1998; 
Wimberly et al, 2005). In a study done by Ghizzani and colleagues (1995), 
women were found to be more open to romance and sexuality when their 
spouses were perceived to be emotionally supportive. The feeling that a spouse 
is emotionally available also adds to feelings of femininity and attractiveness 
positively and leads to better marital satisfaction (Wimberly et al, 2005). 
 
Husbands often reported that they were unable to function and struggled 
to help their wives to cope with the disease and therapy (Sabo, Brown and 
Smith, 1990). In a study conducted by Maguire (1981), 25%-33% of husbands 
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reported that the surgical treatment for breast cancer had adversely affected their 
sexual relationship and marital intimacy. In a different study involving 50 Israeli 
husbands whose wives were diagnosed with breast cancer, 75% of the subjects 
reported changes in their relationship, more than a third had a reduction in 
communication with their families and 72% had change in their sexual activity, 
with 13% experienced moderate difficulty and 59% had slight difficulty in terms 
of their sexual activity (Kadmon et al, 2008). 
 
Communication in couples is important in battling with breast cancer. 
The amount and quality of communication regarding the worries and stressors 
encountered has vital implication on the couples’ adjustment to cancer and also 
the satisfaction of the marital relationship. Two basic communication patterns 
were identified in couples when dealing with psychological issues related to 
early stage of breast cancer. Couples who perceived that talking was essential 
talked openly and demonstrated fewer problems in their communication (Hilton, 
1994). A longitudinal study was conducted by Manne and colleagues (2006) 
involving 147 patients with early stage of breast cancer and 127 partners during 
cancer treatment and 9 months later to examine the association between types of 
communication strategies to handle stressors and psychological distress and 
relationship satisfaction. Distress and relationship satisfaction were associated 
with the couples’ perceptions of their communication with regards to cancer-
related issues and difficulties. Lower level of distress and higher relationship 
satisfaction for both partners was associated with constructive communication 
between them. The demand-withdraw communication (one partner pressures 
the other partner to talk about the cancer-related issue while the other partner 
withdraw) demonstrated greater level of distress and lower marital satisfaction 
for both partners. Struggles in a relationship and marital dissatisfaction can also 
 133 
 
be an outcome of partners’ different perceptions about their communication 
behaviours (Gottman, 1979). Alterations in partner communication and 
responsiveness were also found to be associated with sexuality and intimacy 
after a diagnosis of breast cancer (Manne et al, 2004; Wimberly et al, 2005), 
hence affecting sexual response in breast cancer survivors. 
“Cancer-related demands of illness are deﬁned as the concerns 
attributed to the cancer experienced by spouses” (Haberman et al, 1990). In a 
cross-sectional study conducted among 151 partners of women newly diagnosed 
with non-metastatic breast cancer, 5 groups of cancer-related demands were 
recognized. These are worries related to their own ability to function, their role 
as a source of support to their wives, sexual relationship, wife’s general health 
and the outcome of cancer therapies, and also the family members including the 
children’s general health. Partners were worried about themselves, including 
their own mortality, the necessity to rearrange their life priorities and felt 
unprepared to handle the uncertainties and often ruminate on how they were 
facing and tackling the situation. They were also worried about their wives’ 
cancer treatment outcome, wanted more information about the therapies and 
were tremendously engrossed about metastasis of the disease and failure of 
detection by the doctor, even when their wives are on active cancer treatment. 
They were also concerned about the impacts on their sexual relationship with 
their wives which includes the quality, frequency, and the lack of time to be 
sexually intimate with their wives. The family’s well-being such as what would 
happen to their family and their children were also identified as the spouses’ 
concern. They were worried about the likelihood that their children might be at 
risk of developing the illness or might need psychological support more than 
they do. They were also worried about their capabilities to help their wives 
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fighting the battle with breast cancer and they were often concerned about 
defending their wives from stress. This study also found that spouses who had 
more depressive symptoms, lack of  confidence in their capability to self-
manage the cancer and the inability to avoid negative thoughts during 
communication about the cancer with their wives had higher amount of breast 
cancer-related concerns (Fletcher el al, 2010). 
 
In this study, the prevalence of marital dissatisfaction experienced by the 
participants was reported to be 55%. The score on marital dissatisfaction was 
found to be inversely associated with sexual dysfunction score with r= -0.49. 
This would indicate that women who experienced greater marital dissatisfaction 
would have lower FSFI score, indicating a greater severity of sexual 
dysfunction. From the multivariate linear regression analysis done in this study, 
this association was found to be statistically significant with p< 0.001. This 
confers with the evidence from previous studies that found women who 
relatively have poorer relationship with their spouse would report more sexual 
problems (Dow et al, 1996; Ganz et al, 1996 & 1998; Kornblith and Ligibel, 
2003). 
 
This finding substantiate to the observation made in a study conducted 
by Kinsinger and colleagues (2011) which found that perceived greater levels of 
support, both emotional and informational, from the spouse at baseline were 
associated with less sexual problems amongst breast cancer women concurrently 
and 6 months after surgery. Bre´dart and colleagues (2011) in their study also 
found that there was an association between absence of sexual activity and 
sexual dissatisfaction with the feeling of emotional separation in the couple or of 
spousal fear of sexual intercourse amongst women with breast cancer. 
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6.7 ASSOCIATION OF DEPRESSION WITH SEXUAL DYSFUNCTION 
 
 
Depressive symptoms in this study were assessed using the depression 
sub-scale of the Hospital Anxiety and Depression Scale (HADS-D). A score of ≥ 
8 is indicative of a possible case of depression. 
 
In cancer patients, depression was found to be 15% to 25% more 
prevalent compared to the healthy general population (Massie and Popkin, 
1998). Depression is usually diagnosed after therapy of breast cancer. There are 
wide variations observed in the prevalence of depression in breast cancer, which 
very much depended on the study population. The prevalence rate ranges from 
3% to 55% (Fulton, 1997). In this study, we found the prevalence of possible 
depression cases amongst breast cancer survivors to be 9% using the depression 
sub-scale of the HADS questionnaire. This finding is similar to the prevalence of 
depression in breast cancer survivors when HADS were used that ranged from 
1% to 22%, with a median of 10%, in a systematic review of observational 
studies conducted recently (Zainal et al, 2013).  
 
Most of the literature concluded that 20% to 30% of these women had 
depressive symptoms that led to significant impairment, even though the 
prevalence of major depressive disorder is possibly low (Schou et al, 2004). This 
disorder has an adverse impact on all facets of quality of life in cancer patients 
as a whole and is also associated with reduced medical compliance, diminished 
understanding of treatment recommendations and worries about negative 
implications of therapies (Ayres et al, 1994; Ell et al, 2005). It also leads to a 
greater morbidity and possibly mortality in cancer patients (Hjerl et al, 2003). 
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Many factors can lead to depression in breast cancer patients. 
Psychosocial factors that may be associated with an increased risk of the 
disorder are previous history of depression, poor social function, and existence 
of any other stressful live events. Pain, disability, and poor body image are 
amongst somatic factors that showed modest associations with the disorder 
(Bardwell et al, 2006). On a contrary, disease and treatment variables that 
include stage of cancer, modality of treatment received and Tamoxifen use are 
not consistently associated with depression (Bardwell et al, 2006). These 
evidences point towards strong influence of psychosocial and physical factors on 
depression amongst breast cancer patients instead of disease severity or 
treatment modalities (Kim et al, 2012). 
 
Depression is a psychological disorder not only characterized by mood 
disturbances but also involves loss of interest (anhedonia). It is also associated 
with biological symptoms such as sleep difficulties, appetite and weight 
disturbances, lethargy and reduced sexual libido. Both anhedonia (which may 
lead to decreased sexual pleasure), and reduced sexual desire can play an 
important role in sexual dysfunction experienced by breast cancer survivors. 
These depressive symptoms also could possibly exacerbate sexual problems 
secondary to breast cancer therapies experienced by these women. 
 
Depression in breast cancer patients can have tremendous implication on 
the quality of life and also may lead to changes in the marital relationship (Kim 
et al, 2012). In a study conducted by Milbury and Badr (2013) examining the 
associations between sexual difficulties, depressive symptoms and two types of 
couple communication patterns (mutual constructive and demand-withdraw), 
191 couples were included in which the patient was starting treatment for 
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metastatic breast cancer.  The study found that greater levels of sexual 
difficulties were strongly associated with more depressive symptoms in patients 
who experienced low levels of mutual constructive communication (p< 0.01) 
and high levels of demand-withdraw communication (p< 0.0001). On a contrary, 
greater sexual problems were associated with more depressive symptoms 
irrespective of the communication pattern reported amongst the spouses of these 
patients. 
 
From this study, we found that there was a statistically significant 
inverse correlation between the measure of depressive symptoms as assessed by 
the total HADS-D sub-scale score and the measure of sexual dysfunction as 
assessed by the total FSFI score (r= -0.34, p< 0.001). From the multivariate 
linear regression analysis conducted, this association was found to be 
statistically significant, with p= 0.022. The evidence is in support of studies 
done elsewhere around the world justifying the negative impact of depressive 
symptoms on sexual functioning of women with breast cancers (Kim et al, 2012; 
Webber et al; 2011).  
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This study has found that marital dissatisfaction and depression are  
significantly associated with sexual dysfunction in breast cancer survivors. 
These associations can be multi-directional, the findings of which are illustrated 
below: 
 
Figure 6.1 Association between marital dissatisfaction and depression 
with sexual dysfunction in breast cancer survivors 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Depression Marital dissatisfaction 
Sexual dysfunction 
 139 
 
CHAPTER SEVEN 
 
LIMITATIONS AND STRENGTHS 
 
7.1 LIMITATIONS 
 
This study had limitations that should be taken into consideration when 
evaluating the results. 
1. This was a cross-sectional study, which hindered us from evaluating the 
consistency of sexual dysfunction, body image distress and marital 
dissatisfaction over time and across the disease trajectories. The observations 
were only carried out at a particular time. Thus, the findings of this study 
were only related to one point of time, and we could not conclude that the 
observations made were a constant factor in the study population. 
 
2. The study was conducted in a single, tertiary care hospital, in an urban 
setting.  Thus, the results were not an accurate representation of the whole 
Malaysian population. 
 
3. Patients who could not understand and read English were excluded from the 
study and this further limits the generalization of the results. However, the 
number of breast cancer patients that were excluded from the study was 
relatively small. 
 
4. The total sample of 100 women with breast cancer was relatively small. 
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5. Depressive and anxiety symptoms were assessed using a self-report 
questionnaire which served as, a screening tool instead of criteria from the 
Diagnostic Statistical Manual-IV-TR (DSM-IV-TR). As a result, we could 
not estimate the number of diagnosable disorders. 
 
6. Past psychiatric history may have influenced sexual dysfunction and marital 
dissatisfaction experienced by the participants. We did not have access to the 
data concerning the patient’s past psychiatric history. 
 
7. The use of self-reported questionnaires to assess sexual dysfunction, body 
image distress, marital dissatisfaction, depressive and anxiety symptoms, and 
quality of life may cause recall bias. 
 
8. Participants reported that a number of items in the questionnaire to measure 
body image distress (Breast Impact of Treatment Scale (BITS)) were 
difficult to understand, thus 9 out of the 100 patients did not answer the 
questionnaire completely. Hence, they were excluded in the assessment of 
body image distress. 
 
 
7.2 STRENGTHS 
 
 
1. The questionnaires used in this study were validated and widely used. 
 
2. Stronger associations were observed by conducting multivariate analysis. 
 
3.  This study looked at sexual dysfunction, body image distress and marital 
dissatisfaction in breast cancer patients which is the first one conducted in 
Malaysia. 
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CHAPTER EIGHT 
 
CONCLUSIONS 
 
Breast cancer is still known to be the commonest cancer and common cause of 
cancer-related death amongst Malaysian women. Early detection through improved 
public awareness and early screening programs plus the advances in treatment 
modalities for breast cancer had resulted in an improvement of the survivorship from 
the disease. However, the improvement in the survivorship of breast cancer were also 
associated with delayed and long term implications, either from the disease itself or as a 
result of negative effects of breast cancer therapies. These implications include sexual 
dysfunction, body image distress, marital dissatisfaction, psychological disorders such 
as depression or anxiety and disturbances in the survivors’ quality of life. 
In this study, the prevalence of sexual dysfunction was high amongst breast 
cancer patients recruited in the study who attended follow up at the breast clinic in 
UMMC. Factor that was identified to be significantly associated with sexual 
dysfunction in these women with breast cancer is younger age at the time of disease 
onset (≤ 50 years of age).  
The prevalence of body image distress was moderate. More than half of these 
breast cancer survivors reported marital dissatisfaction. The prevalence for probable 
cases depression was considerably low, but anxiety was noted to have moderate 
prevalence.  
In assessing sexual dysfunction against the independent variables (body image 
distress, marital dissatisfaction, depression, anxiety and quality of life), marital 
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dissatisfaction and depression were found to be significantly associated with sexual 
dysfunction. 
Women with breast cancer should be made aware of these possible late and long 
term implications of the disease and its treatment modalities. This would give them 
ample time and would allow them to cope and handle the matter better if it arises. These 
findings advocate the need for doctors treating breast cancer patients to routinely assess 
and discuss matters related to sexual functioning, marital relationship, depression, 
anxiety and body image as part of a holistic management of these women. Health care 
providers themselves should not feel uncomfortable discussing these intimate and 
private issues. The discussion should be conducted in a professional and yet sensitive 
manner as many of Malaysian women are embarrassed and reluctant to discuss these 
matters openly, due to their cultural and religious boundaries.  
Cancer care services should be made accessible and affordable throughout the 
country. Management of breast cancer patients should involve a multidisciplinary team 
which may consists of oncologist, surgeon, radiologist, palliative care physician, 
psychiatrist, psychologist, nurses and social worker. This would cover all aspects of the 
management of breast cancer patients and would in hand provide a better quality of 
care. 
Although the number of patients with depression and anxiety in this study is 
between low and moderate, the need for routine psychological assessment and 
intervention when indicated could not be put aside. Psychological comorbidity could 
have negative consequence to the outcome of breast cancer and the patients’ quality of 
life, in general. It can possibly occur at any trajectory of the disease. Hence, it should be 
recognized early and prompt referral when appropriate, to the psychiatric services 
should be made for further assessment and management.  
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Educational and awareness programs should be conducted consistently to 
encourage these women to come forward for help when appropriate and also to reduce 
the stigma associated with sexual difficulties and psychological disorder. Breast Cancer 
Support Group should be available in all hospitals to help these patients in coping with 
their illness, dealing with emotional problems and changing of experiences and advise 
on practical issues related to breast cancer. 
Breast cancer does not only affect the patient but also the spouse and the entire 
family as a whole. From this study, the prevalence of marital dissatisfaction was noted 
to be high amongst breast cancer survivors. This finding emphasizes the need for the 
treating doctors to also engage the spouse in their routine assessment for any possibility 
of sexual difficulties, marital and psychological problems faced by them. Carer burnt 
out and other factors that could lead to strain or dissatisfaction in a marriage should not 
be missed out as spousal support is vital in battling with breast cancer. 
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CHAPTER NINE 
 
RECOMMENDATIONS & CLINICAL IMPLICATIONS 
 
9.1 RECOMMENDATIONS 
 
 The recommendations for future studies are as below: 
1. Longitudinal cohort study should be done in the future in order to obtain 
stronger findings and associations between the socio-demographic, clinical, 
disease and marital variables with sexual dysfunction, body image distress 
and marital dissatisfaction amongst breast cancer survivors. 
 
2. Similar study involving data collection from other hospital settings in 
Malaysia could be conducted to make the findings more representative of 
and applicable to the country’s population. 
 
3. The power of the study could be increased by a larger sample size. Thus, the 
study findings would have greater clinical impact to the population. 
 
4. To use a healthy match control groups. 
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9.2 CLINICAL IMPLICATIONS 
 
 
The findings in this study serve as an alarm for the surgeons and the physicians 
who are treating breast cancer patients about the importance of issues related to 
sexual function, body image, marital dissatisfaction and psychological distress 
that may be experienced by these women. Sexual and marital issues are 
considered intimate and private matters amongst Malaysian women. Some even 
considered discussing these issues as taboo and would feel uncomfortable or 
ashamed to talk about them. Hence, the surgeons or physicians should be able to 
discuss and assess these matters in a very professional and sensitive manner. 
Early detection could lead to prompt and appropriate referral to the psychiatric 
services for further assessment and treatment if needed. Sexual dysfunction, 
body image distress, marital dissatisfaction and psychological distress should 
not be ignored or go unrecognized or untreated as these could have tremendous 
effect on the breast cancer survivor’s quality of life. These issues should be 
discussed routinely with the patients and also their partners in order to provide a 
holistic management. Physicians must not feel uncomfortable themselves when 
discussing these sensitive issues. 
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APPENDIX 1 
 
PATIENT INFORMATION SHEET 
 
 
Please read the following information carefully, do not hesitate to 
discuss any questions you may have with your Doctor. 
 
 
Study Title 
  
Sexual Dysfunction, body image distress and marital dissatisfaction in 
breast cancer patients attending follow up at the breast clinic in University 
Malaya Medical Centre (UMMC) 
 
 
Introduction 
 
Breast cancer is one of the commonest cancers seen in woman. It is also 
the commonest female malignancy in Malaysia and all over the world. 
Sexual dysfunction, body image distress and marital dissatisfaction are 
frequent adverse effects of cancer treatment. 
 
 
What is the purpose of this study? 
 
To study sexual dysfunction, body image distress and marital dissatisfaction 
in breast cancer patients attending the breast clinic in University Malaya 
Medical Centre. 
 
 
What are the procedures to be followed? 
 
A Patient’s Information Sheet will be given to participants who are willing to 
participate in this study and explanation about the study will be given by 
the doctor in charge. The participant will need to fill in a consent form prior 
to the commencement of this study. The participants will then be asked to 
fill in 5 sets of questionnaires and the doctor will also interview the 
participants. All the information will be strictly confidential. 
 
 
Who should enter the study? 
 
Breast cancer patients who are in clinical remission- 3 months or more after 
any active treatment other then endocrine treatment. 
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What will be benefits of the study: 
(a) to you as the subject? 
 
The standardized interview format in this study can be used to assess 
sexual dysfunction, body image distress and marital dissatisfaction among 
affected patients. Therefore, early intervention can be offered. 
(b) to the investigator? 
This study may help to identify the percentage of patients with breast 
cancer experiencing sexual dysfunction, body image distress and marital 
dissatisfaction. Also to investigate whether sexual dysfunction and body 
image distress buffers depression or anxiety symptoms. 
 
What are the possible drawbacks? 
Nil 
 
Can I refuse to take part in the study? 
Yes. However, your contribution will be much appreciated. This study will 
not affect your medical treatment. 
 
Who should I contact if I have additional questions during the 
course of the study? 
Doctor’s Names:  
Prof. Dr. Nor Zuraida Zainal  Tel: 03-79493152 
Dr. Norley binti Shuib     Tel: 03-79492629/2432 
            
 
             BK-MIS-1116-E01 
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APPENDIX 2 
 
  
I, ………………………………………………………………   Identity Card No……….………………………………… 
                      
 
of……………………………………………………………………………………………………………………………………...                                                                             
 
hereby agree to take part in the clinical research (clinical study/questionnaire study/drug trial) specified 
below:  
 
 
 
the nature and purpose of which has been explained to me by Dr……………………………………………………  
 
and interpreted by ………………………..……………………………….…..………… 
to the best of his/her ability in …………………….…………… language/dialect. 
 
I have been told about the nature of the clinical research in terms of methodology, possible adverse effects 
and complications (as per patient information sheet).  After knowing and understanding all the possible 
advantages and disadvantages of this clinical research, I voluntarily consent of my own free will to 
participate in the clinical research specified above. 
 
I understand that I can withdraw from this clinical research at any time without assigning any reason 
whatsoever and in such a situation shall not be denied the benefits of usual treatment by the attending 
doctors. 
 
Date: ……………...………..                          Signature or Thumbprint …………….…………………………… 
                                                                                                                          
 
 
Name ………………………………………..….……..… 
                                                                                 
Identity Card No. ………………………….…….……            Signature ……………………………………………             
                                                                                                         (  
Designation ……………………………….…………… 
 
I confirm that I have explained to the patient the nature and purpose of the above-mentioned clinical 
research. 
 
Date …………………………….                                              Signature ………………………………………….. 
                                                                                                                                                
R.N.                                                                    
Name 
Sex 
                                                           Age 
                                                           Unit    
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APPENDIX 3 
 
Serial No. : 
Date  :  
 
Sexual dysfunction, body image distress and marital dissatisfaction in 
breast cancer patients attending follow up at the breast clinic in 
University Malaya Medical Centre (UMMC) 
 
Socio-demographic Data Sheet 
 
All information obtained is strictly confidential and will only be use for the purpose of 
this research. 
 
 
Section 1:  Basic Information 
 
UMMC RN    : 
 
Age     : 
 
Contact number   : 
 
Race     : 1-  Malay  3-  Indian 
2- Chinese  4-  Others 
 
 
Religion    : 1-  Islam  4-  Christianity 
2- Buddhism  5-  Others 
3- Hinduism 
 
 
Educational level   : 1-  Nil   3-  Secondary 
      2-  Primary  4-  Tertiary 
 
 
Employment status   : 1-  Unemployed 4-  Housewife 
2- Part time  5-  Pensioner 
3-  Full time 
 
 
Household income   : 1-  < RM 1, 000 
(per month)     2-  RM 1, 000 – RM 2, 000 
      3-  RM 2, 001 – RM 3, 000 
      4-  RM 3, 001 – RM 4, 000 
      5-  RM 4, 001 – RM 5, 000 
      6-  RM 5, 001 – RM 10, 000 
      7-  > RM 10, 000 
 
 
 
 169 
 
Section 2:  Relationship or Marital Information 
 
Age of partner   :  
 
Duration of relationship  : 
 
Presence of relationship  : 1-  No 
or marital problem    2-  Yes (specify) __________________ 
 
 
 
Section 3:  Illness Information 
 
Date of diagnosis   : 
 
Age of onset    : 
 
Duration of illness   : 
 
Clinical staging at first contact : 
 
Treatment received   :  Surgery    
1- Mastectomy 
2- Lumpectomy 
3- Nil 
 
Chemotherapy regime 
1- Chemo FEC 
2- Chemo TAC (toxotere) 
3- Others 
4- Nil 
 
Radiotherapy 
1- Yes 
2- No 
 
 
Current hormonal   :  1-  Tamoxifen 
Treatment       2-  Femara (letrozole) 
3- Arimidex (anastrozole) 
4- Aromasin (exemastane) 
5- Others ___________________________ 
 
       Date commenced _____________ 
       Date discontinued _____________ 
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Metastasis    :  1-  Bone   3-  Brain 
        2-  Liver   4-  Nil 
        3-  Lungs 
 
 
Other medical co-morbidity  :  1-  Diabetes   4-  IHD 
        2-  Hypertension  5-  Others 
        3-  Asthma   6-  Nil  
 
 
Menopause    :  1-  Yes   2-  No 
If yes, duration   :  _________________   
 
 
 
Section 4: Topometry Measurements 
 
Weight (kg)    : 
 
Height (cm)    : 
 
BMI     : 
 
Waist circumference (cm)  : 
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APPENDIX 4 
 
Female Sexual Function Index (FSFI) 
 
INSTRUCTIONS: These questions ask about your sexual feelings and responses 
during the past 4 weeks. Please answer the following questions as honestly and clearly 
as possible. Your responses will be kept completely confidential. In answering these 
questions the following definitions apply: 
 
Sexual activity can include caressing, foreplay, masturbation and vaginal intercourse. 
Sexual intercourse is defined as penile penetration (entry) of the vagina. 
Sexual stimulation includes situations like foreplay with a partner, self-stimulation 
(masturbation), or sexual fantasy. 
 
CHECK ONLY ONE BOX PER QUESTION. 
 
Sexual desire or interest is a feeling that includes wanting to have a sexual experience, 
feeling receptive to a partner's sexual initiation, and thinking or fantasizing about having 
sex. 
 
1. Over the past 4 weeks, how often did you feel sexual desire or interest? 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
 
2. Over the past 4 weeks, how would you rate your level (degree) of sexual desire 
or interest? 
 - Very high 
 - High 
 - Moderate 
- Low 
- Very low or none at all 
 
Sexual arousal is a feeling that includes both physical and mental aspects of sexual 
excitement. It may include feelings of warmth or tingling in the genitals, lubrication 
(wetness), or muscle contractions. 
 
3. Over the past 4 weeks, how often did you feel sexually aroused ("turned on") 
during sexual activity or intercourse? 
 - No sexual activity 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
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4. Over the past 4 weeks, how would you rate your level of sexual arousal ("turn 
on") during sexual activity or intercourse? 
 - No sexual activity 
 - Very high 
 - High 
 - Moderate 
 - Low 
 - Very low or none at all 
 
5. Over the past 4 weeks, how confident were you about becoming sexually 
aroused during sexual activity or intercourse? 
 - No sexual activity 
 - Very high confidence 
 - High confidence 
 - Moderate confidence 
 - Low confidence 
 - Very low or no confidence 
 
6. Over the past 4 weeks, how often have you been satisfied with your arousal 
(excitement) during sexual activity or intercourse? 
 - No sexual activity 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
 
7. Over the past 4 weeks, how often did you become lubricated ("wet") during 
sexual activity or intercourse? 
 - No sexual activity 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
 
8. Over the past 4 weeks, how difficult was it to become lubricated ("wet") during 
sexual activity or intercourse? 
 - No sexual activity 
 - Extremely difficult or impossible 
 - Very difficult 
 - Difficult 
 - Slightly difficult 
 - Not difficult 
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9. Over the past 4 weeks, how often did you maintain your lubrication ("wetness") 
until completion of sexual activity or intercourse? 
 - No sexual activity 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
 
10. Over the past 4 weeks, how difficult was it to maintain your lubrication 
("wetness") until completion of sexual activity or intercourse? 
 - No sexual activity 
 - Extremely difficult or impossible 
 - Very difficult 
 - Difficult 
 - Slightly difficult 
 - Not difficult 
 
11. Over the past 4 weeks, when you had sexual stimulation or intercourse, how 
often did you reach orgasm (climax)? 
 - No sexual activity 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
 
12. Over the past 4 weeks, when you had sexual stimulation or intercourse, how 
difficult was it for you to reach orgasm (climax)? 
 - No sexual activity 
 - Extremely difficult or impossible 
 - Very difficult 
 - Difficult 
 - Slightly difficult 
 - Not difficult 
 
13. Over the past 4 weeks, how satisfied were you with your ability to reach 
orgasm (climax) during sexual activity or intercourse? 
 - No sexual activity 
 - Very satisfied 
 - Moderately satisfied 
 - About equally satisfied and dissatisfied 
 - Moderately dissatisfied 
 - Very dissatisfied 
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14. Over the past 4 weeks, how satisfied have you been with the amount of 
emotional closeness during sexual activity between you and your partner? 
 - No sexual activity 
 - Very satisfied 
 - Moderately satisfied 
 - About equally satisfied and dissatisfied 
 - Moderately dissatisfied 
 - Very dissatisfied 
 
15. Over the past 4 weeks, how satisfied have you been with your sexual 
relationship with your partner? 
 - Very satisfied 
 - Moderately satisfied 
 - About equally satisfied and dissatisfied 
 - Moderately dissatisfied 
 - Very dissatisfied 
 
16. Over the past 4 weeks, how satisfied have you been with your overall sexual 
life? 
 - Very satisfied 
 - Moderately satisfied 
 - About equally satisfied and dissatisfied 
 - Moderately dissatisfied 
 - Very dissatisfied 
 
17. Over the past 4 weeks, how often did you experience discomfort or pain during 
vaginal penetration? 
 - Did not attempt intercourse 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
 
18. Over the past 4 weeks, how often did you experience discomfort or pain 
following vaginal penetration? 
 - Did not attempt intercourse 
 - Almost always or always 
 - Most times (more than half the time) 
 - Sometimes (about half the time) 
 - A few times (less than half the time) 
 - Almost never or never 
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19.Over the past 4 weeks, how would you rate your level (degree) of discomfort or 
pain during or following vaginal penetration? 
 - Did not attempt intercourse 
 - Very high 
 - High 
 - Moderate 
 - Low      
 - Very low or none at all 
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APPENDIX 5 
 
Breast-Impact of Treatment Scale  
 
Please mark X at the appropriate answers. 
 
 Not at 
all 
0 
Rarely 
 
1 
 
 
2 
Sometimes 
 
3 
 
 
4 
Often 
 
5 
1. How my body has changed 
pops into my mind. 
      
2. I have waves of strong 
feelings about the way my 
body looks. 
      
3. I think about how my body 
used to look. 
      
4. Things I see or hear remind 
me that my body is different 
now. 
      
5. When I see other women, I 
think that my body appears 
different than theirs. 
      
6. I feel uncomfortable about 
being seen naked. 
      
7. I am bothered by feelings or 
thoughts of body 
disfigurement. 
      
8. I am reminded of my breasts 
when I pick out clothes to 
wear. 
      
9. I don’t want to deal with how 
my body looks. 
      
10. I avoid letting myself get 
emotional when I think of 
how my body has changed. 
      
11. I try not to think about the 
size and shape of my breasts. 
      
12. I avoid looking at and/or 
touching my breasts. 
      
13. I feel self-conscious about 
letting my partner (person 
with whom I am sexually 
intimate) see my breasts. 
(Even if you do not have a 
partner now, rate how you 
believe you would feel.) 
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APPENDIX 6 
 
Golombok Rust Inventory of Marital State (GRIMS) 
 
We would like to ask you questions regarding your relationship with your spouse mainly on 
your marital satisfaction.   Please tick the appropriate box that described you best. 
 
 
  Strongly 
disagree 
Disagree Agree Strongly 
agree 
1. My partner is usually sensitive to and 
aware of my needs. 
 
    
2. I really appreciate my partner’s sense of 
humour.  
 
    
3. My partner doesn’t seem to listento me 
anymore. 
 
    
4. My partner has never been disloyal to 
me. 
 
    
5. I would be willing to give up my friends 
if it mean saving our relationship. 
 
    
6. I am dissatisfied with our relationship.  
 
    
7. I wish my partner was not so lazy and 
didn’t keep putting things off. 
 
    
8. I sometimes feel lonely even when I am 
with my partner. 
 
    
9. If my partner left me, life would not be 
worth living. 
 
    
10. We can’t agree to disagree with  each 
other. 
 
    
11. It is useless carrying on with a marriage 
beyond a certain point. 
 
    
12. We both seem to like the same things. 
 
    
13. I find it difficult to show my partner  
that I am feeling affectionate. 
 
    
14. I never have second thoughts about our 
relationship. 
 
    
15. I enjoy just sitting and talking to my 
partner. 
 
    
 178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Strongly 
disagree 
Disagree Agree Strongly 
agree 
16. I find the idea of spending the rest of my 
life with my partner rather boring. 
 
    
17. There is always plenty of ‘give and take’ 
in our relationship. 
 
    
18. We become competitive when we have 
to make decisions. 
 
    
19. I no longer feel I can really trust  my 
partner. 
 
    
20. Our relationship is still full of joy and 
excitement. 
 
    
21. One of us is continually talking  and the 
other is usually silent. 
 
    
22. Our relationship is continually evolving. 
 
    
23. Marriage is really more about  security 
and money then about love. 
 
    
24. I wish there was more warmth and 
affection between us. 
 
    
25. I am totally committed to my 
relationship with my partner. 
 
    
26. Our relationship is sometimes strained 
because my partner is always correcting 
me. 
 
    
27. I suspect we may be on the brink of 
separation. 
 
    
28. We can always make up quickly  after an 
argument. 
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APPENDIX 7 
 
HOSPITAL ANXIETY AND DEPRESSION SCALE  
Patients are asked to choose one response from the four given for each interview.   They 
should give an immediate response and be dissuaded from thinking too long about their 
answers.  Instruct the patient to answer how it currently describes their feelings. 
1. I feel tense or 'wound up'        
a. Most of the time        
b. A lot of the time        
c. From time to time, occasionally      
d. Not at all 
         
2. I still enjoy the things I used to enjoy       
a. Definitely as much        
b. Not quite so much        
c. Only a little 
d. Hardly at all  
        
3. I get a sort of frightened feeling as if something awful is about to happen  
a. Very definitely and quite badly      
b. Yes, but not too badly        
c. A little, but it doesn't worry me      
d. Not at all        
  
4. I can laugh and see the funny side of things      
a. As much as I always could       
b. Not quite so much now       
c. Definitely not so much now       
d. Not at all        
  
5. Worrying thoughts go through my mind      
a. A great deal of the time       
b. A lot of the time        
c. From time to time, but not too often      
d. Only occasionally       
  
6. I feel cheerful          
a. Most of the time        
b. Sometimes         
c. Not often         
d. Not at all        
  
7. I can sit at ease and feel relaxed       
a. Definitely         
b. Usually         
c. Not often         
d. Not at all        
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8. I feel as if I am slowed down        
a. Nearly all the time        
b. Very often         
c. Sometimes         
d. Not at all        
  
9. I get a sort of frightened feeling like 'butterflies' in the stomach   
a. Not at all         
b. Occasionally         
c. Quite Often         
d. Very Often        
  
10. I have lost interest in my appearance       
a. Definitely         
b. I don't take as much care as I should      
c. I may not take quite as much care      
d. I take just as much care as ever     
  
11. I feel restless as I have to be on the move      
a. Very much indeed        
b. Quite a lot         
c. Not very much        
d. Not at all         
 
12. I look forward with enjoyment to things      
a. As much as I ever did        
b. Rather less than I used to       
c. Definitely less than I used to       
d. Hardly at all        
  
13. I get sudden feelings of panic        
a. Very often indeed        
b. Quite often         
c. Not very often         
d. Not at all        
  
14. I can enjoy a good book or radio or TV program     
a. Often          
b. Sometimes         
c. Not often         
d. Very seldom        
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APPENDIX 8 
 
Psychological General Well-being Index (PGWBI) 
 
This section of examination contains questions about how you feel and how things have 
been going with you. For each question check the answer which best applies to you. 
 
1. How have you been feeling in general? (DURING THE PAST MONTH) 
 In excellent spirits 
 In very good spirits 
 In good spirits mostly 
 I have been up and down in spirits a lot 
 In low spirits mostly 
 In very low spirits 
 
2. How often were you bothered by an illness, bodily disorder, aches or pains? 
(DURING THE PAST MONTH) 
 Every day 
 Almost every day 
 About half of the time 
 Now and then, but less than half of the time 
 Rarely 
 None of the time 
 
3. Did you feel depressed? (DURING THE PAST MONTH) 
 Yes- to the point that I felt like taking my life 
 Yes- to the point that I did not care about anything 
 Yes- very depressed almost every day 
 Yes- quite depressed several times 
 Yes- a little depressed now and then 
 No- never felt depressed at all 
 
4. Have you been in firm control of your behaviour, thoughts, emotions or 
feelings? (DURING THE PAST MONTH) 
 Yes, definitely so 
 Yes, for the most part 
 Generally so 
 Not too well 
 No, and I am somewhat disturbed 
 No, and I am very disturbed 
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5. Have you been bothered by nervousness or your “nerves”? (DURING THE 
PAST MONTH) 
 Extremely so- to the point where I could not work or take care of things 
 Very much so 
 Quite a bit 
 Some- enough to bother me 
 A little 
 Not at all 
 
6. How much energy, pop, or vitality did you have or feel? (DURING THE PAST 
MONTH) 
 Very full of energy- lots of pep 
 Fairly energetic most of the time 
 My energy level varied quite a bit 
 Generally low in energy or pep 
 Very low in energy or pep most of the time 
 No energy or pep al all- I felt drained, sapped 
 
7. I felt downhearted and blue DURING THE PAST MONTH. 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
8. Were you generally tense or did you feel tension? (DURING THE PAST 
MONTH) 
 Yes- extremely tense, most or all of the time 
 Yes- very tense most of the time 
 Not generally tense, but did feel fairly tense several times 
 I felt a little tense a few times 
 My general tension level was quite low 
 I never felt tense or any tension at all 
 
9. How happy, satisfied, or pleased have you been with your personal life? 
(DURING THE PAST MONTH) 
 Extremely happy- could not have been more satisfied or pleased 
 Very happy most of the time 
 Generally satisfied- pleased 
 Sometimes fairly happy, sometimes fairly unhappy 
 Generally dissatisfied, unhappy 
 Very dissatisfied or unhappy most or all the time 
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10. Did you feel healthy enough to carry out the things you like to do or had to do? 
(DURING THE PAST MONTH) 
 Yes- definitely so 
 For the most part 
 Health problems limited me in some important ways 
 I was only healthy enough to take care of myself 
 I needed some help in taking care of myself 
 I needed someone to help me with most or all the things I had to do 
 
11. Have you felt so sad, discouraged, hopeless, or had so many problems that you 
wondered if anything was worthwhile? (DURING THE PAST MONTH) 
 Extremely so- to the point that I have just about given up 
 Very much so 
 Quite a bit 
 Some- enough to bother me 
 A little bit 
 Not at all 
 
12. I woke up feeling fresh and rested DURING THE PAST MONTH. 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
13. Have you been concerned, worried, or had any fears about your health? 
(DURING THE PAST MONTH) 
 Extremely so 
 Very much so 
 Quite a bit 
 Some, but not a lot 
 Practically never 
 Not at all 
 
14. Have you had any reason to wonder if you were losing your mind, or losing 
control over the way you act, talk, think, feel or of your memory? (DURING 
THE PAST MONTH) 
 Not at all 
 Only a little 
 Some- but not enough to be concerned or worried about 
 Some and I have been a little concerned 
 Some and I am quite concerned 
 Yes, very much so and I am very concerned 
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15. My daily life was full of things that were interesting to me DURING THE 
PAST MONTH. 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
16. Did you feel active, vigorous, or dull, sluggish? (DURING THE PAST 
MONTH) 
 Very active, vigorous every day 
 Mostly active, vigorous- never really dull, sluggish 
 Fairly active, vigorous- seldom active, vigorous 
 Fairly dull, sluggish- seldom active, vigorous 
 Mostly dull, sluggish- never really active, vigorous 
 Very dull, sluggish every day 
 
17. Have you been anxious, worried, or upset? (DURING THE PAST MONTH) 
 Extremely so- to the point of being sick or almost sick 
 Very much so 
 Quite a bit 
 Some- enough to bother me 
 A little bit 
 Not at all 
 
18. I was emotionally stable and sure of myself DURING THE PAST MONTH. 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
19. Did you feel relaxed, at ease or high strung, tight, or keyed-up? (DURING THE 
PAST MONTH) 
 Felt relaxed and at ease the whole month 
 Felt relaxed and at ease most of the time 
 Generally felt relaxed but at times felt fairly high strung 
 Generally felt high strung but at times felt fairly relaxed 
 Felt high strung, tight, or keyed up most of the time 
 Felt high strung, tight, or keyed up the whole month 
 
20. I felt cheerful, lighthearted DURING THE PAST MONTH. 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
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21. I felt tired, worn out, used up, or exhausted DURING THE PAST MONTH. 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time  
 All of the time 
 
22. Have you been under or felt you were under any strain, stress, or pressure? 
(DURING THE PAST MONTH) 
 Yes, almost more than I could bear or stand 
 Yes, quite a bit of pressure 
 Yes, some- more than usual 
 Yes, some- bout about usual 
 Yes, a little 
 Not at all 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
